Page last updated: 2024-11-13

transforming growth factor beta

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56842206
MeSH IDM0024757

Synonyms (8)

Synonym
tgf-beta
tgfbeta
bone-derived transforming growth factor
transforming growth factor beta
tgf beta
milk growth factor
122304-04-5
platelet transforming growth factor

Research Excerpts

Overview

Transforming growth factor beta (TGF-β) is a multifunctional cytokine abundantly expressed in the multiple myeloma bone marrow niche, where it promotes an immunosuppressive tumor microenvironment. TGF-beta is a well-known and multitasking cytokine that regulates a wide range of reactions and interactions within tumor and normal tissues.

ExcerptReferenceRelevance
"Transforming growth factor beta (TGF-β) is a multifunctional cytokine abundantly expressed in the multiple myeloma bone marrow niche, where it promotes an immunosuppressive tumor microenvironment."( Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β.
Alabanza, LM; Dash, P; Dropulic, B; Hu, P; Schneider, D; Vu, B; Webster, B; Wu, D; Xiong, Y; Zhu, Z, 2022
)
1.44
"Transforming growth factor beta (TGF- β) is a promotor in advanced stages of prostate cancer."( CORRELATION OF EXPRESSION OF TGF- β AND MMP2 BETWEEN PROSTATIC ADENOCARCINOMA AND ADJACENT UNAFFECTED PARENCHYMA.
Bacalja, J; Čupić, H; Krušlin, B; Mašić, S; Skenderi, F; Spajić, B; Tomas, D; Ulamec, M; Vučić, M, 2022
)
1.44
"Transforming growth factor beta (TGFβ) is a potent inducer of EMT with implications for cancer invasion and metastasis."( Sumoylated SnoN interacts with HDAC1 and p300/CBP to regulate EMT-associated phenotypes in mammary organoids.
Bonni, A; Bonni, S; Chanda, A; Deng, L; Sarkar, A, 2023
)
1.63
"Transforming Growth Factor beta 1 (TGFβ) is an established genetic modifier of CF lung disease and a known driver of abnormal ASM function."( CFTR dysfunction in smooth muscle drives TGFβ dependent airway hyperreactivity.
Clancy, JP; Davidson, CR; Hudock, KM; Kramer, EL, 2023
)
1.63
"Transforming growth factor beta (TGF-β) is a pleiotropic cytokine that signals through membrane receptors and intracellular Smad proteins, which enter the nucleus upon receptor activation and act as transcription factors."( Contextual Regulation of TGF-β Signaling in Liver Cancer.
Huang, C; Huang, W; Luo, Z; Tu, S; Yan, X, 2019
)
1.24
"Transforming growth factor beta (TGF-β) is a well-known and multitasking cytokine that regulates a wide range of reactions and interactions within tumor and normal tissues."( TGF-β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury.
Eleojo Musa, A; Farhood, B; Hoseini-Ghahfarokhi, M; Khodamoradi, E; Mirtavoos-Mahyari, H; Motevaseli, E; Najafi, M, 2020
)
1.28
"Transforming growth factor beta (TGF-β) is a potent pleiotropic polypeptide cytokine, with a complex and context dependent control of its activation, signaling and effector functions. "( Transforming growth factor beta (TGF-β) activity in immuno-oncology studies.
Aranda, F; Di Scala, M; Dotor, J; Gallo-Oller, G, 2020
)
3.44
"Transforming growth factor beta (TGFβ) is a multipotent immunosuppressive cytokine. "( TGFβ suppresses CD8
Ahmad, R; Alice, A; Blair, T; Crittenden, MR; Crocenzi, T; Fox, N; Gough, MJ; Gunderson, AJ; Hayman, A; Kiely, MX; McCarty, K; O'Brien, D; Phillips, M; Whiteford, M; Yamazaki, T; Young, KH, 2020
)
2
"Transforming growth factor beta (TGFB) is a pleiotropic cytokine known to be dysregulated in many neurodegenerative disorders and particularly in amyotrophic lateral sclerosis (ALS). "( Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis.
Casarotto, E; Chierichetti, M; Crippa, V; Cristofani, R; Ferrari, V; Galbiati, M; Messi, E; Piccolella, M; Poletti, A; Rusmini, P; Tedesco, B, 2020
)
2.33
"Transforming growth factor beta (TGFβ) is a pleiotropic cytokine that plays a key role in both physiologic and pathologic conditions, including cancer. "( Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.
Ciardiello, D; Elez, E; Seoane, J; Tabernero, J, 2020
)
2
"Transforming growth factor beta (TGFβ) is a pleiotropic growth factor. "( TGFβ Signaling in the Tumor Microenvironment.
Goulet, CR; Pouliot, F, 2021
)
2.06
"Transforming growth factor beta (TGF-β) is a typical immuno-inhibitory cytokine and highly secreted by lung cancer cells. "( Downregulation of NKG2DLs by TGF-β in human lung cancer cells.
Bae, J; Cho, HR; Choi, H; Kang, CD; Lee, YS; Park, YS; Son, WC, 2021
)
2.06
"Transforming growth factor beta (TGFβ) is a well-known factor that induces the production of CSPGs, and in this study, we report a novel mechanism underlying TGFβ's effects on CSPG secretion in primary rat astrocytes."( Inhibition of Autophagy Flux Promotes Secretion of Chondroitin Sulfate Proteoglycans in Primary Rat Astrocytes.
Alizadeh, J; Drewnik, DA; Ghavami, S; Hannila, SS; Kochan, MM; Stewart, VD, 2021
)
1.34
"Transforming growth factor beta (TGF-β) is a multifunctional protein that induces gene expression of cartilage-specific molecules, but its exact role in the process of chondrogenesis is unclear. "( TGF-β Stimulates Endochondral Differentiation after Denervation.
Chen, S; Du, H; Li, H; Li, Y; Ophene, J; Sun, X; Tian, AY; Tian, MY; Yao, Z, 2017
)
1.9
"Transforming growth factor beta (TGF-β) is a pleiotropic cytokine present in vertebrate and invertebrate organisms that functions in numerous physiological and pathological processes. "( The role of TGF-beta signaling in dendritic cell tolerance.
Esebanmen, GE; Langridge, WHR, 2017
)
1.9
"Transforming growth factor beta (TGF-β) is a multipurpose cytokine, which plays a role in many cellular functions such as proliferation, differentiation, migration, apoptosis, cell adhesion and regulation of epithelial to mesenchymal transition. "( The clinical and biological roles of transforming growth factor beta in colon cancer stem cells: A systematic review.
Chruścik, A; Gopalan, V; Lam, AK, 2018
)
2.2
"Transforming growth factor beta (TGFβ) is a cytokine involved in fibrosis, inflammation, and injury response as well as a genetic modifier and biomarker of CF lung disease."( TGFβ as a therapeutic target in cystic fibrosis.
Clancy, JP; Kramer, EL, 2018
)
1.2
"Transforming growth factor beta (TGF-β) is a multi-functional polypeptide that plays a critical role in regulating a broad range of cellular functions and physiological processes. "( Feedback regulation of TGF-β signaling.
Chen, YG; Xiong, X; Yan, X, 2018
)
1.92
"Transforming growth factor beta (TGF-β) is an important growth factor that regulates many cellular functions in development and disease."( Spatiotemporal Control of TGF-β Signaling with Light.
Deng, D; Heo, WD; Kim, JM; Kim, N; Lee, M; Li, Y; Liu, X; Wu, G; Zi, Z, 2018
)
1.2
"Transforming growth factor beta 1 is a key molecule in the development of postoperative fibrosis."( Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation.
Bolia, I; Briggs, K; Huard, J; Lowe, WR; Philippon, MJ; Utsunomiya, H, 2018
)
1.2
"Transforming growth factor beta (TGF-β) is an important growth factor that plays essential roles in regulating tissue development and homeostasis. "( Molecular Engineering of the TGF-β Signaling Pathway.
Zi, Z, 2019
)
1.96
"Transforming growth factor beta or TGF-β is a polypeptide member of the transforming growth factor beta superfamily of cytokines, while far fewer clinical studies addressing the association between TGF-β expression and the disease prognosis have been reported up to now."( Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis.
Che, G; Lai, Y; Li, J; Li, P; Liu, L; Shen, C; Wang, X; Zhou, K, 2019
)
1.24
"Transforming growth factor beta (TGF-β) is a cytokine with an active role in radiation-induced fibrosis, which could be used as an early biomarker for the development of fibrosis."( Breast-conserving surgery in breast cancer and intraoperative radiotherapy. Can we predict the fibrosis?
Barra Pardos, MV; Carrasquer Puyal, A; Casamayor Franco, MDC; Martínez Lahoz, Y; Pallarés Segura, JL; Pérez-Tierra Ruiz, JV; Sánchez Marín, JP; Vallejo Bernad, C, 2019
)
1.24
"Transforming growth factor beta (TGFβ) is a known inducer of epithelial to mesenchymal transition (EMT), and studies in other systems have shown that nuclear localization of the myocardin-related transcription factor (MRTF) is downstream of TGFβ. "( Nuclear translocation of myocardin-related transcription factor-A during transforming growth factor beta-induced epithelial to mesenchymal transition of lens epithelial cells.
Gupta, M; Korol, A; West-Mays, JA, 2013
)
2.06
"Transforming growth factor beta (TGF-β) is an important cytokine with dual regulatory functions in the immune system and in the responses against viral infections."( Important roles played by TGF-β in hepatitis B infection.
Arababadi, MK; Daneshvar, H; Ebrahim, M; Hassanshahi, G; Karimi-Googheri, M; Kennedy, D; Nosratabadi, R; Zare-Bidaki, M, 2014
)
1.12
"Transforming growth factor beta-1 (TGF-β1) is a profibrotic cytokine that plays a pivotal role in fibrosis."( ALK1-Smad1/5 signaling pathway in fibrosis development: friend or foe?
González-Núñez, M; López-Novoa, JM; Muñoz-Félix, JM, 2013
)
1.11
"Transforming growth factor beta (TGF β ) is a family of genes that play a key role in mediating tissue remodeling in various forms of acute and chronic lung disease. "( Over, and underexpression of endothelin 1 and TGF-beta family ligands and receptors in lung tissue of broilers with pulmonary hypertension.
Bojalil, R; Dominguez-Avila, N; Escoto, J; Espinosa-Cervantes, R; Fernandez-Jaramillo, N; González-Ramírez, J; Marquez-Velasco, R; Ruiz-Castañeda, G; Sánchez, F; Sánchez-Muñoz, F, 2013
)
1.83
"Transforming growth factor beta is a pleiotropic cytokine which plays a central role in the homeostasis of the immune system. "( Severe inflammatory bowel disease associated with congenital alteration of transforming growth factor beta signaling.
Arrigo, S; Fabretto, A; Loganes, C; Lonardi, S; Martelossi, S; Naviglio, S; Tommasini, A; Ventura, A; Vignola, S; Villanacci, V, 2014
)
2.08
"Transforming growth factor beta (TGFβ) is a pleiotropic cytokine with important roles in mediating inflammatory response. "( Structural and functional characterization of a TGFβ molecule from amphioxus reveals an ancient origin of both immune-enhancing and -inhibitory functions.
Hu, L; Li, F; Li, H; Liu, S; Wang, S; Zhang, S, 2014
)
1.85
"Transforming growth factor beta (TGF-β) is a potent inhibitor of cell growth. "( TGFBR1 and cancer susceptibility.
Jimenez, H; Pasche, B; Pennison, MJ; Wang, M, 2014
)
1.85
"Transforming growth factor beta (TGFβ) is a multifunctional cytokine that regulates important cellular processes including epithelial-mesenchymal transition (EMT)."( Role of TGF-β signaling in uterine carcinosarcoma.
Bhattacharya, R; Dwivedi, SK; McMeekin, SD; Slaughter, K, 2015
)
1.14
"Transforming growth factor beta (TGF-β) is a multi-functional growth factor expressed in many tissues and organs. "( TGF-Beta Negatively Regulates the BMP2-Dependent Early Commitment of Periodontal Ligament Cells into Hard Tissue Forming Cells.
Ikegami, K; Kawahara, T; Kitamura, M; Murakami, S; Nakamura, T; Yamada, S; Yamashita, M; Yanagita, M, 2015
)
1.86
"Transforming Growth Factor beta (TGFbeta) is a member of a large family of pleiotropic cytokines with three different isoforms (TGFbeta1,2,3)."( Immunopathogenesis of psoriasis: a possible role of TGFbeta/Smads pathway.
Corbelli, E; Fargnoli, MC; Gaudio, E; Pellegrini, C; Peris, K; Sferra, R; Vetuschi, A, 2014
)
1.12
"Transforming growth factor beta (TGF-β) is a cytokine with a dual role in the regulation of immune responses including those against parasites."( TGF-β in Toxoplasmosis: Friend or foe?
Abdollahi, SH; Arababadi, MK; Assar, S; Hakimi, H; Kennedy, D; Nosratabadi, R; Zare-Bidaki, M, 2016
)
1.16
"Transforming growth factor beta (TGF-β) is a multifunctional regulatory cytokine that regulates many aspects of cellular function, including cellular proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immune surveillance, and survival."( TGF-β Effects on Prostate Cancer Cell Migration and Invasion Require FosB.
Barrett, CS; Khan, SA; Millena, AC, 2017
)
1.18
"Transforming growth factor beta (TGF-β) is a pleiotropic cytokine that has been shown to influence the differentiation and function of T cells. "( TGF-β regulation of encephalitogenic and regulatory T cells in multiple sclerosis.
Lee, PW; Lovett-Racke, AE; Severin, ME, 2017
)
1.9
"Transforming growth factor beta (TGF-β) is a key multifunctional factor from modulation of immunosurveillance to angiogenesis."( Tumor growth factor-β is an important factor for immunosuppression and tumorgenesis in Polyoma BK virus infection; a systematic review article.
Kariminik, A; Kheirkhah, B, 2017
)
1.18
"Transforming growth factor beta (TGFbeta) is an extracellular cytokine that regulates such critical cellular responses as proliferation, apoptosis, differentiation, angiogenesis and migration, and it is assumed that the latency-associated protein LTBP-1 plays a relevant role in TGFbeta targeting and activation in the extracellular matrix (ECM)."( Fitting a xenobiotic receptor into cell homeostasis: how the dioxin receptor interacts with TGFbeta signaling.
Carvajal-Gonzalez, JM; Fernandez-Salguero, PM; Gomez-Duran, A; Mulero-Navarro, S; Puga, A; Santiago-Josefat, B, 2009
)
1.07
"Transforming growth factor beta (TGF-beta) is a pleiotropic cytokine with vital homeostatic functions. "( Transforming growth factor beta as a therapeutic target in systemic sclerosis.
Pasche, B; Varga, J, 2009
)
3.24
"Transforming growth factor beta (TGFbeta) is a profibrotic factor that increases fibroblast proliferation, stimulates the synthesis and deposition of connective tissue, and inhibits connective tissue breakdown."( Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast.
Gharaee-Kermani, M; Gyetko, MR; Hu, B; Phan, SH, 2009
)
1.07
"Transforming growth factor beta (TGF-beta) is a crucial mediator of breast development, and loss of TGF-beta-induced growth arrest is a hallmark of breast cancer. "( A functional connection between pRB and transforming growth factor beta in growth inhibition and mammary gland development.
Bergsied, J; Chakrabarti, S; Coschi, CH; Dick, FA; Dimattia, GE; Francis, SM; Hojilla, CV; Isaac, CE; Khoka, R; Martens, AL; Wang, JY, 2009
)
2.06
"Transforming growth factor beta (TGF-beta) is a potent inhibitor of 17alpha-hydroxylase/17,20 lyase activity and CYP17 gene expression. "( TGF-beta inhibits CYP17 transcription in H295R cells acting via activin receptor-like kinase 5.
Derebecka-Holysz, N; Holysz, M; Lehmann, TP; Trzeciak, WH, 2009
)
1.8
"The transforming growth factor beta (TGFbeta) is a potent regulator of tumor initiation, progression and metastasis. "( Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis.
Bierie, B; Moses, HL, 2009
)
0.91
"Transforming growth factor beta-1 (TGF-beta1) is a pleiotropic cytokine with both pro- and antiinflammatory properties, depending on its environment and concentration. "( Preliminary studies on the effects of orally-administered Transforming Growth Factor-beta on protozoan diseases in mice.
Inoue, N; Namangala, B; Sugimoto, C, 2009
)
1.8
"Transforming growth factor beta (TGF-beta) is a crucial cytokine with pleiotropic functions on immune cells. "( Smad3 differentially regulates the induction of regulatory and inflammatory T cell differentiation.
Chung, Y; Dong, C; Feng, XH; Jetten, AM; Lin, X; Martinez, GJ; Reynolds, JM; Zhang, Z, 2009
)
1.8
"Transforming growth factor beta 1 (TGF-beta1) is a causal factor in ascending aortic dilatation; however, a role in AAA pathology is unclear."( Assessment of the association between genetic polymorphisms in transforming growth factor beta, and its binding protein (LTBP), and the presence, and expansion, of Abdominal Aortic Aneurysm.
Biros, E; Cooper, JA; Drenos, F; Golledge, J; Hafez, H; Humphries, SE; Jones, GT; Norman, PE; Thompson, AR; van Bockxmeer, FM; van Rij, AM; Walker, PJ, 2010
)
1.32
"Transforming growth factor beta (TGFbeta) is a growth factor with many faces. "( A role for age-related changes in TGFbeta signaling in aberrant chondrocyte differentiation and osteoarthritis.
Blaney Davidson, EN; van den Berg, WB; van der Kraan, PM, 2010
)
1.8
"Transforming growth factor beta (TGF-beta) acts as a tumor promoter by inducing epithelial-mesenchymal transition (EMT), which leads to a motile phenotype, enabling invasion and metastasis of cancer cells. "( TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
Räsänen, K; Vaheri, A, 2010
)
1.8
"Transforming growth factor beta (TGF-beta) is a master regulator of autocrine and paracrine signaling pathways between a tumor and its microenvironment. "( Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.
Aakre, ME; An, AQ; Cheng, N; Eng, J; Jovanovic, B; Link, AJ; Moses, HL; Xu, BJ; Yan, W; Yi, Y, 2010
)
1.8
"Transforming growth factor beta (TGFbeta) is a key-player in fibroblast activation and tissue fibrosis in SSc."( Vascular alterations upon activation of TGFbeta signaling in fibroblasts--implications for systemic sclerosis.
Distler, JH; Horn, A, 2010
)
1.08
"Transforming growth factor beta (TGF-beta) is a major fibrotic mediator known to stimulate fibrosis."( IM-412 inhibits transforming growth factor beta-induced fibroblast differentiation in human lung fibroblast cells.
Ahn, JY; Jeong, G; Kim, MH; Lee, SL; Lim, MJ; Park, S; Song, JY; Yun, YS, 2010
)
1.43
"Transforming growth factor beta (TGFβ) is a key regulator of epithelial cell proliferation, immune function and angiogenesis. "( TGFβ signaling in head and neck squamous cell carcinoma.
Malkoski, SP; Wang, XJ; White, RA, 2010
)
1.8
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine pivotal in the regulation of hepatic cell growth, differentiation, migration, extracellular matrix production, stem cell homeostasis, and hepatocarcinogenesis."( Cytosolic phospholipase A2alpha and peroxisome proliferator-activated receptor gamma signaling pathway counteracts transforming growth factor beta-mediated inhibition of primary and transformed hepatocyte growth.
Bowen, WC; Demetris, AJ; Han, C; Li, G; Michalopoulos, GK; Wu, T, 2010
)
1.29
"Transforming growth factor beta (TGFB) is a multifunctional cytokine that regulates proliferation, differentiation, and invasiveness of multiple cell lineages."( Transforming growth factor Beta regulates proliferation and invasion of rat placental cell lines.
Asselin, E; Chaudhry, P; Lafleur, MJ; Lafontaine, L; Soares, MJ; Van Themsche, C, 2011
)
2.53
"The transforming growth factor beta (TGFβ) is a potent inducer of EMT like effects, but the mechanisms that regulate TGFβ-induced EMT remain incompletely understood."( Suppression of TGFβ-induced epithelial-mesenchymal transition like phenotype by a PIAS1 regulated sumoylation pathway in NMuMG epithelial cells.
Bonni, S; Netherton, SJ, 2010
)
0.84
"Transforming growth factor beta (TGF-β) is an important regulator of cell growth, and loss of TGF-β signaling is a hallmark of carcinogenesis. "( Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer.
Baek, HJ; Berry, DL; Kallakury, B; Kim, SS; Kim, TH; Mendelson, J; Mishra, B; Mishra, L; Pishvaian, MJ; Reddy, EP; Shetty, K; Shin, KH; Tang, Y; Yang, S; Zouhairi, ME, 2011
)
1.81
"Transforming growth factor beta 1 (TGF-beta1) is a major participant in the airway remodeling of asthma, a component of cellular stress response pathways, and enhanced epithelial immunoreactivity is known to occur in allergic rhinitis."( Transforming growth factor beta: a role in the upper airway and rhinosinusitis-Dermatophagoides pteronyssinus-induced apoptosis with pulmonary alveolar cells.
Frieri, M; Frisella, PD; Joks, R; Silverberg, J,
)
2.3
"Transforming growth factor beta (TGFβ) is a multipotent cytokine that is sequestered in the extracellular matrix (ECM) through interactions with a number of ECM proteins. "( Matrix-dependent perturbation of TGFβ signaling and disease.
Dietz, HC; Doyle, JJ; Gerber, EE, 2012
)
1.82
"Transforming growth factor beta (TGF-beta) is a cytokine with numerous activities related to wound healing."( Flexor tendon healing in vitro: effects of TGF-beta on tendon cell collagen production.
Chang, J; Klein, MB; Longaker, MT; Pham, H; Yalamanchi, N, 2002
)
1.04
"Transforming growth factor beta (TGF beta) is a family of multifunctional cytokines, which play a central role in wound healing and fibrosis."( Genetic susceptibility to keloid disease and transforming growth factor beta 2 polymorphisms.
Bayat, A; Bock, O; Ferguson, MW; Mrowietz, U; Ollier, WE, 2002
)
1.3
"Transforming growth factor beta1 is a multifunctional cytokine involved in many aspects of wound healing. "( Latent and active transforming growth factor beta1 released from genetically modified keratinocytes modulates extracellular matrix expression by dermal fibroblasts in a coculture system.
Bauer, BS; Ghahary, A; Marcoux, Y; Scott, PG; Tredget, EE, 2002
)
2.09
"Transforming growth factor beta3 (TGF-beta3) is an important mediator of growth, maintenance, and repair processes in human cells. "( Dynamics-modulated biological activity of transforming growth factor beta3.
Arseniev, AS; Arvinte, T; Billeter, M; Blommers, MJ; Bocharov, EV; Korzhnev, DM; Orekhov, VY, 2002
)
2.02
"Transforming growth factor beta (TGF-beta) is a major promoter of diabetic nephropathy. "( Streptozocin diabetes elevates all isoforms of TGF-beta in the rat kidney.
Lane, PH; Langer, WJ; Snelling, DM, 2001
)
1.75
"Transforming growth factor beta1 (TGF-beta1) is an abundant growth factor that is known to stimulate bone formation."( TGF-beta1 inhibits multiple caspases induced by TNF-alpha in murine osteoblastic MC3T3-E1 cells.
Chen, Z; Chua, BH; Chua, CC; Hamdy, RC; Landy, C, 2002
)
1.04
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine that is frequently expressed in multiple types of malignant brain tumors."( The role of transforming growth factor-beta in primary brain tumors.
Rich, JN, 2003
)
1.04
"Transforming growth factor beta (TGF-beta) is a multifunctional protein that has been shown to possess potent growth-inhibitory activity. "( Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase.
Aakre, ME; Anderson, SN; Glaser, KB; Lee, P; Li, J; Morgan, DW; Moses, HL; Mussatto, DJ; O'Connor, CZ; Pollock, J; Sheppard, G; Stewart, KD; Wegner, CW, 2002
)
3.2
"Transforming growth factor beta1 (TGF-beta 1) is a potent VSMC differentiation factor; however, it is not known if other TGF-beta-superfamily members, in particular the bone morphogenetic proteins (BMPs), modulate VSMC phenotype."( Krüppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor beta 1 in the regulation of vascular smooth muscle cell phenotype.
Iyemere, VP; King, KE; Shanahan, CM; Weissberg, PL, 2003
)
1.27
"Transforming growth factor beta (TGFbeta) is a critical immunosuppressive cytokine that inhibits the cell-mediated immune responses partly via inhibition of immunostimulatory cytokine production from T cells, NK cells, and macrophages. "( TGFbeta down-regulates IFN-gamma production in IL-18 treated NK cell line LNK5E6.
Hayashi, H; Inoue, Y; Nakanishi, K; Okamura, H; Onozaki, K; Tsutsui, H, 2003
)
1.76
"Transforming growth factor beta1 (TGFbeta1) is a negative growth regulator in keratinocytes, and in vitro studies lead to the concept that loss of TGFbeta1 responsiveness is a critical step in epithelial carcinogenesis."( Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis.
Brentani, MM; Brentani, RR; Federico, MH; Kowalski, LP; Logullo, AF; Miguel, RE; Nishimoto, IN; Nonogaki, S; Pasini, FS, 2003
)
3.2
"Transforming growth factor beta (TGFbeta) is a regulator of embryonic development. "( Expression of the type III TGFbeta receptor during chick organogenesis.
Barnett, JV; Olivey, HE; Ridley, BD, 2003
)
1.76
"As transforming growth factor beta is a potent inhibitor of keratinocyte proliferation, we hypothesized that transforming growth factor beta contributes to epidermal growth factor-mediated keratinocyte growth inhibition."( Keratinocyte growth inhibition by high-dose epidermal growth factor is mediated by transforming growth factor beta autoinduction: a negative feedback mechanism for keratinocyte growth.
Fujii, M; Gamou, S; Hanakawa, Y; Hashimoto, K; Miyazono, K; Ohtsubo, M; Sayama, K; Shimizu, N; Shirakata, Y; Takayanagi, A; Toriu, N; Yamasaki, K, 2003
)
1.06
"Transforming growth factor beta (TGF-beta) is a growth-inhibitory cytokine for epithelial cells. "( Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model.
Glick, AB; Lee, J; Vijayachandra, K, 2003
)
1.76
"Transforming growth factor beta 1 (TGFbeta1) is a major fibrogenic cytokine, the expression of which is increased in the livers of children with cystic fibrosis liver disease (CFLD) and in the bronchoalveolar lavage fluid of patients with cystic fibrosis pulmonary disease (CFPD). "( Plasma markers of platelet activation in cystic fibrosis liver and lung disease.
Durant, M; Jones, L; Narkewicz, MR; Potter, C; Rosensweig, J; Schwarz, KB; Sharma, S, 2003
)
1.76
"Transforming growth factor beta1 (TGFbeta1) is a potent inhibitor of epithelial cell growth, thus playing an important role in tissue homeostasis. "( TGFbeta1 signaling via alphaVbeta6 integrin.
Kracklauer, MP; Schmidt, C; Sclabas, GM, 2003
)
1.76
"Transforming growth factor beta1 (TGF-beta1) is a pleiotropic cytokine, which displays potent profibrogenic effects and is highly expressed in fibrotic livers. "( A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury.
Blanco, G; Borrás-Cuesta, F; Bustos, M; Castilla-Cortázar, I; Dotor, J; Ezquerro, IJ; Greenwel, P; Lasarte, JJ; Lechuga, Mdel C; Peñuelas, I; Prieto, J; Rodríguez, C; Rojkind, M, 2003
)
2.07
"Transforming growth factor beta (TGF-beta) is an immunoregulatory cytokine present in high concentration in maternal milk."( Maternal milk regulation of cell infiltration and interleukin 18 in the intestine of suckling rat pups.
Flesch, IE; McCue, AL; Penttila, IA; Powell, BC; Read, LC; Zhou, FH; Zola, H, 2003
)
1.04
"Transforming growth factor beta (TGFbeta) is a multifunctional growth factor that is produced by many cells in bone and is abundant in the bone matrix. "( Transforming growth factor-beta induces osteoclast formation in the absence of RANKL.
Athanasou, NA; Danks, L; Ferguson, D; Fujikawa, Y; Itonaga, I; Kudo, O; Sabokbar, A; Sun, SG, 2004
)
1.77
"Transforming growth factor beta (TGFbeta) is a multifunctional polypeptide. "( Tumor-suppressive and promoting function of transforming growth factor beta.
Sun, L, 2004
)
2.03
"Transforming growth factor beta (TGF-beta) is a cytokine which has been shown to suppress the antimycobacterial immune responses of humans and experimental animals. "( Effect of neutralizing transforming growth factor beta1 on the immune response against Mycobacterium tuberculosis in guinea pigs.
Allen, SS; Cassone, L; Lasco, TM; McMurray, DN, 2004
)
2.08
"Transforming growth factor beta (TGF-beta) is an example for a large and still-growing family of growth factors. "( Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5'-untranslated-region and exon-1 polymorphisms.
Bairwa, NK; Bamezai, R; Gupta, V; Malhotra, D; Saha, A, 2004
)
1.77
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine endowed with both tumor-suppressing and tumor-promoting activities."( Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells.
Schiemann, WP; Sokol, JP, 2004
)
1.36
"Transforming growth factor beta (TGF-beta) is a key cytokine in the pathogenesis of tissue fibrosis."( Inhibition of TGF-beta-induced collagen production in rabbit flexor tendons.
Chang, J; Ho, F; Longaker, MT; Pham, H; Teng, K; Zhang, AY, 2004
)
1.04
"Transforming growth factor beta (TGF-beta) is a potent regulator of cell growth and differentiation in many cell types. "( Smad7 is required for TGF-beta-induced activation of the small GTPase Cdc42.
Aspenström, P; Edlund, S; Heldin, CH; Landström, M, 2004
)
1.77
"Transforming growth factor beta (TGF-beta) is a potent growth inhibitor and has tumor-suppressing activity in the early phases of carcinogenesis."( The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Emi, M; Kim, R; Tanabe, K; Toge, T; Uchida, Y, 2004
)
1.34
"Transforming growth factor beta1 (TGF-beta1) is a multifunctional poly-peptide that regulates cell growth and differentiation, ECM deposition, cellular adhesion properties, angiogenesis, and also immune functions."( Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells.
Hirakawa, K; Maeda, K; Nishihara, T; Ohira, M; Sawada, T; Uchima, Y, 2004
)
1.04
"Transforming growth factor beta (TGFbeta) is a multifunctional cytokine with effects on many cell types. "( TGFbeta down-regulation of the CFTR: a means to limit epithelial chloride secretion.
Howe, KL; Hunter, MM; McKay, DM; Stanton, BA; Wang, A, 2004
)
1.77
"Transforming growth factor beta (TGF-beta) is a multifunctional growth factor that variably affects proliferation, differentiation, and extracellular matrix formation. "( Expression of transforming growth factor beta isoforms and their receptors in malignant fibrous histiocytoma of soft tissues.
Akisue, T; Fujita, I; Hitora, T; Kawamoto, T; Kurosaka, M; Marui, T; Matsumoto, K; Nagira, K; Nakatani, T; Yamamoto, T, 2004
)
2.13
"Transforming growth factor beta (TGF-beta) is a pluripotent cytokine that controls key tumour suppressive functions, but cancer cells are often unresponsive to it. "( Cytoplasmic PML function in TGF-beta signalling.
Bergmann, S; Lin, HK; Pandolfi, PP, 2004
)
1.77
"Transforming growth factor beta (TGF-beta) is a potent inhibitor of hepatocyte proliferation in vitro and is suggested to be a key negative regulator of liver growth. "( Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice.
Conner, EA; Factor, VM; Karlsson, S; Larsson, J; Lemmer, ER; Levéen, P; Oe, S; Thorgeirsson, SS, 2004
)
2.09
"Transforming growth factor beta (TGFbeta) is a central mitoinhibitory factor for epithelial cells, and alterations of TGFbeta signalling have been demonstrated in many different human cancers. "( Factors of transforming growth factor beta signalling are co-regulated in human hepatocellular carcinoma.
Breuhahn, K; Longerich, T; Odenthal, M; Petmecky, K; Schirmacher, P, 2004
)
2.16
"Transforming growth factor beta (TGFbeta) is a secreted protein present in the circulation and is a critical regulator of the body's immune system. "( Genotypic analysis of the TGF beta-509 allele in patients with systemic lupus erythematosus and Sjogren's syndrome.
Arnett, FC; Brown, TL; Caserta, TM; Knisley, AA; Tan, FK,
)
1.57
"Transforming growth factor beta (TGF-beta) is a polypeptide found in high concentrations in bone and is produced by and acts on primary adult human derived osteoblast-enriched cultures (PHO cells). "( TGF-beta and PDGF act synergistically in affecting the growth of human osteoblast-enriched cultures.
Coats, SR; Hoover, RL; Kells, AF; Schwartz, HS, 1995
)
1.73
"Transforming growth factor beta1 (TGFbeta1) is a profibrotic cytokine that stimulates excessive collagen production in patients with scleroderma or other fibrotic diseases."( Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts.
Arnett, FC; Guo, X; Milewicz, DM; Tan, FK; Wallis, D; Xue, S; Zhou, X, 2005
)
1.28
"Transforming growth factor beta (TGF(beta)) is a major coupling factor for bone turnover and is known to stimulate osteoblastic proliferation. "( Prostaglandin-dependent activation of ERK mediates cell proliferation induced by transforming growth factor beta in mouse osteoblastic cells.
Caverzasio, J; Ghayor, C; Rey, A, 2005
)
2
"Transforming growth factor beta1 (TGF beta1) is a well-characterized cytokine that suppresses epithelial cell growth. "( TGF beta1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells.
Choi, KS; Hwang, SC; Lee, JH; Yoon, G; Yoon, YS, 2005
)
1.77
"Transforming growth factor beta (TGFbeta) is a key regulator of epithelial-to-mesenchymal transition (EMT)."( Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity.
Barrios-Rodiles, M; Bose, R; Ozdamar, B; Wang, HR; Wrana, JL; Zhang, Y, 2005
)
1.05
"Transforming growth factor beta (TGF-beta) is a ubiquitous and essential regulator of cellular and physiologic processes including proliferation, differentiation, migration, cell survival, angiogenesis, and immunosurveillance. "( Role of transforming growth factor Beta in human cancer.
Blobe, GC; Elliott, RL, 2005
)
2.21
"Transforming growth factor beta1 (TGFbeta1) is a potent negative immunoregulatory molecule. "( Elimination of both CD4+ and CD8+ T cells but not B cells eliminates inflammation and prolongs the survival of TGFbeta1-deficient mice.
Babcock, GF; Boivin, GP; Bommireddy, R; Doetschman, T; Engle, SJ; Ormsby, I,
)
1.57
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine involved in the regulation of cell proliferation, differentiation and survival/or apoptosis of many cells. "( TGF beta signalling and its role in tumour pathogenesis.
Danilkiewicz, M; Kaminska, B; Wesolowska, A, 2005
)
1.77
"Transforming growth factor beta (TGFbeta) is a multifunctional peptide that plays play a crucial role in inducing and maintaining chondrogenic differentiation."( In-vitro analysis of the expression of TGFbeta -superfamily-members during chondrogenic differentiation of mesenchymal stem cells and chondrocytes during dedifferentiation in cell culture.
Bieback, K; Bugert, P; Deml, M; Goessler, UR; Hormann, K; Riedel, F; Sadick, H, 2005
)
1.05
"Transforming growth factor beta1 (TGFbeta1) is a bioactive molecule that has been shown to affect fibroblast function."( Altered fibroblast function following myocardial infarction.
Escobar, GP; Flack, EC; Goshorn, DK; Leonardi, RA; Lindsey, ML; Mains, IM; Mingoia, JT; Payne, JF; Sheats, NJ; Squires, CE, 2005
)
1.05
"Transforming Growth Factor beta 1 (TGFbeta1) is a key cytokine in the development of fibrotic diseases which are characterized by a pathological excess of extracellular matrix involving multiple organs."( [Involvement of TGFbeta1 in fibrotic diseases: role of its effectors, the Smad proteins].
Dennler, S; Farge, D; Laboureau, J; Mauviel, A; Verrecchia, F, 2006
)
1.78
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine that exhibits potent immunoregulatory and anti-inflammatory properties and may prolong graft survival."( Transforming growth factor beta-1 influence on fetal allografts during pregnancy.
Ayatollahi, M; Geramizadeh, B; Samsami, A, 2005
)
2.49
"Transforming growth factor beta 1 (TGF-beta1) is a proposed regulator of Ids (inhibitors of DNA binding/differentiation) gene expression in epithelial cells. "( TGF-beta1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells.
Damdinsuren, B; Dono, K; Hanada, H; Kato, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Natsag, J; Takeda, Y; Umeshita, K; Wada, H, 2006
)
1.78
"Transforming growth factor beta (TGF-beta) is a biologically multipotent regulatory protein implicated in functions that include the regulation of cellular growth, differentiation, extracellular matrix formation, and wound healing. "( The role of transforming growth factor beta signaling in messenger RNA stability.
Amara, FM; Dibrov, A; Kashour, T, 2006
)
2.16
"Transforming growth factor beta (TGF-beta) is a pluripotent cytokine that regulates cell growth and differentiation in a cell type-dependent fashion. "( Cell type-dependent control of NF-Y activity by TGF-beta.
Alabert, C; Blanchard, JM; Cerulis, S; Fafet, P; Hipskind, RA; Kahn, L; Niellez, S; Rogers, L; Vignais, ML, 2006
)
1.78
"Transforming growth factor beta-1 (TGF-beta1) is a pleiotropic cytokine known to have powerful effects on cell growth, apoptosis, cell differentiation, and extracellular matrix synthesis."( Transforming growth factor-beta1 antisense treatment of rat vein grafts reduces the accumulation of collagen and increases the accumulation of h-caldesmon.
Heaton, NS; Hoch, JR; Hullett, DA; Malinowski, RL; Wolff, RA, 2006
)
1.06
"Transforming growth factor beta (TGF-beta) is a ubiquitous cytokine that plays a critical role in numerous pathways regulating cellular and tissue homeostasis. "( The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs.
Barcellos-Hoff, MH; Fleisch, MC; Maxwell, CA, 2006
)
2.08
"Transforming growth factor beta (TGF-beta) is an important tumor suppressor in the colon, and it is inactivated during later stages of colorectal carcinogenesis."( TGF-beta inhibits Akt-induced transformation in intestinal epithelial cells.
Cao, Y; Deng, C; Ko, TC; Townsend, CM, 2006
)
1.06
"Transforming growth factor beta (TGF-beta) is an extracellular signaling molecule known to mediate programmed cell death (PCD) in the developing retina. "( Transforming growth factor beta mediates apoptosis in the ganglion cell layer during all programmed cell death periods of the developing murine retina.
Beier, M; Dünker, N; Franke, A; Paunel-Görgülü, AN; Scheerer, N, 2006
)
3.22
"Transforming Growth Factor beta 1(TGF-beta1) is a key effector cytokine in the development of lung fibrosis."( Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells.
Doran, PP; Egan, JJ; Keating, DT; Patricelli, A; Sadlier, DM; Smith, SM; Walls, D, 2006
)
1.06
"Transforming growth factor beta (TGFbeta) is a potent trophic factor for midbrain dopamine (DA) neurons, but its in vivo function and signaling mechanisms are not entirely understood. "( Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons.
Bonasera, SJ; Hellmuth, J; Holtzman, J; Huang, EJ; Janak, PH; Pho, V; Tang, AT; Tang, S; Tecott, LH; Zhang, J, 2007
)
1.78
"Transforming growth factor beta (TGF-beta) is a major mitogen mediating mesenchymal cell proliferation and epithelial to mesenchymal cell transition in CAN."( The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression.
Rintala, JM; Rintala, SE; Savikko, J; von Willebrand, E, 2006
)
1.06
"Transforming growth factor beta (TGF-beta) is a cytokine engaged in a wide range of diverse and often contradictory functions. "( Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'.
Dabek, J; Gasior, Z; Kułach, A; Monastyrska-Cup, B,
)
3.02
"Transforming growth factor beta (TGFbeta) is a pleiotropic factor that regulates cell proliferation, angiogenesis, metastasis, and immune suppression. "( Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Chakravarty, S; Damm, DL; Gaspar, NJ; Henson, M; Higgins, LS; Kapoun, AM; Li, G; Li, L; Medicherla, S; Muiru, GT; Murphy, A; O'Young, G; Quon, D; Reddy, M; Wong, DH, 2007
)
2.14
"Transforming growth factor beta (TGF-beta) is a highly pleiotropic cytokine that plays an important role in wound healing, angiogenesis, immunoregulation and cancer. "( Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations.
Prud'homme, GJ, 2007
)
2.13
"Transforming growth factor beta1 (TGFbeta) is a tumor suppressor during the initial stage of tumorigenesis, but it can switch to a tumor promoter during neoplastic progression. "( Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition.
Andarawewa, KL; Barcellos-Hoff, MH; Bissell, MJ; Chou, WS; Costes, SV; Erickson, AC; Gascard, P; Mott, JD, 2007
)
2.01
"Transforming growth factor beta (TGF-beta) is a pleiotropic cytokine with important roles in the regulation of cell proliferation, differentiation, survival, migration, activation and de-activation. "( Molecular and functional characterization of goldfish (Carassius auratus L.) transforming growth factor beta.
Belosevic, M; Grayfer, L; Haddad, G; Hanington, PC; Wilson, EC, 2008
)
2.02
"Transforming growth factor beta (TGF-beta) is a dominant mediator of pancreatic fibrosis. "( Expression of transforming growth factor beta by small duct epithelium in chronic, cancer-associated, obstructive pancreatitis: an in situ hybridization study and review of the literature.
Fukumura, Y; Kumasaka, T; Mitani, K; Suda, K; Takase, M, 2007
)
2.14
"Transforming growth factor beta (TGFbeta) is a key remodelling factor in asthma. "( Tryptase activates TGFbeta in human airway smooth muscle cells via direct proteolysis.
Jenkins, G; Knox, A; Pang, L; Porte, J; Tatler, AL, 2008
)
1.79
"Transforming growth factor beta (TGF-beta) is a potent inhibitor of the proliferation of many cell lines. "( TGF-beta 1 and cAMP attenuate cyclin A gene transcription via a cAMP responsive element through independent pathways.
Barlat, I; Blanchard, JM; Fernandez, A; Henglein, B; Lamb, N; McKenzie, F; Plet, A; Pouysségur, J; Vié, A, 1995
)
1.73
"Transforming growth factor beta (TGF beta) is a potent inhibitor of epithelial cell growth. "( Transforming growth factor-beta 1 (TGF beta 1) enhances apoptosis in human papillomavirus type 16-immortalized human ectocervical epithelial cells.
Jacobberger, JW; Rorke, EA, 1995
)
1.73
"Transforming growth factor beta (TGF-beta) is a bifunctional regulator of the growth of myeloid progenitors and is here demonstrated to directly inhibit the growth of primitive erythroid progenitors by 95% to 100% regardless of the cytokines stimulating growth. "( Transforming growth factor beta (TGF-beta), a potent inhibitor of erythropoiesis: neutralizing TGF-beta antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activ
Dybedal, I; Jacobsen, SE, 1995
)
3.18
"Transforming growth factor beta (TGF beta) is a pluripotent modulator of cell function and an important suppressor of cervical epithelial cell proliferation. "( Transforming growth factor beta regulation of epidermal growth factor receptor in ectocervical epithelial cells.
Gorodeski, G; Jacobberger, JW; Rorke, EA; Sizemore, N, 1995
)
3.18
"Transforming growth factor beta (TGF-beta) is a multifunctional peptide that controls proliferation, differentiation, and other functions in a variety of cell types. "( Development and characterization of murine monoclonal antibodies to the latency-associated peptide of transforming growth factor beta 1.
Fendly, BM; Hongo, JA; Lucas, C; Mora-Worms, M, 1995
)
1.95
"Transforming growth factor beta (TGF-beta) is a hormonally regulated growth inhibitor with autocrine and/or paracrine functions in human breast cancer. "( Transforming growth factor beta secretion from primary breast cancer fibroblasts.
Claassen, C; Eggermont, AM; Foekens, JA; Henzen-Logmans, SC; Klijn, JG; van Ooijen, B; van Roozendaal, CE, 1995
)
3.18
"Transforming growth factor beta (TGF-beta) is a family of proteins which act as a potent growth inhibitor for most cell types including epithelial cells. "( Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue.
Eklöv, S; Funa, K; Kanzaki, T; Miyazono, K; Nilsson, S; Nordgren, H; Olofsson, A, 1993
)
2.06
"Transforming growth factor beta (TGF-beta) is a cytokine that modulates many cellular functions."( Transforming growth factor beta differentially modulates the inducible nitric oxide synthase gene in distinct cell types.
Gilbert, RS; Herschman, HR, 1993
)
2.45
"Transforming growth factor beta (TGF beta) is an important regulator of cellular proliferation. "( Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.
Bast, RC; Berchuck, A; Davis, P; Elbendary, A; Havrilesky, L; Iglehart, JD; Marks, JR, 1994
)
3.17
"Transforming growth factor beta (TGF-beta) is a potent modulator of cell growth in many systems. "( Induction of epidermal growth factor receptor gene transcription by transforming growth factor beta 1: association with loss of protein binding to a negative regulatory element.
Hou, X; Johnson, AC; Rosner, MR, 1994
)
1.97
"Transforming growth factor beta (TGF beta 1) is a prosclerotic cytokine implicated in several disease processes. "( Transforming growth factor beta 1 in renal allograft recipients.
Brenchley, PE; Coupes, BM; Newstead, CG; Short, CD, 1994
)
3.17
"Transforming growth factor beta is a multifunctional protein with known actions on bone and bone cells. "( Systemic administration of recombinant transforming growth factor beta 2 (rTGF-beta 2) stimulates parameters of cancellous bone formation in juvenile and adult rats.
Adams, S; Bentz, H; DeLeon, E; Mathews, M; Miller, SC; Rosen, D; Thompson, AY,
)
1.84
"Transforming growth factor beta (TGF-beta) is an immunomodulatory cytokine regulating the proliferation and differentiation of various cell types. "( Transforming growth factor beta in normal human lung: preferential location in bronchial epithelial cells.
Emilie, D; Fattal, M; Frachon, I; Galanaud, P; Lenot, B; Magnan, A; Monti, G; Peuchmaur, M; Rain, B; Simonneau, G, 1994
)
3.17
"Transforming growth factor beta (TGF-beta) is a multifunctional polypeptide that regulates the proliferation and differentiation of various cells and has an angiogenic effect in vivo, although it inhibits the growth of cultured endothelial cells. "( Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells.
Alitalo, K; Ferrara, N; Kaipainen, A; Mustonen, T; Orpana, A; Pertovaara, L; Saksela, O, 1994
)
1.73
"Transforming growth factor beta (TGF-beta) is a potent inhibitor of epithelial cell growth. "( A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells.
Alexander, D; Hengst, L; Pan, CH; Reed, SI; Slingerland, JM; Stampfer, MR, 1994
)
1.98
"Transforming growth factor beta is a known inhibitor of the proliferation and differentiation of early haematopoietic progenitors but has no effect on mature erythroid cells in vitro. "( Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necrosis factor in vivo.
Caro, J; Carter, CD; Chuncharunee, S; Coffey, RJ; Dessypris, EN; Studtmann, KE, 1993
)
1.73
"Transforming growth factor beta (TGF-beta) is a multipotent regulator of cell proliferation and extracellular matrix production. "( Correlation of the size of type II transforming growth factor beta (TGF-beta) receptor with TGF-beta responses of isolated bovine articular chondrocytes.
Glansbeek, HL; van den Berg, WB; van der Kraan, PM; Vitters, EL, 1993
)
2.01
"Transforming growth factor beta (TGF-beta) is a multifunctional factor that regulates many aspects of cellular functions. "( A transforming growth factor beta type I receptor that signals to activate gene expression.
Bassing, CH; Donahoe, PK; Gustafson, ML; He, WW; Howe, DJ; Shah, P; Wang, T; Wang, XF; Yingling, JM, 1994
)
2.45
"Transforming growth factor beta 1 (TGF-beta) is a potent modulator of immune function."( TGF-beta 1 inhibits both endotoxin-induced prostaglandin synthesis and expression of the TIS10/prostaglandin synthase 2 gene in murine macrophages.
Gilbert, RS; Herschman, HR; Luner, S; Reddy, ST; Xie, W, 1994
)
1.01
"Transforming growth factor beta (TGF-beta) is a cytokine with potent immunosuppressive properties."( Increased production of TGF-beta and Il-6 by aged spleen cells.
Adler, W; Chrest, FJ; Munster, A; Winchurch, RA; Zhou, D, 1993
)
1.01
"Transforming growth factor beta (TGF-beta) is an important regulator of cell growth and differentiation. "( Cranial neural crest cells synthesize and secrete a latent form of transforming growth factor beta that can be activated by neural crest cell proteolysis.
Brauer, PR; Yee, JA, 1993
)
1.96
"Transforming growth factor beta (TGF-beta) is a cytokine with immunoregulatory properties that acts negatively on T lymphocyte proliferation. "( Contrasting effect of transforming growth factor type beta 1 (TGF-beta 1) on proliferation and interleukin-2 receptor expression in activated and rapidly cycling immature (CD3-CD4-CD8-) thymocytes.
Dornand, J; Duperray, C; Dupuy d'Angeac, A; Gao, Q; Jullien, P; Monier, S; Rème, T, 1993
)
1.73
"The transforming growth factor beta s are a homologous family of multifunctional cytokines that regulate cell growth and differentiation. "( Transforming growth factor beta 1: NMR signal assignments of the recombinant protein expressed and isotopically enriched using Chinese hamster ovary cells.
Archer, SJ; Bax, A; Lucas, R; Ogawa, Y; Piez, KA; Roberts, AB; Sporn, MB; Tsang, ML; Weatherbee, JA; Zheng, BL, 1993
)
2.29
"Transforming growth factor beta was shown to be a biphasic stimulator of [3H]thymidine uptake in HOS TE85, with maximal stimulation occurring at 0.5 nM transforming growth factor beta."( Fluoride-stimulated [3H]thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor beta.
Antich, PP; Pak, CY; Reed, BY; Zerwekh, JE, 1993
)
1.22
"Transforming growth factor beta (TGF-beta) is a putative mediator of fibrosis in several chronic diseases. "( Transforming growth factor beta promotes development of fibrosis after repeated courses of acute pancreatitis in mice.
Devière, J; Résibois, A; Robberecht, P; Van Laethem, JL, 1996
)
3.18
"Transforming growth factor beta (TGF beta) is a multipotent growth modulator thought to play a role in numerous developmental processes."( Expression of transforming growth factor beta in the embryonic avian lens coincides with the presence of mitochondria.
Bassnett, S; Beebe, DC; Potts, JD, 1995
)
1.37
"Transforming growth factor beta (TGF-beta) is a potent growth inhibitor of non-malignant breast tissue, and TGF-beta resistance could play a role in tumorigenesis. "( Growth inhibition by anti-estrogens and progestins in TGF-beta-resistant and -sensitive breast-tumor cells.
Beraldi, E; De Winter, JP; Kalkhoven, E; Panno, ML; Thijssen, JH; Van Der Burg, B, 1996
)
1.74
"Transforming growth factor beta1 (TGF-beta1) is an immunomodulator and potent chemotactic molecule present at elevated levels in HIV-1-infected patients, and its expression may thus be induced by viral trans-activating proteins such as Tat."( Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression.
Amini, S; Glorioso, JC; Gordon, J; Khalili, K; Rasty, S; Thatikunta, P, 1996
)
1.21
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine commonly produced by cultured melanoma cells."( Melanoma-associated expression of transforming growth factor-beta isoforms.
Elder, DE; Halpern, AC; Nuamah, I; Rodeck, U; Van Belle, P, 1996
)
1.02
"Transforming growth factor beta (TGF beta) is a multifunctional cytokine with potentially important roles in both host defence and immunopathogenesis. "( Activation of latent transforming growth factor beta during Chlamydia trachomatis-induced murine pneumonia.
Bonewald, LF; Grubbs, BG; Park-Snyder, S; Rank, RG; Williams, DM, 1996
)
2.06
"Transforming growth factor beta1 (TGF-beta1) is a potent growth inhibitor for a variety of cultured cells."( Transforming growth factor beta1 induces differentiation in human papillomavirus-positive keratinocytes.
Meyers, C; Ozbun, MA, 1996
)
2.46
"Transforming growth factor beta (TGF-beta) is an important regulator of bone metabolism, and is found in large quantities in embryonic and adult bone tissue. "( The influence of transforming growth factor beta 1 on the development of embryonic mouse long bones.
Burger, EH; Dieudonné, SC; Prahl-Andersen, B; Scheijmans, CM, 1996
)
2.08
"Transforming growth factor beta (TGF-beta) is a family of potent growth inhibitor proteins, often produced as a precursor and often secreted in a complex with the latent TGF-beta binding protein (LTBP). "( Expression of transforming growth factor beta isoforms and their receptors during hair growth phases in mice.
Funa, K; Lange, D; Paus, R; Wollina, U, 1996
)
2.1
"Transforming growth factor beta s (TGF beta) are a family of multifunctional growth factors that are important embryonic morphogens. "( Transforming growth factor beta in bovine placentas.
Boltz, VF; Munson, L; Wilhite, A; Wilkinson, JE, 1996
)
3.18
"Transforming growth factor beta 1 (TGF beta) is a multifunctional cytokine that orchestrates response to injury via ubiquitous cell surface receptors. "( Redox-mediated activation of latent transforming growth factor-beta 1.
Barcellos-Hoff, MH; Dix, TA, 1996
)
1.74
"Transforming growth factor beta (TGF-beta) is a family of proteins secreted by virtually all cells in a biologically inactive form. "( Influenza virus neuraminidase activates latent transforming growth factor beta.
Hinshaw, VS; Schultz-Cherry, S, 1996
)
1.99
"Transforming growth factor beta (TGF-beta) is a multifunctional factor that induces a wide variety of cellular processes which affect growth and differentiation. "( Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling.
Atfi, A; Chastre, E; Davis, R; Djelloul, S; Gespach, C, 1997
)
1.95
"Transforming growth factor beta (TGF-beta) is a major member of a cytokine family with pluripotent biological activity. "( Variation of immunocytochemical expression of transforming growth factor (TGF)-beta in hepatocytes in culture and liver slices.
Gressner, AM; Wulbrand, U, 1997
)
1.74
"Transforming growth factor beta1 (TGF-beta1) is an important modulator of skin morphogenesis and cutaneous wound repair. "( Differential expression of the calpactin I subunits annexin II and p11 in cultured keratinocytes and during wound repair.
Gerke, V; Gillitzer, R; Munz, B; Werner, S, 1997
)
1.74
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine that modulates biological events as diverse as wound healing and angiogenesis and which may be important in the pathogenesis of choroidal neovascularization. "( Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization.
Matsushima, M; Miyashiro, M; Ogata, N; Uyama, M; Yamada, H; Yamamoto, C, 1997
)
1.74
"Transforming growth factor beta1 (TGF-beta1) is a member of a gene superfamily involved in the regulation of cell growth and differentiation, tissue repair, fibrosis, and inflammatory responses. "( TGF-beta1 inhibits the release of histamine and tumor necrosis factor-alpha from mast cells through an autocrine pathway.
Befus, AD; Bissonnette, EY; Enciso, JA, 1997
)
1.74
"Transforming growth factor beta (TGF-beta) is a physiological regulator of thyroid epithelial cell growth and differentiation. "( Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.
Colletta, G; Lazzereschi, D; Mincione, G; Nardi, F; Ranieri, A; Taccogna, S, 1997
)
1.98
"Transforming growth factor beta-1 (TGF-beta1) is a potent inhibitor of hepatocyte growth both in vivo and in vitro. "( Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice.
Factor, VM; Jensen, MR; Kao, CY; Santoni-Rugiu, E; Thorgeirsson, SS; Woitach, JT, 1997
)
2.02
"Transforming growth factor beta (TGF-beta) is a multifunctional growth factor which promotes the inflammatory process. "( Enhancement of human neutrophil survival and activation by TGF-beta 1.
Gagnon, L; Lagraoui, M, 1997
)
1.74
"Transforming growth factor beta (TGF-beta) is a major secretory product of macrophages which, through autocrine/paracrine pathways, play a central role in normal reproductive tissues as well as in disorders such as endometriosis and intraperitoneal adhesion formation. "( Inhibition of transforming growth factor-beta 1 alters the growth, anchor-dependent cell aggregation and integrin mRNA expression in human promonocytes: implications for endometriosis and peritoneal adhesion formation.
Chegini, N; Dou, Q; Williams, RS, 1997
)
1.74
"Transforming growth factor beta (TGF-beta) is a potent growth-regulatory and immunomodulatory cytokine that exerts a diverse range of effects on many types of cells. "( Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo.
Fitzpatrick, DR; Marzo, AL; Robinson, BW; Scott, B, 1997
)
2.01
"Transforming growth factor beta-1 (TGF-beta1) is a ubiquitous cytokine with potent fibrogenic effects in both postnatal and fetal wounds."( Differential collagen I gene expression in fetal fibroblasts.
Alman, BA; Crombleholme, TM; Gallivan, K; Moriarty, KP; O'Donnell, C; Pajerski, ME, 1997
)
1.02
"Transforming growth factor beta-1 is a cytokine that plays multiple roles in wound healing but is also implicated in the pathogenesis of excessive scar formation."( Gene expression of transforming growth factor beta-1 in rabbit zone II flexor tendon wound healing: evidence for dual mechanisms of repair.
Chang, J; Hui, K; Lineaweaver, WC; Longaker, MT; Most, D; Siebert, JW; Stelnicki, E, 1997
)
1.35
"Transforming growth factor beta (TGF-beta) is a pluripotent peptide hormone that regulates various cellular activities, including growth, differentiation, and extracellular matrix protein gene expression. "( Regulation of the transforming growth factor beta-responsive transcription factor CTF-1 by calcineurin and calcium/calmodulin-dependent protein kinase IV.
Alevizopoulos, A; Dusserre, Y; Mermod, N; Rüegg, U, 1997
)
2.07
"Transforming growth factor beta (TGF-beta) is a potent inhibitor of the proliferation of many cell types. "( Regulation of cell cycle-related genes in rat hepatocytes by transforming growth factor beta1.
Moriwaki, H; Muto, Y; Nagaki, M; Shidoji, Y; Sugiyama, A, 1997
)
1.98
"Transforming growth factor beta1 (TGF-beta1) is a potent growth differentiation and morphogenesis factor. "( Role of carbohydrate structures in the binding of beta1-latency-associated peptide to ligands.
Dignam, JD; Gentry, LE; Yang, Y, 1997
)
1.74
"Transforming growth factor beta1 (TGFbeta1) is a potent growth inhibitor for most cells, including neoplastic cells. "( Transforming growth factor beta type I receptor acts as a potent tumor suppressor in rat bladder carcinoma.
Hattori, K; Okamoto, M; Oyasu, R, 1997
)
3.18
"Transforming growth factor beta (TGF-beta) is a potent inhibitor of cell growth and tumor progression. "( Decreased stability of transforming growth factor beta type II receptor mRNA in RER+ human colon carcinoma cells.
Banerji, SS; Brattain, MG; Jiang, W; Tillekeratne, MP, 1997
)
2.05
"Transforming growth factor beta1 (TGF-beta1) is a potent modulator of cell proliferation in vitro, and recent studies have demonstrated its overexpression in several different tumours; nevertheless, the molecular mechanisms of TGF-beta1 action on cell growth and differentiation have not been fully elucidated. "( Down-regulated expression of transforming growth factor beta 1 mRNA in endometrial carcinoma.
Cazzolla, A; Fiore, MG; Giannini, T; Loverro, G; Maiorano, E; Marra, E; Napoli, A; Perlino, E; Ricco, R; Selvaggi, L, 1998
)
2.03
"Transforming growth factor beta1 (TGF beta1) is a multifunctional factor that regulates many aspects of cellular functions such as epithelial cell growth and synthesis of extracellular matrices. "( Expression of transforming growth factor beta1 (TGFbeta1) and its receptors in pancreatic duct cell carcinoma and in chronic pancreatitis.
Hirota, M; Koizumi, M; Satoh, K; Shimosegawa, T; Toyota, T, 1998
)
2.1
"Transforming Growth Factor beta (TGF beta) is a regulatory peptide that acts by both autocrine and paracrine mechanisms to control proliferation and differentiation, and there is previous evidence that TGF beta may exert an antimitotic effect on human fetal adrenal cells in vitro."( Role of transforming growth factor beta 1 (TGF beta 1) in mediating androgen-induced growth inhibition in human adrenal cortex in vitro.
degli Uberti, EC; del Senno, L; Rossi, R; Zatelli, MC,
)
1.29
"The transforming growth factor beta's (TGFbeta) are a multipotent family of cytokines with strong immunosuppressive and neurotrophic effects. "( Transforming growth factor beta's 1, 2 and 3 inhibit proliferation of ramified microglia on an astrocyte monolayer.
Jones, LL; Kreutzberg, GW; Raivich, G, 1998
)
2.3
"Transforming growth factor beta is a potent immunomodulator with both pro- and antiinflammatory activities. "( Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model.
Gu, M; Jin, WW; Klinman, DM; Song, XY; Wahl, SM, 1998
)
1.74
"Transforming growth factor beta1 (TGF-beta1) is a potent immunosuppressive cytokine that promotes fibrosis by enhancing the synthesis of extracellular matrix components. "( Transforming growth factor-beta1 and lung allograft fibrosis.
Awad, M; Deiraniya, A; Egan, J; El-Gamel, A; Hasleton, P; Hutchinson, IV; Sim, E; Yonan, N, 1998
)
1.74
"Transforming growth factor beta (TGF beta) is a cytokine important in regulating tissue repair and regeneration after injury, and stimulating fibroblast proliferation and the production of FN and collagens."( Autocrine transforming growth factor beta stimulation of extracellular matrix production by fibroblasts from fibrotic human gingiva.
Dabbous, MK; Tipton, DA, 1998
)
1.42
"Transforming growth factor beta1 (TGF-beta1) is a multifunctional, profibrotic cytokine involved in cellular growth and differentiation. "( Tyrosine phosphorylation regulates H2O2 production in lung fibroblasts stimulated by transforming growth factor beta1.
Aldweib, KD; Fanburg, BL; Thannickal, VJ, 1998
)
1.97
"Transforming growth factor beta (TGF-beta) is a highly conserved peptide with growth-inhibitory activity in multiple normal and transformed cell types. "( TGF-beta and its receptor complex in leukemic B-cell precursors.
Becker, D; Buske, C; Feuring-Buske, M; Griesinger, F; Hannig, H; Hiddemann, W; Wörmann, B, 1998
)
1.74
"Transforming growth factor beta1 (TGF-beta1) is a cytokine known to play a key role in the control of cell growth. "( Controlled release of TGF-beta1 impedes rat colon carcinogenesis in vivo.
Fich, A; Kost, Y; Lamprecht, SA; Mikhailowski, R; Polak-Charcon, S; Segal, C; Segal, Y; Shpitz, B, 1998
)
1.74
"Transforming growth factor beta (TGF-beta) is an extracellular ligand that binds to a heterodimeric receptor, initiating signals that regulate growth, differentiation, and apoptosis. "( Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Goggins, M; Hruban, RH; Kern, SE; Shekher, M; Turnacioglu, K; Yeo, CJ, 1998
)
2.04
"Transforming growth factor betas (TGF-betas) are a group of homologous polypeptides that exert pleiotropic effects on various cell types and stimulate the formation of extracellular matrix and fibrosis. "( Transforming growth factor betas and their receptors in human liver cirrhosis.
Abou-Shady, M; Baer, HU; Berberat, P; Büchler, MW; Friess, H; Gold, LI; Korc, M; Zimmermann, A, 1998
)
3.19
"Transforming growth factor beta is a multifunctional polypeptide growth factor implicated in a variety of renal diseases. "( The transforming growth factor beta system in kidney disease and repair: recent progress and future directions.
Basile, DP, 1999
)
2.3
"Transforming growth factor betas are a group of polypeptide growth factors that have a wide range of activities in the musculoskeletal and immunological systems. "( Transforming growth factor beta in fracture repair.
Asnis, P; Bostrom, MP, 1998
)
3.19
"Transforming growth factor beta (TGFbeta) is a potent inhibitor of epithelial cell proliferation, delaying or arresting cell cycle progression in mid-late G1. "( Regulation by transforming growth factor-beta 1 of G1 cyclin-dependent kinases in human retinal epithelial cells.
Casagrande, F; Darbon, JM; Malecaze, F; Manenti, S; Pillaire, MJ, 1999
)
1.75
"Transforming growth factor beta 1 is believed to be a key regulator of extravillous cytotrophoblast invasion during the first trimester of pregnancy. "( Regulated expression of cadherin-11 in human extravillous cytotrophoblasts undergoing aggregation and fusion in response to transforming growth factor beta 1.
Chen, GT; Getsios, S; Huang, DT; MacCalman, CD, 1998
)
1.95
"Transforming growth factor beta1 (TGFbeta1) acts as an inhibitor of the actions of interleukin-1beta (IL-1beta) in various organ systems. "( Transforming growth factor-beta1 is a potent inhibitor of interleukin-1beta action in whole ovarian dispersates.
Adashi, EY; Ben-Shlomo, I; Derman, SG; Kol, S; Resnick, CE; Rohan, RM, 1999
)
1.75
"Transforming growth factor beta1 (TGF-beta1) is a secreted polypeptide that is thought to play a major role in the regulation of folliculogenesis and differentiation of thyroid cells. "( Influence of transforming growth factor beta1 (TGF-beta1) on the behaviour of porcine thyroid epithelial cells in primary culture through thrombospondin-1 synthesis.
Bellon, G; Chaqour, B; Claisse, D; Haye, B; Martiny, I; Petitfrere, E; Schneider, C; Wegrowski, Y, 1999
)
2.12
"Transforming growth factor beta1 (TGF-beta1) is a pleiotropic cytokine that regulates both cell growth and cell death."( Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages.
Chin, BY; Choi, AM; Choi, ME; Petrache, I, 1999
)
2.47
"Transforming growth factor beta (TGF-beta) is an antiproliferative and profibrogenic cytokine that signals through a receptor consisting of type I and type II (TbetaRII) components. "( Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats.
Coste, T; Marullo, S; Roulot, D; Sevcsik, AM; Strosberg, AD, 1999
)
2.18
"Transforming growth factor beta1(TGF-beta1) is a stimulator of malignant progression in mouse skin carcinogenesis. "( Urokinase expression and binding activity associated with the transforming growth factor beta1-induced migratory and invasive phenotype of mouse epidermal keratinocytes.
Frontelo, P; Iglesias, M; Martínez, J; Quintanilla, M; Santibáñez, JF, 1999
)
1.99
"Transforming growth factor beta (TGFbeta) is an immunosuppressive cytokine that contributes to the immunological escape of tumor cells. "( Interferon gamma and antisense transforming growth factor beta transgenes synergize to enhance the immunogenicity of a murine mammary carcinoma.
Akporiaye, ET; Besselsen, DG; McEarchern, JA,
)
1.86
"Transforming growth factor beta (TGF-beta) is a potent growth inhibitor and inducer of cell death in B-lymphocytes and is essential for immune regulation and maintenance of self-tolerance. "( Transforming growth factor beta induces caspase 3-independent cleavage of alphaII-spectrin (alpha-fodrin) coincident with apoptosis.
Brown, TL; Cianci, CD; Howe, PH; Morrow, JS; Patil, S, 1999
)
3.19
"Transforming growth factor beta (TGF-beta) is a major fibrogenic cytokine produced by eosinophils."( Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta).
Emonard, H; Garbuzenko, E; Gillery, P; Levi-Schaffer, F; Maquart, FA; Nagler, A; Pickholz, D; Reich, R; Rubin, A, 1999
)
1.24
"Transforming growth factor beta1 (TGF-beta1) is a potent growth factor implicated in the regulation of osteogenesis and fracture repair."( Adenovirus-mediated gene therapy of osteoblasts in vitro and in vivo.
Dudziak, M; Gittes, GK; Greenwald, JA; Longaker, MT; Mehrara, BJ; Saadeh, PB; Spector, JA; Steinbrech, DS, 1999
)
1.02
"Transforming growth factor betas (TGF-betas) are a growth factor family with negative autocrine growth functions for most epithelial cells including colon carcinoma cell lines. "( Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
Brattain, MG; Foster, JM; Gong, J; Li, W; Liang, J; Venkateswarlu, S; Willson, JK; Ye, SC; Zborowska, E, 1999
)
2.06
"Transforming growth factor beta (TGF-beta) is an important family of cytokines that may promote tumor growth in vivo through several mechanisms including interference with antitumor T-cell immune responses, alteration of factors in the stroma and matrix, and the promotion of angiogenesis. "( Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma.
Atkinson, EN; Freedman, RS; Gordinier, ME; Katz, RL; Levy, LB; Nash, MA; Patenia, R; Platsoucas, CD; Zhang, HZ, 1999
)
2.05
"Transforming growth factor beta (TGF-beta) is a well characterized cytokine that appears to play a major role in directing the cellular response to injury, driving fibrogenesis, and, thus, potentially underlying the progression of chronic injury to fibrosis. "( In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis.
Bissell, DM; George, J; Koteliansky, VE; Roulot, D, 1999
)
1.99
"Transforming growth factor beta (TGF-beta) is a cytokine that upregulates the production by fibroblasts of extracellular matrix proteins."( Transforming growth factor-beta1: a possible signal molecule for posthemorrhagic hydrocephalus?
Christie, S; Pople, I; Whitelaw, A, 1999
)
1.02
"Transforming growth factor beta (TGF-beta) 1 is a ubiquitous bifunctional cytokine implicated in the regulation of haemopoietic stem cells and bone marrow stromal cells. "( Reduced TGF-beta1 in patients with aplastic anaemia in vivo and in vitro.
Ball, SE; Dilger, P; Gibson, FM; Gordon-Smith, EC; Killick, SB; Patel, S; Rizzo, S; Wadhwa, M, 1999
)
1.75
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine which plays an important role in cutaneous wound repair. "( Suppression of keratin 15 expression by transforming growth factor beta in vitro and by cutaneous injury in vivo.
Munz, B; Werner, S, 2000
)
2.02
"Transforming growth factor beta (TGF-beta) is an important regulator of inflammation, being proinflammatory at low concentrations and anti-inflammatory at high concentrations. "( Maintaining the immunological balance in parasitic infections: a role for TGF-beta?
Kurtzhals, JA; Omer, FM; Riley, EM, 2000
)
1.75
"Transforming growth factor beta (TGF-beta) is an immunosuppressive cytokine which can induce immunoglobulin A (IgA) switch and Epstein-Barr virus (EBV) replication in latently infected cells. "( Elevated serum transforming growth factor beta1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM.
Ahmad, A; Dolcetti, R; Jones, JF; Menezes, J; Prasad, U; Vaccher, E; Xu, J, 2000
)
2.1
"Transforming growth factor beta (TGF-beta) is a potent modulator of the extracellular matrix, enhancing collagen synthesis and regulating expression of several genes that encode the matrix metalloproteinases (MMPs), enzymes that degrade the extracellular matrix. "( Transforming growth factor beta inhibitory element in the rabbit matrix metalloproteinase-1 (collagenase-1) gene functions as a repressor of constitutive transcription.
Brinckerhoff, CE; Mitchell, TI; White, LA, 2000
)
3.19
"Transforming growth factor beta (TGF-beta) is a powerful inhibitor of cell proliferation and a potent inducer of differentiation. "( Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas.
Borriello, A; Carbone, R; Della Ragione, F; Gambini, C; Giordani, L; Iolascon, A; Izzo, A; Tonini, GP, 2000
)
1.75
"Transforming growth factor beta (TGF-beta) is an important regulator of bone metabolism, its effects being intertwined with those of estrogen and vitamin D. "( Association of transforming growth factor beta1 genotype with therapeutic response to active vitamin D for postmenopausal osteoporosis.
Harada, A; Hosoi, T; Ikeda, K; Miyauchi, A; Ohta, H; Shiraki, M; Yamada, Y, 2000
)
2.1
"Transforming growth factor beta (TGF-beta) is an important regulator of apoptosis in some cell types, but the underlying molecular mechanisms are largely unknown. "( Smad7 mediates apoptosis induced by transforming growth factor beta in prostatic carcinoma cells.
Bu, S; Heldin, CH; Heldin, NE; Hermansson, A; Itoh, S; Landström, M; ten Dijke, P, 2000
)
2.02
"Transforming growth factor beta (TGF-beta) is a multifunctional regulator of cellular growth and differentiation in many cell types and has a growth inhibitory effect on mammary epithelial cells. "( Effect of transforming growth factor beta 2 on oestrogen metabolism in the MCF-7 breast cancer cell line.
Erbas, H; Lai, LC, 2000
)
2.15
"Transforming growth factor beta is a multi-functional growth and differentiation factor responsible for regulating many diverse biological processes in both vertebrate and invertebrate species. "( Transforming growth factor beta signaling mediators and modulators.
Padgett, RW; Zimmerman, CM, 2000
)
3.19
"Transforming growth factor beta (TGF) is a well-known inhibitor of myogenic differentiation as well as an autocrine product of rhabdomyosarcoma cells. "( TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells.
Bouché, M; Canipari, R; Melchionna, R; Molinaro, M; Senni, MI; Willems, D, 2000
)
1.75
"Transforming growth factor beta1 (TGF-beta1) is a polypeptide that is secreted in an inactive form, cleaved to produce an active form, and then deactivated in the tissues."( Immunolocalization of activated transforming growth factor beta1 in juvenile nasopharyngeal angiofibroma.
Cohen, C; Del Gaudio, J; Dillard, DG; Gal, AA; Muller, S; Parrish, B; Rackley, D; Reichman, O, 2000
)
1.31
"Transforming growth factor beta (TGF-beta) is a pleiotropic cytokine that exerts its effects through a heteromeric complex of transmembrane serine/threonine kinase receptors. "( c-Jun inhibits transforming growth factor beta-mediated transcription by repressing Smad3 transcriptional activity.
Atfi, A; Dennler, S; Ferrand, N; Gauthier, JM; Prunier, C, 2000
)
2.1
"The transforming growth factor beta1 (TGFbeta1) is a major regulator of human endometrial function. "( Kappa opioids and TGFbeta1 interact in human endometrial cells.
Castanas, E; Chatzaki, E; Georgoulias, V; Gravanis, A; Makrigiannakis, A; Margioris, AN, 2000
)
0.87
"Transforming growth factor beta (TGF beta) is a potent growth inhibitor of epithelial cells. "( The progression of invasiveness regarding the role of transforming growth factor beta receptor type II in gastric cancer.
Kusaba, I; Masuda, H; Matsumata, T; Sugimachi, K; Tanaka, T; Tateishi, M, 2000
)
2
"Transforming growth factor beta3 (TGF-beta3) is a potent suppressor of human hematopoietic progenitor cells. "( Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis.
Carlo-Stella, C; Colla, S; Curti, A; Fogli, M; Lemoli, RM; Ragazzi, E; Ratta, M; Santucci, AM; Tazzari, PL; Tura, S, 2000
)
3.19
"Transforming growth factor beta (TGFbeta) is a tumor suppressor acting as inhibitor of cell cycle progression of epithelial cells. "( TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation.
Adler, G; Giehl, K; Gierschik, P; Menke, A; Seidel, B, 2000
)
1.75
"Transforming growth factor beta1 is an important growth regulator in many cell types, usually exerting a negative effect on cellular growth. "( Transforming growth factor beta1 selectively regulates ferritin gene expression in malignant H-ras-transformed fibrosarcoma cell lines.
Hurta, RA; Lo, J, 2000
)
3.19
"Transforming growth factor beta (TGF-beta) is a pivotal driver of glomerulosclerosis and tubulointerstitial fibrosis in renal diseases. "( Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis.
Brady, HR; Clarkson, MR; Duggan, J; Gupta, S, 2000
)
1.75
"Transforming growth factor beta (TGF-beta) is an effective and ubiquitous mediator of cell growth. "( Role of transforming growth factor beta in cancer.
Pasche, B, 2001
)
2.19
"Transforming growth factor beta (TGF-beta) is a multifunctional cytokine capable of regulating diverse cellular processes. "( Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for Bcl-2.
Arrick, BA; Brown, MK; Douville, K; Eastman, A; Payne, DC; Tobin, SW, 2001
)
2.11
"Transforming growth factor beta (TGF-beta) is a potent natural antiproliferative agent that plays an important role in suppressing tumorigenicity. "( Mechanism for mutational inactivation of the tumor suppressor Smad2.
Atfi, A; Ferrand, N; Frottier, B; Pessah, M; Prunier, C, 2001
)
1.75
"Transforming growth factor beta (TGF-beta) is an important mediator of wound healing and tissue regeneration, which stimulates fibroblasts to produce extracellular matrix materials."( TGF-beta isoforms and TGF-beta receptors in drug-induced and hereditary gingival overgrowth.
Chapple, IL; Matthews, JB; Wright, HJ, 2001
)
1.03
"Transforming growth factor beta (TGF-beta) is a member of a family of cytokines that regulate differentiation and proliferation in a wide variety of tissues including the pituitary gland. "( Decreased proliferation and cell cycle arrest in neoplastic rat pituitary cells is associated with transforming growth factor-beta1-induced expression of p15/INK4B.
Farrell, WE; Frost, SJ; Simpson, DJ, 2001
)
1.75
"Transforming growth factor beta (TGFbeta) is a multifunctional cytokine required for embryonic development and is an important regulator of human trophoblast function."( Characterization of a TGFbeta-responsive human trophoblast-derived cell line.
Brown, TL; Carter, QL; Kniss, DA; Smith, AN, 2001
)
1.03
"Transforming growth factor beta 1 (TGF-beta1) is a potent inducer of extracellular matrix production by mesenchymal cells, and we have shown that this peptide is produced in the lung after asbestos exposure."( Increased TGF-beta1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF-alpha receptor knockout mice.
Brody, AR; Liu, JY, 2001
)
1.03
"Transforming growth factor beta1 (TGF-beta1) is a potent cytokine that affects growth inhibition of various cells and stimulates extracellular matrix production and angiogenesis."( High tumor grade in salivary gland mucoepidermoid carcinomas and loss of expression of transforming growth factor beta receptor type II.
Bloch, D; Cohen, C; Del Gaudio, JM; Dillard, DG; Gal, AA; Muller, S, 2001
)
1.25
"Transforming growth factor beta (TGF-beta) is a pleiotropic regulator of all stages of hematopoieis. "( Transforming growth factor beta, pleiotropic regulator of hematopoietic stem cells: potential physiological and clinical relevance.
Bartelmez, SH; Ruscetti, FW, 2001
)
3.2
"Transforming growth factor beta1 (TGF-beta1) acts as a tumor suppressor at early stages of carcinogenesis, however, it has also been suggested to promote tumor progression at late stages. "( Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis.
He, W; Olson, KL; Wang, XJ; Weeks, BH, 2001
)
2.06
"Transforming growth factor beta1 (TGFbeta1) is a Th2 cytokine encoded on chromosome 19q13, a region possibly linked to multiple sclerosis (MS). "( Genetic variation in the transforming growth factor beta1 gene in multiple sclerosis.
Atkinson, E; Hebrink, D; Kantarci, OH; McMurray, CM; Schaefer-Klein, J; Schaid, D; Weinshenker, BG, 2001
)
2.06
"Transforming growth factor beta (TGF-beta) is a family of growth factors that is involved in scar formation, wound healing, and nerve regeneration."( Gene expression of transforming growth factor beta isoforms in interposition nerve grafting.
Bogdan, MA; Chang, J; Hentz, VR; Karanas, YL; Lineaweaver, WC; Longaker, MT, 2001
)
1.36
"Transforming growth factor beta (TGF-beta) is a secreted growth factor that regulates the transcriptional program of cells via heteromeric complexes of transmembrane type II and type I Ser/Thr kinase receptors and the Smad intracellular signal transduction pathway [1]. "( Phosphoserine-dependent regulation of protein-protein interactions in the Smad pathway.
Wrana, JL, 2002
)
1.76
"Transforming growth factor beta1 (TGFbeta1) is a multifunctional cytokine involved in pro- and anti-inflammatory pathways and is expressed in several cell types. "( TGFbeta1 allele association with asthma severity.
Adcock, IM; Barnes, PJ; Newton, R; Pulleyn, LJ, 2001
)
1.75
"Transforming growth factor beta 1 (TGFB1) is a cytokine involved in the development of both acute and late cutaneous radiation syndromes. "( Promoter sequences involved in transforming growth factor beta1 gene induction in HaCaT keratinocytes after gamma irradiation.
Calenda, A; Gault, N; Lefaix, JL; Martin, MT; Vozenin-Brotons, MC, 2002
)
2.04
"Transforming growth factor beta-1 (TGF-beta1) is a multifunctional growth factor and known to inhibit the proliferation of epithelial cell. "( The concentration of serum transforming growth factor beta-1 (TGF-beta1) is decreased in cervical carcinoma patients.
Chou, CI; Hung, MW; Li, YF; Tsai, LC; Wu, HS; Yuan, CC, 2002
)
2.05
"Transforming growth factor beta1 (TGFbeta1) is a multifunctional growth factor involved in immune function, atherosclerosis, fibrotic disease, diabetic complications and bone turnover. "( Circulating transforming growth factor beta1 (TGFbeta1) is elevated by extensive exercise.
Hellmich, B; Hering, S; Jost, C; Pfeiffer, H; Schatz, H; Schulz, H, 2002
)
2.14
"Transforming growth factor beta1 (TGF-beta1) is a pleiotropic cytokine involved in cellular proliferation and differentiation."( Molecular mechanism of transforming growth factor (TGF)-beta1-induced glutathione depletion in alveolar epithelial cells. Involvement of AP-1/ARE and Fra-1.
Donaldson, K; Jardine, H; MacNee, W; Rahman, I, 2002
)
1.04
"Transforming growth factor beta (TGF-beta) is a secreted protein that regulates proliferation, differentiation and death of various cell types. "( Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation.
Gaal, A; Heldin, CH; Moustakas, A; Pardali, K, 2002
)
1.76
"Transforming growth factor beta1 (TGF-beta1) is a potent fibrotic factor responsible for the synthesis of extracellular matrix. "( Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Bomberger, J; Butter, S; Callahan, JF; Fornwald, J; Gaster, L; Grygielko, E; Harling, J; Laping, NJ; Lehr, R; Martin, W; Mathur, A; Olson, BA; Tweed, C, 2002
)
1.76
"Transforming growth factor beta (TGF-beta) is a member of a large family of pleiotropic cytokines that are involved in many biological processes, including growth control, differentiation, migration, cell survival, adhesion, and specification of developmental fate, in both normal and diseased states."( SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Callahan, JF; Gaster, LM; Harling, JD; Hill, CS; Inman, GJ; Laping, NJ; Nicolás, FJ; Reith, AD, 2002
)
1.04
"Transforming growth factor beta (TGF-beta) is a multi-functional regulatory protein which can affect growth, immune responses, angiogenesis and the formation of extracellular matrix. "( Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast.
Dearing, SJ; Walker, RA, 1992
)
3.17
"Transforming growth factor beta (TGF beta) is a multifunctional regulator of cell growth that has either a stimulatory or inhibitory effect on cell proliferation, depending on TGF beta concentration and on cell type, history and culture conditions. "( Cadmium's action on NRK-49F cells to produce responses induced also by TGF beta is not due to cadmium induced TGF beta production or activation.
Enger, MD; Tang, N, 1992
)
1.73
"Transforming growth factor beta is a strong growth inhibitor for many types of normal and transformed cells, although little is known on the mechanism of this anti-proliferative effect. "( Regulation of amphiregulin mRNA by TGF-beta in the human lung adenocarcinoma cell line A549.
Bennett, KL; Buckley, SD; Plowman, GD; Purchio, AF; Skonier, J, 1992
)
1.73
"Transforming growth factor beta (TGF-beta) is a multifunctional homodimeric polypeptide with potent actions upon many target cells, including those of mesenchymal and haemopoietic lineage. "( Induction of swelling, synovial hyperplasia and cartilage proteoglycan loss upon intra-articular injection of transforming growth factor beta-2 in the rabbit.
Aeberhard, M; Elford, PR; Graeber, M; Legendre, B; MacKenzie, AR; Ohtsu, H; Wishart, WL, 1992
)
1.94
"Transforming growth factor beta (TGF beta) is a secreted polypeptide factor that is thought to play a major role in the regulation of proliferation of many cell types and various differentiation processes. "( TGF beta inhibits rat thyroid cell proliferation without alterations in the expression of TSH-induced cell cycle-related genes.
Cirafici, AM; Colletta, G; Esposito, D; Mincione, G; Pepe, S, 1992
)
1.73
"Transforming growth factor beta (TGF-beta) is a potent immunosuppressive cytokine that is produced by neoplastic and normal cells. "( Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Barrett, SK; Bear, HD; Hoover, SK; Inge, TH; Susskind, BM, 1992
)
1.96
"Transforming growth factor beta (TGF beta) is an extremely potent chemoattractant for macrophages, mononuclear leukocytes, and fibroblasts. "( Effect of transforming growth factor beta on postoperative adhesion formation and intact peritoneum.
Chegini, N; Rossi, AM; Schultz, G; Williams, RS, 1992
)
2.13
"Transforming growth factor beta (TGF beta) is a multifunctional protein which has been suggested to play a central role in the pathogenesis of chronic inflammation and fibrosis. "( Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1).
Banwatt, D; Clark, DA; Denburg, J; Dolovich, J; Flanders, KC; Gauldie, J; Harley, CB; Jordana, M; Lea, RG; Ohno, I, 1992
)
1.96
"Transforming growth factor beta (TGF beta) is a family of important regulators of chondrocyte growth and differentiation. "( Differential expression of TGF beta isoforms by human articular chondrocytes in response to growth factors.
Lotz, M; Villiger, PM, 1992
)
1.73
"Transforming growth factor beta (TGF-beta) is a cytokine secreted by megakaryocytes and platelets which inhibits the proliferation of megakaryocyte progenitors in vitro. "( Effects of transforming growth factor beta on megakaryocytic cell fusion and endomitosis.
Avraham, H; Cowley, SA; Groopman, JE, 1992
)
2.12
"Transforming growth factor beta (TGF beta) is a multifunctional polypeptide presenting various biological activities depending on the cellular context where it is studied. "( [Autocrine regulation of adrenal steroidogenesis by growth factor transforming TGF-beta 1].
Chambaz, EM; Cochet, C; Feige, JJ; Lafeuillade, B, 1991
)
1.72
"Transforming growth factor beta (TGF-beta) is a potent and selective growth inhibitor of early hematopoietic progenitors and leukemic cells. "( Transforming growth factor-beta trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines.
Boone, TC; Dubois, CM; Jacobsen, SE; Keller, JR; Lee, J; Ruscetti, FW, 1991
)
1.72
"Transforming growth factor beta (TGF beta) is a family of polypeptides that modulate growth and differentiation. "( Phosphorylation of nuclear protein is an early event in TGF beta 1 action.
de Groot, RP; de Laat, SW; de Vries, C; Koornneef, I; Kramer, IM; Kruijer, W; van den Eijnden-van Raaij, AJ, 1991
)
1.72
"Transforming Growth Factor beta is a potent autocrine inhibitor of the growth of untransformed keratinocytes. "( High frequency of resistance of human squamous carcinoma cells to the anti-proliferative action of transforming growth factor beta.
Reiss, M; Stash, EB, 1990
)
1.94
"Transforming growth factor beta (TGF-beta) is a multifunctional mediator with effects on cellular growth, differentiation, and extracellular matrix (ECM) metabolism. "( Transforming growth factor-beta modulates plasminogen activator activity and plasminogen activator inhibitor type-1 expression in human keratinocytes in vitro.
Clark, RA; Elder, JT; Mink, P; Persichitte, KA; Wikner, NE, 1990
)
1.72
"Transforming growth factor beta-1 (TGF-beta) is a multi-potent immunoregulatory peptide that has effects on numerous cell types. "( Transforming growth factor-beta 1 inhibits activation of macrophage cell line RAW 264.7 for cell killing.
Czuprynski, CJ; Haak-Frendscho, M; Paulnock, D; Wynn, TA, 1990
)
1.72
"Transforming growth factor beta (TGFB) is a potent inhibitor of DNA synthesis in adult rat hepatocytes in vitro. "( Changes in sensitivity of hepatocytes isolated from regenerating rat liver to the growth inhibitory action of transforming growth factor beta.
Hill, DJ; Strain, AJ, 1990
)
1.93

Effects

Transforming growth factor beta (TGF-beta) has a growth-inhibitory effect on numerous different cell types of the immune system, including T lymphocytes. It has a dual role in carcinogenesis, acting as a growth inhibitor in early tumor stages and a promoter of cell proliferation in advanced diseases.

Transforming growth factor beta (TGFbeta) has been reported to be a potent growth inhibitor of epithelial cells. TGFbeta mediates stromal cell-epithelial cell interactions in a variety of different tissues.

ExcerptReferenceRelevance
"Transforming growth factor beta (TGF-β) has an important role in mediating T-cell suppression in B-cell non-Hodgkin lymphoma (NHL). "( TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.
Ansell, SM; Grote, DM; Hodge, LS; Novak, AJ; Price-Troska, TL; Xiu, B; Yang, ZZ; Yates, DM; Ziesmer, SC, 2014
)
1.85
"Transforming growth factor beta (TGF-beta) has a dual role in carcinogenesis, acting as a growth inhibitor in early tumor stages and a promoter of cell proliferation in advanced diseases. "( Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation.
Adhikary, T; Eilers, M; Ellenrieder, V; Fernandez-Zapico, ME; Gress, TM; König, A; Nye, MD; Reutlinger, K; Singh, G; Singh, SK, 2010
)
1.8
"Transforming growth factor beta (TGF-β) has an important role in tendon healing and adhesion formation. "( Inhibition effect of mannose-6-phosphate on expression of transforming growth factor Beta receptor in flexor tendon cells.
Tian, S; Wang, Y; Xia, C; Yang, XY, 2011
)
2.06
"Transforming growth factor beta (TGF-β) has a crucial role in the differentiation of ectodermal cells to neural or epidermal precursors. "( TGF-β/BMPs: crucial crossroad in neural autoimmune disorders.
Antonelou, RCh; Kitsos, DK; Stamboulis, E; Tsiodras, S; Voumvourakis, KI, 2011
)
1.81
"Transforming growth factor beta (TGF-β) has a dual role during tumor progression, initially as a suppressor and then as a promoter. "( Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
Aakre, M; Ashby, WJ; Chytil, A; Gorska, AE; Matise, LA; Moses, HL; Nashabi, A; Palmer, TD; Pickup, MW; Zijlstra, A, 2012
)
1.82
"Transforming growth factor beta1 (TGF-beta1) has a number of actions that make it a candidate for a role in the pathogenesis of COPD."( Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease.
Black, PN; Chau, J; Hopkins, R; McLean, L; Mills, GD; Pokorny, V; Wu, L; Young, RP, 2004
)
1.04
"Transforming growth factor beta (TGF-beta) has a major role in cell proliferation, differentiation and apoptosis in many cell types. "( PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3.
Michnick, SW; Montmarquette, A; Remy, I, 2004
)
1.77
"Transforming growth factor beta (TGF-beta) has an established role in interstitial damage of renal transplants during chronic rejection (CR). "( Increased mRNA expression of transforming growth factor beta in the arterial wall of chronically rejected renal allografts in humans.
Gornicka, B; Gorski, A; Kosieradzki, M; Kwiatkowski, A; Michalska, W; Paczek, L; Pawlowska, M; Rowinski, W; Wyczalkowska, A; Zegarska, J; Ziarkiewicz-Wroblewska, B; Ziolkowski, J,
)
1.87
"Transforming growth factor beta1 (TGF-beta1) has a relevant role in the origin and maintenance of glomerulosclerosis and tubule-interstitial fibrosis. "( Involvement of H- and N-Ras isoforms in transforming growth factor-beta1-induced proliferation and in collagen and fibronectin synthesis.
Fuentes-Calvo, I; García-Cenador, B; López-Novoa, JM; Martínez-Salgado, C; Santos, E, 2006
)
1.78
"Transforming growth factor beta (TGF-beta) has a strong impact on liver development and physiopathology, exercised through its pleiotropic effects on growth, differentiation, survival, and migration. "( Transforming growth factor beta controls the directional migration of hepatocyte cohorts by modulating their adhesion to fibronectin.
Binamé, F; Hibner, U; Lassus, P, 2008
)
3.23
"Transforming growth factor beta (TGF-beta) has a growth-inhibitory effect on numerous different cell types of the immune system, including T lymphocytes. "( Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site.
Brabletz, T; Pfeuffer, I; Schorr, E; Serfling, E; Siebelt, F; Wirth, T, 1993
)
3.17
"Transforming growth factor beta (TGF-beta) has a critical role in the remodeling process."( Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects.
Balzar, S; Chu, HW; Trudeau, JB; Wenzel, SE, 2000
)
1.28
"Transforming growth factor beta has a wide range of physiological effects on cell growth and metabolism. "( Immediate early gene responses of NIH 3T3 fibroblasts and NMuMG epithelial cells to TGF beta-1.
Alitalo, K; Bravo, R; Koskinen, PJ; Sistonen, L, 1991
)
1.72
"Transforming growth factor beta (TGF-β) has been shown to play a critical role in pathogenesis of pulmonary arterial hypertension (PAH) although the precise role of TGF-β signaling remains uncertain. "( Periostin-expressing cell-specific transforming growth factor-β inhibition in pulmonary artery prevents pulmonary arterial hypertension.
Arakawa, H; Conway, SJ; Furukawa, N; Koitabashi, N; Kurabayashi, M; Obokata, M; Seki, M, 2019
)
1.96
"Transforming growth factor beta (TGFβ) has been shown to be an important driver of the endothelial cell phenotype transition."( Fibroblast growth factor-transforming growth factor beta dialogues, endothelial cell to mesenchymal transition, and atherosclerosis.
Chen, PY; Simons, M, 2018
)
1.51
"Transforming growth factor beta (TGFβ) has been reported to induce EMT in tumor cells, which is a critical step in the process of metastasis leading to cancer spreading and treatment failure."( miR-639 regulates transforming growth factor beta-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting FOXC1.
Chen, W; Fan, S; Li, J; Li, Y; Lin, Z; Liu, B; Sun, L; Wang, Y, 2014
)
1.46
"Transforming growth factor beta (TGFbeta) has been known to play a role in anterior subcapsular cataract (ASC) formation and posterior capsule opacification (PCO), both of which are fibrotic pathologies of the lens. "( Temporal changes in MMP mRNA expression in the lens epithelium during anterior subcapsular cataract formation.
Dwivedi, DJ; Margetts, PJ; Nathu, Z; Reddan, JR; Sheardown, H; West-Mays, JA, 2009
)
1.8
"Transforming growth factor beta (TGFbeta) has been suggested to be an effective inhibitor of the increased keratinocyte proliferation in psoriasis. "( Downregulation of SMAD2, 4 and 6 mRNA and TGFbeta receptor I mRNA in lesional and non-lesional psoriatic skin.
Mrowietz, U; Seifert, O; Yu, H, 2009
)
1.8
"The transforming growth factor beta (TGF-beta) has been studied with regard to the regulation of cell behavior for over three decades. "( Transforming growth factor beta (TGF-beta) and inflammation in cancer.
Bierie, B; Moses, HL, 2010
)
2.36
"Transforming growth factor beta (TGF-β) has been shown to affect epithelial cell differentiation and proliferation through epithelial-mesenchymal and epithelial-immune cell interaction. "( Nutritional supplementation with transforming growth factor-beta inhibits intestinal adaptation after massive small bowel resection in a rat.
Bashenko, Y; Ben Lulu, S; Chemodanov, E; Coran, AG; Mogilner, JG; Shaoul, R; Sukhotnik, I, 2011
)
1.81
"Transforming growth factor beta (TGF-β) has been implicated in the pathogenesis of several diseases including infection with intracellular pathogens such as the Mycobacterium avium complex. "( TGF-β-mediated sustained ERK1/2 activity promotes the inhibition of intracellular growth of Mycobacterium avium in epithelioid cells surrogates.
Carneiro, CR; Cipriano, I; L'Abbate, C; Leão, SC; Machado, J; Pérez-Hurtado, EC, 2011
)
1.81
"Transforming growth factor beta (TGF-β) has been recognized as an important mediator in the genesis of chronic kidney diseases (CKD), which are characterized by the accumulation of extracellular matrix (ECM) components in the glomeruli (glomerular fibrosis, glomerulosclerosis) and the tubular interstitium (tubulointerstitial fibrosis). "( Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects.
López-Hernández, FJ; López-Novoa, JM, 2012
)
1.82
"Transforming Growth Factor beta (TGFß) has been involved in several regulatory steps of T."( Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease.
Araújo-Jorge, TC; Bailly, S; de Oliveira, FL; de Oliveira, GM; de Souza, EM; Degrave, WM; Feige, JJ; Waghabi, MC, 2012
)
1.35
"Transforming growth factor beta (TGF-beta) has been suggested to play an important role in the development of airway remodeling in asthma; this suggestion is based on evidence that expression levels of TGF-beta are correlated with unique parameters of airway remodeling, such as thickness of basement membrane. "( Activation of TGF-beta/Smad2 signaling is associated with airway remodeling in asthma.
Fukuda, T; Nakao, A; Ogawa, H; Okada, T; Okumura, K; Ra, C; Sagara, H, 2002
)
1.76
"Transforming growth factor beta1 (TGFbeta1) has been reported to have important roles in unresolved inflammation, immune suppression, fibrosing processes, and angiogenesis."( Transforming growth factor beta1 gene polymorphism in rheumatoid arthritis.
Banno, S; Maeda, H; Naniwa, T; Niimi, T; Sato, S; Shimizu, S; Sugiura, Y; Ueda, R; Yoshinouchi, T, 2002
)
2.48
"Transforming growth factor beta1 (TGFbeta1) has been shown to exert strong inhibitory effects on adrenocortical cell steroidogenesis. "( Transforming growth factor beta1 inhibits aldosterone and cortisol production in the human adrenocortical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression.
Bernhardt, R; Defaye, G; Feige, JJ; Lenz, D; Liakos, P, 2003
)
3.2
"Transforming growth factor beta3 (TGF-beta3) has been shown to accelerate gastric ulcer healing in rats. "( TGF-beta3 inhibits pentagastrin-stimulated gastric acid secretion in rats.
Beckert, S; Coerper, S; Farrahi, F; Wolf, SC; Zittel, TT, 2005
)
1.77
"Transforming growth factor beta (TGF-beta) has been shown to induce apoptotic cell death in normal and transformed hepatocytes. "( Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells.
Ganten, TM; Grosse-Wilde, A; Herzer, K; Koschny, R; Krammer, PH; Schulze-Bergkamen, H; Walczak, H, 2005
)
3.21
"Transforming growth factor beta (TGF-beta) has been shown to be a central immunomodulator used by leishmaniae to escape effective mechanisms of protection in human and murine infections with these parasites. "( Transforming growth factor beta 1 production by CD4+ CD25+ regulatory T cells in peripheral blood mononuclear cells from healthy subjects stimulated with Leishmania guyanensis.
Bourreau, E; Couppié, P; Kariminia, A; Launois, P; Pascalis, H; Sainte-Marie, D; Tacchini-Cottier, F, 2005
)
3.21
"Transforming growth factor beta (TGF-beta) has been implicated in the maintenance of homeostasis in various organs, including the gastric epithelium. "( Transforming growth factor beta-dependent sequential activation of Smad, Bim, and caspase-9 mediates physiological apoptosis in gastric epithelial cells.
Fukamachi, H; Kuida, K; Kuroki, S; O'Reilly, LA; Ohgushi, M; Strasser, A; Yonehara, S, 2005
)
3.21
"Transforming growth factor beta (TGF-beta) has been recognized as a key mediator of renal fibrogenesis; therefore, the present study was conducted to ascertain immunoexpression of TGF-beta in ARTR."( Correlative insights into the immunoexpression of transforming growth factor beta-1 in acutely rejected renal allografts.
Danilewicz, M; Wagrowska-Danilewicz, M, 2006
)
1.31
"Transforming growth factor beta 1 (TGF-beta1) has been shown to induce epithelial-mesenchymal transition (EMT) during various stages of embryogenesis and progressive disease. "( Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition.
Goodenough, DA; Hay, ED; Medici, D, 2006
)
1.78
"Transforming growth factor beta (TGF-beta) has been implicated in many chronic fibrotic conditions such as pulmonary and hepatic fibrosis. "( Role of increased transforming growth factor beta protein expression in the pathogenesis of Peyronie's disease.
El-Sakka, A; Hassoba, H; Lue, T, 2005
)
2.1
"Transforming growth factor beta (TGF-beta) has been implicated in pathophysiology of CF."( Chloroquine normalizes aberrant transforming growth factor beta activity in cystic fibrosis bronchial epithelial cells.
Deretic, V; Ornatowski, W; Perkett, EA; Poschet, JF, 2006
)
1.34
"Transforming growth factor beta (TGFbeta) has been proposed to play a major role in the process of colonic wound healing, and its expression is believed to be modulated by interleukin-2 (IL2)."( Effect of blood transfusion on gene expression of transforming growth factor beta-1 and the alpha subunit of interleukin-2 receptor in a model of colonic wound healing.
Apostolidis, S; Gigis, P; Goulas, A; Mirtsou-Fidani, V, 2006
)
1.31
"Transforming growth factor beta (TGF-beta) has been implicated in these processes."( Expression and activation of TGF-beta isoforms in acute allergen-induced remodelling in asthma.
Fan Chung, K; Hew, M; Oates, T; Sukkar, M; Torrego, A, 2007
)
1.06
"Transforming growth factor beta (TGFbeta) has been implicated as a candidate cytokine to mediate this communication."( Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling.
Bandyopadhyay, A; Elkahloun, AG; Sun, LZ; Verona, EV; Yang, J; Yeh, IT, 2007
)
1.06
"Transforming growth factor beta (TGF-beta) has been implicated in scar formation through the activation of fibroblasts and the acceleration of collagen deposition."( A novel truncated TGF-beta receptor II downregulates collagen synthesis and TGF-beta I secretion of keloid fibroblasts.
Chu, Y; Guo, F; Guo, Y; Li, X; Li, Y; Zhou, T, 2008
)
1.07
"Transforming growth factor beta (TGF-beta) has been extensively studied as an exogenous agent that stimulates the expression of extracellular matrix proteins and their cell-surface integrin receptors in a variety of cell types. "( Autocrine transforming growth factor beta 1 modulates the expression of integrin alpha 5 beta 1 in human colon carcinoma FET cells.
Birkenmeier, TM; Brattain, MG; Gong, J; Sun, L; Wang, D; Zhou, GH, 1995
)
2.14
"Transforming growth factor beta (TGF-beta) has been identified as an immunosuppressive factor in human seminal plasma."( Characterization of latent transforming growth factor-beta from human seminal plasma.
Chu, TM; Nocera, M, 1995
)
1.01
"Transforming growth factor beta activities have been implicated in a variety of diseased states including arthritis, prostate cancer, and AIDS, and in the repair of tissue injury caused by trauma, burns, and surgery."( Development and characterization of murine monoclonal antibodies to the latency-associated peptide of transforming growth factor beta 1.
Fendly, BM; Hongo, JA; Lucas, C; Mora-Worms, M, 1995
)
1.23
"Transforming growth factor beta (TGF-beta) has been proposed to play a number of roles in central nervous system (CNS) development and response to injury. "( Overexpression of TGF-beta 1 in the central nervous system of transgenic mice results in hydrocephalus.
Brenner, M; Galbreath, E; Kim, SJ; Messing, A; Park, K, 1995
)
1.73
"Transforming growth factor beta (TGF-beta) has been clearly linked in several model systems to the development of pathologic extracellular matrix deposition in the glomerulus and interstitium. "( Immunoregulation and TGF-beta 1. Suppression of a nephritogenic murine T cell clone.
Kelly, CJ; Meyers, CM, 1994
)
1.73
"Transforming growth factor beta (TGF-beta) has been shown to promote bone formation and is present in bone in high quantities."( The effect of sterilization on transforming growth factor beta isolated from demineralized human bone.
Puolakkainen, PA; Ranchalis, JE; Strong, DM; Twardzik, DR, 1993
)
1.29
"Transforming growth factor beta (TGF-beta) has been shown to affect wound repair. "( Effect of transforming growth factor beta 1 on stromal haze following excimer laser photorefractive keratectomy in rabbits.
Eagle, RC; Gomes, JA; Myers, JS; Rapuano, CJ; Siepser, SB; Thom, SB,
)
1.98
"Transforming growth factor beta (TGF-beta) has been implicated in the pathogenesis of various human diseases. "( Transforming growth factor beta peptide antagonists and their conversion to partial agonists.
Huang, JS; Huang, SS; Johnson, FE; Konish, Y; Liu, Q, 1997
)
3.18
"Transforming growth factor beta (TGF-beta) has been regarded as a 'blackguard molecule' that induces glomerular diseases. "( Evidence for TGF-beta-mediated 'defense' of the glomerulus: a blackguard molecule rehabilitated?
Fine, LG; Kitamura, M,
)
1.57
"Transforming growth factor beta1 (TGF-beta1) has been implicated as inhibitor of cell proliferation and a potent inducer of apoptosis in vitro and in vivo after the administration of high doses. "( Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia.
Bursch, W; Grasl-Kraupp, B; Kammerer, B; Müllauer, L; Rossmanith, W; Ruttkay-Nedecky, B; Schulte-Hermann, R, 1998
)
2.15
"Transforming growth factor beta1 (TGFbeta1) has been reported to be a potent inhibitor of differentiated functions of many steroidogenic cells. "( Antisense oligonucleotide targeting the transforming growth factor beta1 increases expression of specific genes and functions of Leydig cells.
Langlois, D; Le Roy, C; Leduque, P; Saez, JM; Yuan Li, J, 1998
)
2.01
"Transforming growth factor beta1 (TGF-beta1) has been previously shown to modulate interleukin 2 (IL-2) secretion by activated T-cells. "( Transforming growth factor-beta 1 (TGF-beta1) promotes IL-2 mRNA expression through the up-regulation of NF-kappaB, AP-1 and NF-AT in EL4 cells.
Han, SH; Jeon, YJ; Kaminski, NE; Yang, KH; Yea, SS, 1998
)
1.74
"Transforming growth factor beta1 (TGF-beta1) has been implicated in formation of astrocyte scars, which prevents axonal regeneration. "( Dependence of neurones on astrocytes in a coculture system renders neurones sensitive to transforming growth factor beta1-induced glutamate toxicity.
Brown, DR, 1999
)
1.97
"Transforming growth factor beta (TGF-beta) has been shown to be a specific inhibitor of early human myeloid progenitors. "( Transforming growth factor beta inhibits growth of more differentiated myeloid leukemia cells and retinoblastoma protein phosphorylation at serine 795.
Hu, X; Moscinski, LC; Zuckerman, KS, 1999
)
3.19
"Transforming growth factor beta (TGF-beta) has been implicated in the pathogenesis of keloids."( Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids.
Chau, D; Chin, GS; Gittes, GK; Kim, WJ; Lee, TY; Longaker, MT, 1999
)
1.39
"Transforming growth factor beta (TGFbeta) has been reported to be a potent growth inhibitor of epithelial cells. "( Overexpression of a dominant-negative type II TGFbeta receptor tagged with green fluorescent protein inhibits the effects of TGFbeta on cell growth and gene expression of mouse adrenal tumor cell line Y-1 and enhances cell tumorigenicity.
Langlois, D; Le Roy, C; Leduque, P; Li, JY; Maisnier-Patin, K; Saez, JM, 1999
)
1.75
"Transforming growth factor beta1 (TGF-beta1) has been shown to exhibit anti-proliferative activity for mammary gland epithelial cells and for human breast cancer cells. "( Modulation of transforming growth factor beta1 gene expression in the mammary gland by insulin-like growth factor I and octreotide.
Beamer, W; Chan, TW; Huynh, H; Pollak, M, 2000
)
2.11
"Transforming growth factor beta (TGF-beta) has been implicated as a factor in uterine progesterone responses."( Regulation of sialomucin complex/Muc4 in the female rat reproductive tract.
Carraway, KL; Idris, N, 2001
)
1.03
"Transforming growth factor beta (TGFbeta) has been shown to often be a mesenchymal cell-derived growth factor that mediates stromal cell-epithelial cell interactions in a variety of different tissues."( Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, TGFbeta3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer.
Doraiswamy, V; Nilsson, E; Parrott, JA; Skinner, MK, 2001
)
1.34
"Transforming growth factor beta (TGF-beta) has been considered as a candidate for gene therapy of orthopedic diseases. "( Regeneration of hyaline cartilage by cell-mediated gene therapy using transforming growth factor beta 1-producing fibroblasts.
Choi, KB; Choi, MS; Hwang, TS; Kim, SJ; Lee, JY; Lee, KH; Oh, IS; Song, SU; Yi, Y, 2001
)
1.99
"Transforming growth factor beta 1 (TGF-beta1) has been implicated in the pathogenesis of a number of diseases including infection with intracellular pathogens such as Mycobacterium avium complex (MAC). "( Analysis of transforming growth factor-beta 1 (TGF-beta1) expression in human monocytes infected with Mycobacterium avium at a single cell level by ELISPOT assay.
Aung, H; Sherman, J; Tary-Lehman, M; Toossi, Z, 2002
)
1.76
"Transforming growth factor beta (TGFbeta) has been shown to induce subcapsular plaques in cultured rat lenses as well as in lenses of transgenic mice. "( TGFbeta induces morphological and molecular changes similar to human anterior subcapsular cataract.
Chamberlain, CG; Hales, AM; Lovicu, FJ; McAvoy, JW; Overbeek, PA; Schulz, MW; Vincent, LN, 2002
)
1.76
"Transforming growth factor beta1 has been implicated in the regulation of both cellular proliferation and differentiation."( Transforming growth factor beta1 regulates melanocyte proliferation and differentiation in mouse neural crest cells via stem cell factor/KIT signaling.
Hosaka, E; Ito, M; Kawa, Y; Kawakami, T; Mizoguchi, M; Ohsumi, K; Soma, Y; Watabe, H; Yajima, K; Yamasaki, E, 2002
)
2.48
"Transforming growth factor beta has been implicated as a mediator of excessive extracellular matrix deposition in scar tissue and fibrosis, including systemic sclerosis. "( Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts.
Gore, EA; McDermott, PJ; Sato, M; Shegogue, D; Smith, EA; Trojanowska, M, 2002
)
2.08
"Transforming growth factor beta (TGF beta 1) has been shown to modulate the response of cultured auditory neurons to bFGF through the induction of high affinity receptors for bFGF in the neurons."( TGF beta 1 expression is initiated in adult auditory neurons by sectioning of the auditory nerve.
Lefebvre, PP; Martin, D; Moonen, G; Staecker, H; Van de Water, TR; Weber, T, 1992
)
1
"Transforming growth factor beta (TGFss1) has been implicated in the modulation of cellular receptors for bFGF in several cell types."( TGFSS1 modulates bFGF receptor message expression in cultured adult auditory neurons.
Lefebvre, PP; Moonen, G; Rogister, B; Staecker, H; Van de Water, TR; Weber, T, 1991
)
1
"Transforming growth factor beta (TGF beta) has been shown to influence the growth and differentiation of many cell types in vitro. "( Effects of transforming growth factor type beta on expression of cytoskeletal proteins in endosteal mouse osteoblastic cells.
Lomri, A; Marie, PJ, 1990
)
1.72

Actions

Transforming growth factor beta (TGF-beta) plays a key role in cancer metastasis, signaling through the TGF-Beta type I/II receptors (TbetaRI/II) The transforming growth factor Beta (T GF-beta 1) plays an important role in anterior segment wound healing, by controlling the cell proliferation and differentiation.

ExcerptReferenceRelevance
"Transforming growth factor beta (TGFβ) plays a key role in liver carcinogenesis. "( DNA Methylation of TGFβ Target Genes: Epigenetic Control of TGFβ Functional Duality in Liver Cancer.
Abdel Wahab, AHA; Abdel Wahab, SA; Bévant, K; Coulouarn, C; Desoteux, M; Metwally, AM, 2021
)
2.06
"Transforming growth factor beta (TGF-β) plays key roles in regulating cellular proliferation and maintaining tissue homeostasis. "( TGF-beta signaling in cancer radiotherapy.
Du, G; Lun, L; Wang, J; Wang, Z; Xu, Z, 2021
)
2.06
"Transforming growth factor beta (TGF-β) plays a key role in tumor progression, notably as a potent inducer of epithelial-mesenchymal transition (EMT). "( TGFβ-induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer.
Angenard, G; Bévant, K; Caruso, S; Coulouarn, C; Desoteux, M; Gilot, D; Louis, C; Papoutsoglou, P; Pineau, R; Sulpice, L; Zucman-Rossi, J, 2022
)
2.16
"Transforming growth factor beta (TGFβ) promotes tumorigenesis by suppressing immune surveillance and inducing epithelial to mesenchymal transition (EMT). "( Assessing methods to quantitatively validate TGFβ-dependent autophagy.
Di Guglielmo, GM; Trelford, CB, 2020
)
2
"Transforming growth factor beta 1 (TGF-β1) plays an important role in bone mineralization and has been reported to promote osteoblast proliferation and differentiation. "( The Effect of Transforming Growth Factor Beta 1 on the Mineralization of Human Cementoblasts.
Goda, S; Hamada, N; Kitagawa, M; Koba, T; Mutoh, N; Tani-Ishii, N; Watanabe, K, 2021
)
2.42
"Transforming growth factor beta (TGF-β) plays an important role in the viral liver disease progression via controlling viral propagation and mediating inflammation-associated responses. "( TGF-β isoforms inhibit hepatitis C virus propagation in transforming growth factor beta/SMAD protein signalling pathway dependent and independent manners.
Dong, B; Gao, RM; Li, H; Li, JR; Li, YH; Liu, NN; Peng, ZG; Tan, JL; Wang, MX; Wang, XK; Yan, HY; Zou, LL, 2021
)
2.31
"Transforming growth factor beta 1 (TGFβ1) plays an essential role in maintaining cartilage homeostasis. "( TGFβ1-Induced Transglutaminase-2 Triggers Catabolic Response in Osteoarthritic Chondrocytes by Modulating MMP-13.
Bae, HC; Han, HS; Lee, MC; Park, JY; Pyo, SH, 2021
)
2.06
"Transforming growth factor beta (TGF-β) plays vital roles in maintaining GSC stemness and GBM pathogenesis."( Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
Cahill, DP; Chi, AS; Curry, W; Esaki, S; Iafrate, AJ; Kiyokawa, J; Luk, S; Martuza, RL; Moon, E; Nigim, F; Rabkin, SD; Wakimoto, H, 2017
)
1.18
"Transforming growth factor beta (TGF-β) plays a major role in tissue fibrosis, including downregulation of caveolin-1 (Cav-1); however, its role in defective angiogenesis is less clear."( Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor.
Abignano, G; Cipriani, P; Del Galdo, F; Denton, CP; Derrett-Smith, EC; El-Sherbiny, YM; Elies, J; Emery, P; Esteves, F; Giacomelli, R; Grant, G; Liakouli, V; Mavria, G; Scarcia, M, 2018
)
1.2
"Transforming growth factor beta 1 (TGF-β1) plays a major role in tissue fibrosis."( ALK1 heterozygosity increases extracellular matrix protein expression, proliferation and migration in fibroblasts.
Eleno, N; López-Novoa, JM; Martínez-Salgado, C; Muñoz-Félix, JM; Perretta-Tejedor, N, 2014
)
1.12
"Transforming growth factor beta (TGF-β) plays a crucial role and takes part in many processes in the human body both in physiology and pathology. "( [SMAD family proteins: the current knowledge on their expression and potential role in neoplastic diseases].
Smolewski, P; Witkowska, M, 2014
)
1.85
"Transforming growth factor beta (TGF-β) plays a critical role in the pathogenesis of of ALI."( Effects of high-dose intravenous immunoglobulin on lipopolysaccharide-induced acute lung injury.
Akcan, AB; Coskun, M; Oygucu, SE; Oygur, N; Ozbilim, G; Ozbudak, IH; Ozel, D, 2014
)
1.12
"Transforming growth factor beta (TGF-β) plays different roles in health and disease. "( Novel patents and cancer therapies for transforming growth factor-beta and urokinase type plasminogen activator: potential use of their interplay in tumorigenesis.
Krstic, J; Maslovaric, I; Santibanez, JF, 2014
)
1.85
"Transforming growth factor beta (TGFβ) plays a major role in the regulation of tumor initiation, progression, and metastasis. "( Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.
Aakre, M; Chytil, A; Forrester, E; Gorska, AE; Moses, HL; Novitskiy, SV; Owens, P; Pickup, MW; Polosukhina, D; Shyr, Y; Ye, F; Yusupova, DR; Zhao, Z, 2014
)
2.23
"Transforming growth factor beta (TGF-β) plays a significant role in the regulation of the tumor microenvironment. "( Transforming growth factor-β synthesized by stromal cells and cancer cells participates in bone resorption induced by oral squamous cell carcinoma.
Harada, K; Kayamori, K; Nakamura, R; Oue, E; Sakamoto, K; Yamaguchi, A, 2015
)
1.86
"Transforming growth factor beta (TGF-β) promotes tumor growth, invasion and metastasis in established tumors. "( Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells.
Ardaiz, N; Berraondo, P; Gomar, C; Medina-Echeverz, J; Vasquez, M, 2015
)
2.11
"Transforming growth factor beta (TGF-β) plays a major role in tumorigenesis. "( Smad2/3/4 Pathway Contributes to TGF-β-Induced MiRNA-181b Expression to Promote Gastric Cancer Metastasis by Targeting Timp3.
Chen, L; Jiang, J; Wu, C; Xu, B; Yang, X; Zheng, X; Zhou, Q, 2016
)
1.88
"Transforming growth factor beta (TGFbeta) promotes epithelial cell differentiation but induces Schwann cell proliferation. "( Expression and localization of Ski determine cell type-specific TGFbeta signaling effects on the cell cycle.
Atanasoski, S; Grabner, H; Jacob, C; Suter, U, 2008
)
1.79
"Transforming growth factor beta (TGF-beta) plays a significant role in scar formation."( A novel TGF-beta antagonist speeds reepithelialization and reduces scarring of partial thickness porcine burns.
Huang, JS; Huang, SS; McClain, SA; Romanov, A; Rooney, J; Singer, AJ; Zimmerman, T,
)
0.85
"Transforming growth factor beta (TGF-beta) plays a role both in the induction of Treg and in the differentiation of the IL-17-secreting T cells (Th17) which drive inflammation in experimental autoimmune encephalomyelitis (EAE). "( Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis.
Carrier, Y; Hadzipasic, M; Masli, S; Rizzo, LV; Schatzmann Peron, JP; Vega, JL; Weiner, HL; Yang, K; Zhu, B, 2009
)
1.8
"Transforming growth factor beta (TGFbeta) plays a central role in extracellular matrix remodeling. "( The role of transforming growth factor beta in cervical remodeling within the rat cervix.
Chien, EK; Dailey, T; Ji, H; Long, V, 2009
)
2.17
"Transforming Growth Factor beta (TGF-beta) plays an important role in tumor invasion and metastasis. "( Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
Banach-Petrosky, W; Biswas, S; Ganapathy, V; Ge, R; Grazioli, A; Kang, Y; Lonning, S; McPherson, J; Mundy, GR; Reiss, M; Xie, W; Yingling, JM, 2010
)
1.8
"Transforming growth factor beta (TGF-beta) plays an important role in tumor initiation and progression, functioning as both a suppressor and a promoter. "( TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.
Moses, HL; Pang, Y; Yang, L, 2010
)
1.8
"Transforming growth factor beta (TGF-beta) plays an important role in diabetic retinopathy. "( High glucose-induced apoptosis in bovine retinal pericytes is associated with transforming growth factor beta and betaIG-H3: betaIG-H3 induces apoptosis in retinal pericytes by releasing Arg-Gly-Asp peptides.
Ha, SW; Han, JH; Kim, BW; Kim, JG; Lee, IK, 2010
)
2.03
"Transforming growth factor beta (TGF-beta) increase was evaluated semi-quantitatively with immunohistochemical staining methods."( [Healing of osteochondral defects in canine knee with avocado/soybean unsaponifiables: a morphometric comparative analysis].
Altınel, L; Baş, O; Köse, KC; Ozen, OA; Pamuk, K; Sahin, O; Sarıtaş, ZK, 2011
)
1.09
"Transforming growth factor beta (TGF-β) plays a key role in the pathogenesis of SSc fibrosis."( CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts.
Baron, M; Finnson, KW; Man, XY; Philip, A, 2012
)
1.1
"Transforming growth factor beta (TGF-β) plays a pivotal role in Chagas disease, not only in the development of chagasic cardiomyopathy, but also in many stages of the T. "( A phosphoproteomic approach towards the understanding of the role of TGF-β in Trypanosoma cruzi biology.
Araujo-Jorge, TC; de Oliveira, FL; Degrave, WM; Ferrão, PM; Mendonça-Lima, L; Waghabi, MC, 2012
)
1.82
"As transforming growth factor beta plays an important role in regulating cell growth and extracellular matrix synthesis, we investigated expression of transforming growth factor beta isoforms, transforming growth factor beta receptors, and transforming growth factor beta regulated Smad transcription factors following irradiation with an ultraviolet B source and solar-simulated ultraviolet irradiation of human skin in vivo."( Ultraviolet irradiation alters transforming growth factor beta/smad pathway in human skin in vivo.
Fisher, GJ; He, T; Kang, S; Quan, T; Voorhees, JJ, 2002
)
1.11
"Transforming growth factor beta1 (TGF-beta1) plays a central role in wound healing and fibrosis and has been implicated in the pathogenesis of keloid disease and hypertrophic scar."( Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels.
Bayat, A; Bock, O; Ferguson, MW; Mrowietz, U; Ollier, WE, 2003
)
1.28
"The transforming growth factor beta (TGFbeta) plays an important role in cell growth and differentiation. "( Transforming growth factor beta activates Rac1 and Cdc42Hs GTPases and the JNK pathway in skeletal muscle cells.
Charrasse, S; Comunale, F; Gauthier-Rouvière, C; Meriane, M, 2002
)
2.32
"Transforming growth factor beta (TGFbeta) can inhibit the in vitro proliferation, survival and differentiation of B cell progenitors, mature B lymphocytes and plasma cells. "( Differential regulation of mouse B cell development by transforming growth factor beta1.
Burrows, PD; Kaminski, DA; Letterio, JJ, 2002
)
2
"Transforming growth factor beta (TGFbeta) plays a central role in the pathogenesis of fibrosis by inducing and sustaining activation of fibroblasts; however, the underlying mechanisms are poorly understood."( Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts.
Chen, SJ; Mori, Y; Varga, J, 2003
)
1.04
"Transforming growth factor beta (TGF-beta) plays a prominent role in stimulating liver fibrogenesis by MFBs."( p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts.
Fujisawa, J; Furukawa, F; Inagaki, Y; Inoue, K; Matsushita, M; Matsuzaki, K; Mori, S; Nishizawa, M; Seki, T; Sugano, Y; Tahashi, Y; Yamagata, H; Yoshida, K, 2003
)
1.04
"Transforming growth factor beta (TGFbeta) plays an important role in animal development and many cellular processes. "( TGFbeta1 activates c-Jun and Erk1 via alphaVbeta6 integrin.
Luettich, K; Schmidt, C, 2003
)
1.76
"Transforming growth factor beta (TGF-beta) plays an essential role in a wide array of cellular processes. "( Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line.
Aakre, ME; Bhowmick, NA; Edgerton, M; Law, BK; Moses, HL; Shyr, Y; Xie, L, 2003
)
3.2
"Transforming growth factor beta1 (TGF-beta1) plays an important role in the formation of adhesions after abdominal operations."( Expression of transforming growth factor beta1 in patients with and without previous abdominal surgery.
Cho, K; DeWing, M; Greenhalgh, DG; Ho, HS; Hobson, KG; Wolfe, BM, 2003
)
2.12
"Transforming growth factor beta1 (TGF-beta) plays an important role in cell differentiation and vascular remodeling."( Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation.
Chen, DJ; Chu, JS; Krakowski, A; Li, S; Luo, K; Park, JS; Wang, D, 2004
)
1.28
"Transforming growth factor beta1 (TGF-beta1) plays an important role in tissue fibrosis and has been found to participate in cardiovascular disease (CVD). "( Association of TGF-beta1 polymorphisms with chronic renal disease.
Botey, A; Campos, B; Coll, E; Cormand, B; González-Núñez, D; Iñigo, P; Poch, E,
)
1.57
"Transforming growth factor beta1 (TGF-beta1) plays an important role in the modulation of cellular growth and differentiation in a wide variety of cell types and in the production/degradation of the extracellular matrix (ECM). "( Association between transforming growth factor beta1 gene polymorphisms and IgA nephropathy.
Carturan, S; Davit, A; Di Simone, D; Matullo, G; Menegatti, E; Piazza, A; Roccatello, D; Sena, LM,
)
1.9
"Transforming growth factor beta 2 (TGF-beta2) plays a critical role in growth, differentiation and cell death, but its function in the developing cerebellum is still uncertain. "( TGF-beta2 neutralization inhibits proliferation and activates apoptosis of cerebellar granule cell precurors in the developing cerebellum.
Elvers, M; Kaltschmidt, B; Kaltschmidt, C; Pfeiffer, J, 2005
)
1.77
"Transforming growth factor beta (TGFbeta) plays an essential role in that regulation."( TGFbeta-mediated immunoregulation.
Flavell, RA; Gorelik, L; Laouar, Y; Li, MO; Peng, Y, 2006
)
1.06
"Transforming growth factor beta (TGFbeta) plays an important role in development and maintenance of murine yolk sac vascular development. "( TGFbeta inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development.
Akhurst, RJ; Clermont, F; Firpo, MT; Poon, E, 2006
)
1.78
"Transforming growth factor beta-1 (TGF-beta1) plays important roles in the early development of the nervous system and has been implicated in neuronal plasticity in adult organisms. "( TGF-beta1-induced long-term changes in neuronal excitability in aplysia sensory neurons depend on MAPK.
Byrne, JH; Chin, J; Cleary, LJ; Eskin, A; Liu, RY, 2006
)
1.78
"The transforming growth factor beta (TGF-beta) plays a dual role in allergic disease. "( The role of TGF-beta in allergic inflammation.
Blaser, K; Schmidt-Weber, CB, 2006
)
0.89
"Transforming growth factor beta (TGF-beta) plays a central role in the pathogenesis of sclerotic skin diseases."( Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma.
Altmeyer, P; Breuckmann, F; Gambichler, T; Hyun, J; Kreuter, A; Skrygan, M; Sommer, A; Tomi, NS, 2006
)
1.06
"Transforming growth factor beta 1 (TGF-beta1) plays an important role in the development of radiation- and drug-induced organ diseases. "( Radiation-induced production of PAR-1 and TGF-beta 1 mRNA in lung of C57Bl6 and C3H murine strains and influence of pharmacoprophylaxis by ACE inhibitors.
Housa, D; Matej, R; Olejár, T; Poucková, P; Zadinová, M, 2007
)
1.78
"Transforming growth factor beta (TGFbeta) plays a critical role in connective tissue remodeling by fibroblasts during development, tissue repair, and fibrosis. "( FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype.
Abraham, DJ; Black, CM; Carter, DE; Chen, Y; Eastwood, M; Kennedy, L; Leask, A; Liu, S; Pala, D; Xu, SW, 2007
)
1.78
"Transforming growth factor beta (TGFbeta) plays a key role in the onset and resolution of autoimmune diseases and chronic inflammation. "( Female mice are more susceptible to developing inflammatory disorders due to impaired transforming growth factor beta signaling in salivary glands.
Amarnath, S; Ambudkar, IS; Bandyopadhyay, BC; Baum, BJ; Chen, W; Goldsmith, CM; Hall, B; Karlsson, S; Kulkarni, AB; Larsson, J; Molinolo, A; Nandula, SR; Sreenath, T; Zheng, C, 2007
)
2.01
"Transforming growth factor beta (TGF-beta) plays a critical role in the pathogenesis of the peritoneal fibrosis that complicates long-term peritoneal dialysis (PD). "( Smad7 transgene attenuates peritoneal fibrosis in uremic rats treated with peritoneal dialysis.
Chan, LY; Guo, H; Lai, KN; Lam, MF; Lan, HY; Leung, JC; Tsang, AW, 2007
)
1.78
"Transforming growth factor beta (TGF-beta) plays a central role in the pathogenesis of fibrosis by inducing and sustaining activation of keloid fibroblasts."( Inhibition of Smad3 expression decreases collagen synthesis in keloid disease fibroblasts.
Gao, Z; Hou, T; Jiang, H; Jin, Y; Lin, Z; Shi, Y; Sun, Y; Wang, Q; Wang, Z; Wu, H; Yuan, X; Zhu, X, 2007
)
1.06
"Transforming growth factor beta (TGFbeta) promotes hepatocellular apoptosis and suppresses hepatic lymphocyte responses in part through activation of Smad3. "( Pivotal role of Smad3 in a mouse model of T cell-mediated hepatitis.
Hines, IN; Kremer, M; Milton, RJ; Perry, AW; Rippe, RA; Wheeler, MD, 2008
)
1.79
"Transforming growth factor beta (TGFbeta) plays a key role in maintaining tissue homeostasis by inducing cell cycle arrest, differentiation and apoptosis, and ensuring genomic integrity. "( Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype.
Bharathy, S; Reiss, M; Xie, W; Yingling, JM, 2008
)
2.12
"Transforming growth factor beta (TGF-beta) plays a key role in cancer metastasis, signaling through the TGF-beta type I/II receptors (TbetaRI/II)."( LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q, 2008
)
1.4
"Transforming growth factor beta (TGFbeta) plays a dual role in oncogenesis, acting as both a tumor suppressor and a tumor promoter. "( Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells.
Alvarez, SE; Lebman, DA; Miller, AV; Spiegel, S, 2008
)
2.03
"Transforming growth factor beta (TGF-beta) plays active roles in tendon healing. "( Expression of transforming growth factor beta isoforms and their roles in tendon healing.
Chan, KM; Cheuk, YC; Fu, SC; Hui, WC; Wong, MW; Wong, YP,
)
1.93
"Transforming growth factor beta (TGF-beta1) promotes cartilage matrix synthesis and induces tissue inhibitor of metalloproteinases-3 (TIMP-3), which inhibits matrix metalloproteinases, aggrecanases and TNF-alpha-converting enzyme implicated in articular cartilage degradation and joint inflammation. "( Smad signaling pathway is a pivotal component of tissue inhibitor of metalloproteinases-3 regulation by transforming growth factor beta in human chondrocytes.
Qureshi, HY; Ricci, G; Zafarullah, M, 2008
)
2
"The transforming growth factor beta(TGF-beta 1) plays a central role in regulating tissue repair and remodeling after injury."( Effect of glucose on TGF-beta 1 expression in peritoneal mesothelial cells.
Chen, YG; Chen, YX; Li, HQ; Li, SL; Wang, T; Ye, RG, 1995
)
0.77
"Transforming growth factor beta (TGF-beta) plays an important role in anterior segment wound healing, by controlling the cell proliferation and differentiation, angiogenesis, extracellular matrix composition and mediating the immunosuppressive properties of the aqueous humor. "( Aqueous transforming growth factor-beta-I levels in rabbit eyes after excimer laser photoablation.
Bilgihan, A; Bilgihan, K; Gürelik, G; Hasanreisoglu, B; Imir, T; Okur, H, 1997
)
1.74
"The transforming growth factor beta (TGF-beta) plays an important role in constraining cellular proliferation, but it is also a potent inducer of programmed cell death or apoptosis. "( Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-beta.
Atfi, A; Bourgeade, MF; Ferrand, N; Gespach, C; Mazars, A; Mollat, P; Prunier, C; Tournigand, C, 2000
)
0.87
"Transforming growth factor beta (TGF-beta) plays important roles in the regulation of proliferation, differentiation, apoptosis, and carcinogenesis. "( Identification of a series of transforming growth factor beta-responsive genes by retrovirus-mediated gene trap screening.
Akiyama, N; Kizaka-Kondoh, S; Matsuo, Y; Noda, M; Sai, H, 2000
)
2.04
"Transforming growth factor beta (TGF-beta) plays an important role in skeletal remodelling. "( Production and action of transforming growth factor-beta in human osteoblast cultures: dependence on cell differentiation and modulation by calcitriol.
Eriksen, EF; Kassem, M; Kveiborg, M, 2000
)
1.75
"Transforming growth factor beta(3) promotes fascial wound healing. "( Transforming growth factor beta3 promotes fascial wound healing in a new animal model.
Bonomo, SR; Marcus, JR; Mogford, JE; Mustoe, TA; Tyrone, JW; Xia, Y, 2000
)
3.19
"Transforming growth factor beta (TGF-beta) plays an important role in the development of tubulointerstitial fibrosis in chronic renal disease. "( Antioxidant treatment induces transcription and expression of transforming growth factor beta in cultured renal proximal tubular cells.
Hannken, T; Schroeder, R; Stahl, RA; Wolf, G; Zahner, G; Ziyadeh, FN, 2001
)
1.99
"Transforming growth factor beta (TGF-beta) plays critical roles in controlling prostate cell proliferation, differentiation, and apoptosis."( SMAD3 represses androgen receptor-mediated transcription.
Hayes, SA; Peehl, DM; Sharma, M; Sun, Z; ten Dijke, P; Yang, F; Zarnegar, M, 2001
)
1.03
"Transforming growth factor beta1 (TGF beta 1) plays important roles in the regulation of cell growth and differentiation in both normal and malignant prostate epithelial cells. "( Down-regulation of Id-1 expression is associated with TGF beta 1-induced growth arrest in prostate epithelial cells.
Ling, MT; Tsao, SW; Wang, X; Wong, YC, 2002
)
1.76
"Transforming growth factor beta1 (TGF-beta1) plays an important role in fibrogenesis."( Distribution of intracellular and extracellular expression of transforming growth factor-beta1 (TGF-beta1) in human testis and their association with spermatogenesis.
Dobashi, M; Fujisawa, M; Kamidono, S; Okada, H; Yamazaki, T, 2002
)
1.04

Treatment

Transforming growth factor beta (TGFbeta) treatment of immortalized human keratinocyte cells inhibits cell-cycle progression. TGFbeta is characterized by down-regulation of c-Myc followed by up- regulation of p21(CIP1) Treatment of keratinocytes results in a suppression of differentiation and an induction of extracellular matrix production.

ExcerptReferenceRelevance
"Transforming growth factor beta (TGF beta)-treated antigen-presenting cells (APC) pulsed with antigen induce tolerance in mice, i.e. "( Mechanisms of tolerance induced by TGF beta-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGF beta.
Alard, P; Clark, SL; Kosiewicz, MM, 2004
)
1.77
"Transforming growth factor beta (TGF beta)-treated LTIC had a preferential increase in the rate of Pro alpha 1(I) gene transcription as compared with control LTIC."( Activation of Ito cells involves regulation of AP-1 binding proteins and induction of type I collagen gene expression.
Armendariz-Borunda, J; Kang, AH; Raghow, R; Roy, N; Seyer, JM; Simkevich, CP, 1994
)
1.01
"Transforming growth factor beta (TGFbeta) treatment of immortalized human keratinocyte cells inhibits cell-cycle progression and is characterized by down-regulation of c-Myc followed by up-regulation of p21(CIP1)."( A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest.
Claassen, GF; Hann, SR, 2000
)
1.26
"Transforming growth factor beta1 treatment of keratinocytes results in a suppression of differentiation, an induction of extracellular matrix production, and a suppression of growth. "( Suppression of keratinocyte growth and differentiation by transforming growth factor beta1 involves multiple signaling pathways.
Cavanagh, LL; Dahler, AL; Saunders, NA, 2001
)
2
"Transforming growth factor beta (TGF-beta) treatment resulted in reduced cell surface plasmin generation and a large increase in plasminogen activator inhibitor-type 1 (PAI-1) antigen production in NCI-H292 cells, whereas no conspicuous effects were observed with IL-1 beta and TNF alpha treatment (regulators in pulmonary epithelial cells)."( Inhibitory role of eosinophils on cell surface plasmin generation by bronchial epithelial cells: inhibitory effects of transforming growth factor beta.
Arakawa, M; Gejyo, F; Hara, K; Hasegawa, T; Igarashi, K; Koya, T; Ooi, H; Suzuki, E; Tanabe, Y; Tsukada, H, 2001
)
1.24
"Transforming growth factor beta (TGF beta)-2-treated peritoneal exudate cells (PEC) functionally resemble "eye-derived" antigen-presenting cells (APC) and contribute to the generation of Tr cells both in vitro and in vivo."( CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance.
Sonoda, KH; Stein-Streilein, J, 2002
)
1.04
"Transforming growth factor beta (TGF beta) treatment of rat osteoblast-rich calvarial cells or of the clonal osteogenic sarcoma cells, UMR 106-01, resulted in dose-dependent inhibition of plasminogen activator (PA) activity, and increased production of 3.2 kb mRNA and protein for PA inhibitor -1 (PAI-1). "( Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan, EH; Fukumoto, S; Gelehrter, TD; Heaton, JH; Martin, TJ; Yee, JA; Zeheb, R, 1991
)
3.17
"Treatment with transforming growth factor beta-1 (TGF-β), secreted from PSCs, decreased AGR2 expression, whereas inhibition of TGF-β signaling using recombinant soluble human TGF-β receptor type II and TGF-β-neutralizing antibodies restored AGR2 expression."( Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition.
Aishima, S; Fujino, M; Hattori, M; Miyazaki, T; Mizumoto, K; Mizuuchi, Y; Oda, Y; Ohuchida, K; Shindo, K; Tanaka, M, 2015
)
0.76
"Treatment with transforming growth factor beta1 (TGFbeta), which is implicated in regulation of genomic stability and is activated by radiation, reduced both the centrosome expression signature and centrosome aberrations in irradiated HMEC."( Targeted and nontargeted effects of ionizing radiation that impact genomic instability.
Barcellos-Hoff, MH; Boissière, A; Costes, SV; Erickson, AC; Fleisch, MC; Gupta, R; Maxwell, CA; Parvin, B; Ravani, SA, 2008
)
0.69
"Treatment with transforming growth factor beta1, which regulates pituitary cell proliferation, reduced Gal-3 as well as p27 expression levels in cultured HP75 pituitary cells and Gal-3 in cultured pituitary cells from p27-null mice, suggesting that p27 is not necessary for the inhibitory effects of transforming growth factor beta1 on the cell cycle in the pituitary."( Differential expression of galectin-3 in pituitary tumors.
Bayliss, J; Jin, L; Kovacs, K; Lloyd, RV; Qian, X; Raz, A; Riss, D; Scheithauer, BW; Vidal, S; Young, WF, 2003
)
0.66
"Treatment with transforming growth factor beta (TGF-beta) of hepatocytes from two different proliferative conditions, such as fetal development and adult liver regeneration, shows that regenerating cells respond to this cytokine in terms of growth inhibition, but are less sensitive than the fetal ones to the apoptosis induced by this factor. "( Resistance to TGF-beta-induced apoptosis in regenerating hepatocytes.
Alvarez, AM; Beltrán, J; Fabregat, I; Fernández, M; Herrera, B; Valdés, F, 2004
)
0.68
"Untreated transforming growth factor beta 1 suppressed the proliferative response of thymocytes to interleukin-1, as did transforming growth factor beta 1 pre-incubated with sulphated glycosaminoglycans."( Transforming growth factor beta 1-hyaluronic acid interaction.
Becchetti, E; Lilli, C; Locci, P; Marinucci, L; Martinese, D, 1995
)
2.11
"Treatment with transforming growth factor beta 1 (TGF-beta 1) results in a marked and rapid downregulation of the low affinity NGF receptor (NGFR) on cultured Schwann cells without induction of P0 gene expression."( Modulation of Schwann cell phenotype by TGF-beta 1: inhibition of P0 mRNA expression and downregulation of the low affinity NGF receptor.
Mews, M; Meyer, M, 1993
)
0.63
"Treatment with transforming growth factor beta 1 (TGF-beta 1) results in stimulation of total protein synthesis in normal dermal fibroblasts but not in keloid fibroblasts, suggesting that the TGF-beta regulatory program is altered in keloid fibroblasts. "( Keloid fibroblasts exhibit an altered response to TGF-beta.
Babu, M; Diegelmann, R; Oliver, N, 1992
)
0.64

Toxicity

ExcerptReferenceRelevance
"TGF-beta(1) injected intravitreally at doses > or = 1 micrograms is toxic to the cornea."( Ocular toxicity of intravitreous transforming growth factor-beta 1.
Federman, J; Liang, C; Peyman, GA, 1996
)
0.29
" Although not directly neurotoxic, TGF-beta1 was toxic to cerebellar cells in the presence of astrocytes."( Dependence of neurones on astrocytes in a coculture system renders neurones sensitive to transforming growth factor beta1-induced glutamate toxicity.
Brown, DR, 1999
)
0.53
" The most striking findings were as follows: rhBMP-2 could induce bone in a nonhuman primate spine; the presence of a laminectomy defect with exposed dura did not preclude the safe use of rhBMP-2 for posterolateral fusion; soft tissue compression of the collagen sponge carrier prevented bone induction at standard BMP doses, presumably due to squeezing of the protein out of the sponge; and longer rhBMP-2 loading time into the collagen carrier and mechanical protection from the soft tissue compression both allowed more bone induction at a lower dose of rhBMP-2."( Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety.
Boden, SD; Marone, MA; Martin, GJ; Moskovitz, PA, 1999
)
0.3
" DAC-30((R)) showed significant toxic effects on haEC and haSMC at each dose after > or =4 h and Lipofectin((R)) (LF) caused complete detachment of haEC and haSMC in medium containing 10% serum."( Toxicity, uptake kinetics and efficacy of new transfection reagents: increase of oligonucleotide uptake.
Axel, DI; Karsch, KR; Riessen, R; Runge, H; Spyridopoulos, I; Viebahn, R,
)
0.13
" Renal and systemic vasoconstriction, increased release of endothelin-1, decreased production of nitric acid and increased expression of TGF-beta are the major adverse pathophysiologic abnormalities of these agents."( Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies.
Bennett, WM; de Mattos, AM; Olyaei, AJ, 2001
)
0.31
" Systemic and local toxicity, significant adverse effects, and harmful effects on distant organs have not been observed in either human or animal studies on rhBMP-2 and OP-1."( Safety profile for the clinical use of bone morphogenetic proteins in the spine.
Lane, JM; Poynton, AR, 2002
)
0.31
"Given the available data, both rhBMP-2 and OP-1 appear to be safe provided they are used appropriately, placed accurately, not allowed to come into contact with decompressed areas, and contained in the region of fusion."( Safety profile for the clinical use of bone morphogenetic proteins in the spine.
Lane, JM; Poynton, AR, 2002
)
0.31
" Over a 6-month period postoperatively, the animals were serially evaluated for bone healing and adverse BMP-related consequences by using the following methods: computerized tomography (CT) scanning, magnetic resonance (MR) imaging, electroencephalography, histological investigations, and cerebrospinal fluid (CSF) analysis."( The safety and utility of recombinant human bone morphogenetic protein-2 for cranial procedures in a nonhuman primate model.
Helm, GA; Quigg, M; Seeherman, H; Sheehan, JM; Sheehan, JP, 2003
)
0.32
"Pulmonary toxicity, including fibrosis, is a serious adverse effect associated with the antidysrhythmic drug amiodarone (AM)."( Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity.
Brien, JF; Card, JW; Margolin, SB; Massey, TE; Racz, WJ, 2003
)
0.32
" All adverse events were recorded prospectively."( A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions.
Albert, TJ; Anderson, DG; Fischgrund, J; Herkowitz, H; Hilibrand, A; Patel, T; Phillips, F; Truumees, E; Vaccaro, AR, 2003
)
0.32
" Of the potential inhibitors tested, IL-4 downregulated the toxic action of microglia when applied to THP-1 cells either before stimulation or 24 h after stimulation."( Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system.
Bissonnette, CJ; Klegeris, A; McGeer, PL, 2005
)
0.33
"Analysis of the results demonstrated that TLIF combined with a BMP-2-soaked ACS is a feasible, effective, and safe method to promote lumbar fusion."( Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2.
Bulsara, KR; Burneikiene, S; Favors, M; Nelson, EL; Thramann, J; Villavicencio, AT, 2005
)
0.33
"Lead is a ubiquitous environmental and industrial pollutant that may have toxic effects on the male reproductive system."( Impacts of ascorbic acid and thiamine supplementation at different concentrations on lead toxicity in testis.
Liang, J; Shan, G; Shi, Q; Wang, C; Wang, Y; Zhang, Y, 2006
)
0.33
" Up to date, many articles evaluating beneficial and adverse effects of CsA have been published."( [Novel action of aldosterone in CsA nephrotoxicity].
Bobadilla, NA; Pérez-Rojas, JM,
)
0.13
" In conclusion, increased toxic interactions by TGF-beta1 plus CYP2E1 can occur by a mechanism involving increased production of intracellular ROS and depletion of GSH, resulting in mitochondrial membrane damage and loss of membrane potential, followed by apoptosis."( Increased toxicity by transforming growth factor-beta 1 in liver cells overexpressing CYP2E1.
Cederbaum, AI; Zhuge, J, 2006
)
0.33
"OP-1 application in the epidural space is safe based on behavioral measures and macroscopic observation on ectopic bone formation at 21 days after surgery."( Safety of epidural administration of Osteogenic Protein-1 (OP-1/BMP-7): behavioral and macroscopic observation.
Chubinskaya, S; Enyo, Y; Hashizume, H; Kawakami, M; Matsumoto, T; Okada, M; Yoshida, M, 2007
)
0.34
"Radiation induced lung toxicity (RILT) is the main adverse effect in the radiation therapy of lung cancer."( Effects of rhubarb extract on radiation induced lung toxicity via decreasing transforming growth factor-beta-1 and interleukin-6 in lung cancer patients treated with radiotherapy.
Cheng, YF; Hou, M; Hu, LK; Liu, YF; Yu, HM, 2008
)
0.35
"This study analyzed wound related or anaphylactic adverse events in patients re-exposed to rhBMP-2."( Adverse events in patients re-exposed to bone morphogenetic protein for spine surgery.
Brock, DC; Campbell, MJ; Carreon, LY; Dimar, JR; Glassman, SD; Puno, RM, 2008
)
0.35
" Here, we investigated the feasibility of applying shRNA-mediated RNA interference in fetal fibroblasts for silencing of the myostatin gene and investigate adverse effects of RNAi."( Adverse effects induced by short hairpin RNA expression in porcine fetal fibroblasts.
Golovan, SP; Li, J; Stewart, CK, 2008
)
0.35
"Properly dosed and directed gene therapy seems to be both safe and potentially efficacious."( Safety assessment of intradiscal gene therapy II: effect of dosing and vector choice.
Gilbertson, LG; Juan, L; Kang, JD; Kim, JS; Larson, JW; Levicoff, EA; Robbins, PD; Sobajima, S; Vadala, G; Wallach, CJ; Xiao, X, 2008
)
0.35
" MSC administration after AKI was not associated with adverse events and proved to be renoprotective in animals with severe renal failure."( Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury.
Cohen, A; Hu, Z; Tögel, F; Westenfelder, C; Yang, Y; Zhang, P, 2009
)
0.35
"Early outcomes using rhBMP-2 in the pediatric population show that it is a safe and efficacious adjunct to posterior spine fusions of the occipitocervical, cervical, thoracic, lumbar, and lumbosacral spine."( Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine: safety profile and efficacy in the early postoperative period.
Curry, DJ; Dauser, RC; Fahim, DK; Jea, A; Luerssen, TG; Whitehead, WE, 2010
)
0.36
"Oral thiopurines are effective and widely used in treatment of inflammatory bowel disease (IBD) in humans, although their use is limited due the development of adverse events."( Safety and efficacy of the immunosuppressive agent 6-tioguanine in murine model of acute and chronic colitis.
de Boer, NK; Jharap, B; Klimesova, K; Kverka, M; Lukas, M; Mulder, CJ; Rossmann, P; Tlaskalova-Hogenova, H; van Bodegraven, AA; Vos, RM, 2011
)
0.37
" In the original peer review, industry-sponsored publications describing the use of rhBMP-2 in spinal fusion, adverse events of these types and frequency were either not reported at all or not reported to be associated with rhBMP-2 use."( A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
Carragee, EJ; Hurwitz, EL; Weiner, BK, 2011
)
0.37
" No rhBMP-2-associated adverse events (0%) were reported in any of these studies (99% confidence interval of adverse event rate <0."( A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
Carragee, EJ; Hurwitz, EL; Weiner, BK, 2011
)
0.37
"Level I and Level II evidence from original FDA summaries, original published data, and subsequent studies suggest possible study design bias in the original trials, as well as a clear increased risk of complications and adverse events to patients receiving rhBMP-2 in spinal fusion."( A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
Carragee, EJ; Hurwitz, EL; Weiner, BK, 2011
)
0.37
" The objective of this analysis was to characterize adverse events reported after the use of rhBMP-2 in oral and maxillofacial procedures."( Adverse events reported after the use of recombinant human bone morphogenetic protein 2.
Woo, EJ, 2012
)
0.38
"The US Food and Drug Administration's Manufacturer and User Facility Device Experience database contains reports of adverse events involving medical devices."( Adverse events reported after the use of recombinant human bone morphogenetic protein 2.
Woo, EJ, 2012
)
0.38
"As of April 30, 2011, the Manufacturer and User Facility Device Experience database contained 83 reports of adverse events after oral and maxillofacial operations involving rhBMP-2."( Adverse events reported after the use of recombinant human bone morphogenetic protein 2.
Woo, EJ, 2012
)
0.38
"Serious adverse events, some of which may require a second operation, can occur after the use of rhBMP-2 in oral and maxillofacial procedures."( Adverse events reported after the use of recombinant human bone morphogenetic protein 2.
Woo, EJ, 2012
)
0.38
" We compared the toxic effects of the titanium dioxide nanoparticle UV-Titan L181 (NanoTiO2), pure or embedded in a paint matrix."( Nanotitanium dioxide toxicity in mouse lung is reduced in sanding dust from paint.
Brunborg, G; Gützkow, KB; Jackson, P; Jacobsen, NR; Jensen, KA; Koponen, IK; Madsen, AM; Mortensen, A; Saber, AT; Szarek, J; Vogel, U; Wallin, H, 2012
)
0.38
"Processed ScL extracts show less toxic than unprocessed extracts and slight reduction in anti-tumor activity, which may be related to the regulation of transforming growth factor TGF-beta."( [Study on impact of vinegar processing on toxic effect of Stellera chamaejasme].
Li, Y; Liu, A; Liu, X; Pan, G; Weng, X; Yang, Q; Zhu, X, 2012
)
0.38
"To characterize adverse events reported to the FDA; to characterize off-label use of rhBMP-2."( Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database.
Woo, EJ, 2012
)
0.38
"Review of adverse events reported to the FDA after the use of rhBMP-2 (INFUSE Bone Graft) in spinal surgery."( Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database.
Woo, EJ, 2012
)
0.38
" Adverse events were reviewed, summarized, and classified by an MD."( Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database.
Woo, EJ, 2012
)
0.38
"4%), stated that the patient required revision surgery or other invasive interventions to address the reported adverse event."( Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database.
Woo, EJ, 2012
)
0.38
"Because of their duration, scope, and expense, prospective studies designed to estimate the risk of rare adverse events may be impractical."( Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database.
Woo, EJ, 2012
)
0.38
" No instances of brain edema, herniation, airway compromise, or other adverse effects directly attributable to rhBMP-2 were observed."( Safety and efficacy of recombinant human bone morphogenetic protein 2 on cranial defect closure in the pediatric population.
Beidas, OE; Denny, AD; Deschamps-Braly, JC; El Amm, CA; Knotts, CD; Morgan, AM; Workman, MC, 2013
)
0.39
" Postoperative fusion of uninvolved sutures in 2 patients indicates that rhBMP-2 may have unreported adverse effects; consideration of this finding should be weighed against the benefit of improved closure of calvarial defects."( Safety and efficacy of recombinant human bone morphogenetic protein 2 on cranial defect closure in the pediatric population.
Beidas, OE; Denny, AD; Deschamps-Braly, JC; El Amm, CA; Knotts, CD; Morgan, AM; Workman, MC, 2013
)
0.39
"Randomized, controlled trials of rhBMP-2 versus iliac crest bone graft (ICBG) in spinal fusion surgery for degenerative disc disease and related conditions and observational studies in similar populations for investigation of adverse events."( Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data.
Brown, JV; Heirs, MK; Higgins, JP; Mannion, RJ; Rodgers, MA; Simmonds, MC; Stewart, LA, 2013
)
0.39
" Additional aggregate adverse event data were extracted from 35 published observational studies."( Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data.
Brown, JV; Heirs, MK; Higgins, JP; Mannion, RJ; Rodgers, MA; Simmonds, MC; Stewart, LA, 2013
)
0.39
"Primary outcomes were pain (assessed with the Oswestry Disability Index [ODI] or Short Form-36), fusion, and adverse events."( Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data.
Brown, JV; Heirs, MK; Higgins, JP; Mannion, RJ; Rodgers, MA; Simmonds, MC; Stewart, LA, 2013
)
0.39
" For adverse events, meta-analysis of the published aggregate data was not possible and we compared the number and type of adverse events reported between data sources."( Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion.
Brown, JV; Heirs, MK; Higgins, JP; Mannion, RJ; Rodgers, MA; Simmonds, MC; Stewart, LA, 2013
)
0.39
" A minority of adverse event data known to have been collected were reported in the published literature."( Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion.
Brown, JV; Heirs, MK; Higgins, JP; Mannion, RJ; Rodgers, MA; Simmonds, MC; Stewart, LA, 2013
)
0.39
" In contrast, reporting of adverse event data in trial publications was inadequate and inconsistent to the extent that any systematic review based solely on the publicly available data would not be able to properly evaluate the safety of rhBMP-2."( Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion.
Brown, JV; Heirs, MK; Higgins, JP; Mannion, RJ; Rodgers, MA; Simmonds, MC; Stewart, LA, 2013
)
0.39
"The main side effect of cyclosporine A (CsA), a widely used immunosuppressive drug, is nephrotoxicity."( Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model.
Burdmann, EA; Carlos, CP; Oliani, SM; Sonehara, NM, 2014
)
0.4
" We concluded that mannose 6-phosphate, although safe and tolerable, had no beneficial effect on finger range of motion after Zone II tendon division."( A multicentre, randomized, double-blind trial of the safety and efficacy of mannose-6-phosphate in patients having Zone II flexor tendon repairs.
Akhavani, M; Boyce, D; Brown, A; Dewer, D; Gillespie, P; Lees, VC; Papanastasiou, S; Ragoowansi, R; Warwick, D; Wong, J, 2015
)
0.42
"Research has indicated that adverse effects terms are increasingly prevalent in the title, abstract or indexing terms of articles that contain adverse drug effects data in MEDLINE and Embase."( Failure or success of search strategies to identify adverse effects of medical devices: a feasibility study using a systematic review.
Golder, S; Rodgers, M; Wright, K, 2014
)
0.4
" For each included study, the corresponding database record on MEDLINE and Embase was assessed to measure the presence or absence of adverse effects terms in the title, abstract or indexing."( Failure or success of search strategies to identify adverse effects of medical devices: a feasibility study using a systematic review.
Golder, S; Rodgers, M; Wright, K, 2014
)
0.4
" Ninety-four percent (48/51) of the records on MEDLINE and 95% (52/55) of the records on Embase contained at least one adverse effects related search term."( Failure or success of search strategies to identify adverse effects of medical devices: a feasibility study using a systematic review.
Golder, S; Rodgers, M; Wright, K, 2014
)
0.4
"The search filters currently available for adverse drug effects are not necessarily useful for searching adverse effects data of medical devices."( Failure or success of search strategies to identify adverse effects of medical devices: a feasibility study using a systematic review.
Golder, S; Rodgers, M; Wright, K, 2014
)
0.4
"Preventive application of SLIT in young children was safe (no relevant side effects in 21,170 single applications)."( Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects.
Bannert, C; Dehlink, E; Eiwegger, T; Graf, A; Gruber, S; Hassler, M; Lupinek, C; Mayer, E; Ronceray, L; Szépfalusi, Z; Urbanek, R; Valenta, R; Wissmann, E, 2014
)
0.4
"Preventive SLIT is safe in children 2-5 yr of age and induces regulatory mechanisms involving allergen-specific IgG and IL10."( Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects.
Bannert, C; Dehlink, E; Eiwegger, T; Graf, A; Gruber, S; Hassler, M; Lupinek, C; Mayer, E; Ronceray, L; Szépfalusi, Z; Urbanek, R; Valenta, R; Wissmann, E, 2014
)
0.4
"AZ876 activation of LXR protects from adverse cardiac remodelling in pathological pressure overload, independently of blood pressure."( The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects.
Candido, WM; Cannon, MV; de Boer, RA; Dokter, MM; Lindstedt, EL; Silljé, HH; van Gilst, WH; Yu, H, 2015
)
0.42
" However, with increasing clinical use of BMP-2, a growing and well-documented side effect profile has emerged."( A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.
Asatrian, G; James, AW; LaChaud, G; Nguyen, V; Shen, J; Soo, C; Ting, K; Zhang, X, 2016
)
0.43
" The incidence of adverse reaction in patients was assayed; the therapeutic efficacy of observation and control groups was judged after treatment curses."( [Effect and Safety of CIK Cell Infusion on Peripheral Blood Immune Cell Level in the Elderly Patients with Multiple Myeloma].
Liu, L; Qin, SF, 2016
)
0.43
" Treatment-related adverse events (AEs) included anemia, fatigue, thrombocytopenia, fever, and injection site reactions."( Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Autio, KA; Bauer, TM; Bendell, JC; Chan, IH; Colen, RR; Falchook, GS; Hong, DS; Infante, JR; Mumm, JB; Naing, A; Oft, M; Ott, PA; Pant, S; Papadopoulos, KP; Patel, MR; Rasco, DR; Tannir, NM; Van Vlasselaer, P; Whiteside, M; Wong, DJ, 2016
)
0.43
" Also, the "critical window" and safe dose of this treatment are largely unknown."( Course-, dose-, and stage-dependent toxic effects of prenatal dexamethasone exposure on fetal articular cartilage development.
Chen, L; Chen, Z; Li, B; Li, Y; Wang, H; Zhang, X; Zhao, Z, 2018
)
0.48
" Adverse effects of TGF-β inhibitors in respiratory clinical trials are comprehensively reviewed, including those of the marketed TGF-β modulators, pirfenidone and nintedanib."( Safer approaches to therapeutic modulation of TGF-β signaling for respiratory disease.
Douglass, J; Lachapelle, P; Li, M; Stewart, A, 2018
)
0.48
"Renal injury is a hallmark adverse reaction to sodium valproate (SVP), and caffeic acid (CAFF) is a phenolic compound that has anti-inflammatory and antioxsidant properties."( Study on the influence of caffeic acid against sodium valproate-induced nephrotoxicity in rats.
Gad, AM, 2018
)
0.48
"This 12-week clinical trial evaluated efficacy and adverse events for two recombinant human bone morphogenetic protein-2 (rhBMP-2) delivery systems in alveolar ridge preservation."( A randomized controlled clinical trial evaluating efficacy and adverse events of different types of recombinant human bone morphogenetic protein-2 delivery systems for alveolar ridge preservation.
Cho, YD; Jo, DW; Kim, YK; Lee, HJ; Lee, YM; Seol, YJ, 2019
)
0.51
" Adverse events were assessed in the same period."( A randomized controlled clinical trial evaluating efficacy and adverse events of different types of recombinant human bone morphogenetic protein-2 delivery systems for alveolar ridge preservation.
Cho, YD; Jo, DW; Kim, YK; Lee, HJ; Lee, YM; Seol, YJ, 2019
)
0.51
"All patients showed good healing without severe adverse events."( A randomized controlled clinical trial evaluating efficacy and adverse events of different types of recombinant human bone morphogenetic protein-2 delivery systems for alveolar ridge preservation.
Cho, YD; Jo, DW; Kim, YK; Lee, HJ; Lee, YM; Seol, YJ, 2019
)
0.51
"The delivery systems showed similar efficacy for alveolar ridge preservation without severe adverse events."( A randomized controlled clinical trial evaluating efficacy and adverse events of different types of recombinant human bone morphogenetic protein-2 delivery systems for alveolar ridge preservation.
Cho, YD; Jo, DW; Kim, YK; Lee, HJ; Lee, YM; Seol, YJ, 2019
)
0.51
"' Two independent investigators screened eligible studies, assessed the bias of original articles, extracted data including fusion success, Oswestry disability index improvement, improved short form 36 questionnaire scores, adverse events and re-operation, and a subgroup analysis."( Comparative Clinical Effectiveness and Safety of Bone Morphogenetic Protein Versus Autologous Iliac Crest Bone Graft in Lumbar Fusion: A Meta-analysis and Systematic Review.
Chen, C; Liang, Z; Liu, S; Wang, Y; Zhou, M, 2020
)
0.56
" Inhibition of TGFβ signaling in nonclinical toxicology species is associated with serious adverse toxicities including cardiac valvulopathies and anemia."( A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys.
Adedeji, AO; Dave, RA; Holdren, MS; Lancaster, K; Liang, WC; Meng, YG; Mitra, MS; Palanisamy, GS; Schutten, MM; Turley, SJ; Vernes, JM; Wu, Y; Zhong, F, 2020
)
0.56
" Six patients (19%) experienced grade 3 treatment-related adverse events (AE); no grade 4 events occurred."( Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Bang, YJ; Chung, HC; Doi, T; Dussault, I; Helwig, C; Kang, YK; Kondo, S; Muro, K; Osada, M, 2020
)
0.56
" Eight patients experienced treatment-related adverse events (TRAEs)."( Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Doi, T; Fujiwara, Y; Helwig, C; Ikeda, M; Koyama, T; Kudo, M; Vugmeyster, Y; Watanabe, M, 2020
)
0.56
" In conclusion, ESMR therapy is safe and effective in most but not all patients with CAD and heart failure."( Effectiveness and Safety of Extracorporeal Shockwave Myocardial Revascularization in Patients With Refractory Angina Pectoris and Heart Failure.
Alexanderson-Rosas, E; Amezcua-Guerra, LM; Azar-Manzur, F; Bojalil, R; Brianza-Padilla, M; Carvajal-Juárez, I; González-Pacheco, H; Gopar-Nieto, R; Hernández, S; López-Mora, E; Márquez-Velasco, R; Martínez-Sánchez, C; Massó, F; Paez-Arenas, A; Sandoval, J; Venegas-Román, A, 2021
)
0.62
"BMP-2 is a safe and effective osteoinductive material in short-level lumbar PLF surgery."( Efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in additional lumbar posterolateral fusion: minimum 1-year follow-up.
Choi, SH; Kang, CN; Lee, MK; Son, HJ, 2021
)
0.62
" Adverse events were minimal."( Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE.
Gilkeson, G; Kamen, DL; Li, Z; Nietert, PJ; Paulos, C; Wallace, C; Wang, H; Wei, C; Wolf, BJ; Wyatt, M, 2022
)
0.72
"This phase 1 trial suggests that umbilical cord (UC) MSC infusions are very safe and may have efficacy in lupus."( Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE.
Gilkeson, G; Kamen, DL; Li, Z; Nietert, PJ; Paulos, C; Wallace, C; Wang, H; Wei, C; Wolf, BJ; Wyatt, M, 2022
)
0.72
" The secondary outcomes will be as follows: clinical outcomes (visual analog scale score, EuroQol-5-dimensions-5-level score, Oswestry Disability Index score, and some surgery-related variables) and adverse effects (radiculitis, heterotrophic ossification, endplate resorption, and osteolysis)."( Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-bli
Choi, JY; Kang, CN; Park, HJ; Park, SM; Song, KS, 2022
)
0.72
" Due to the functional duality of TGFβ in cancer, one can hypothesize that inhibiting this pathway could result in beneficial or adverse effects depending on tumor subtypes."( Transcriptomic evidence for tumor-specific beneficial or adverse effects of TGFβ pathway inhibition on the prognosis of patients with liver cancer.
Angenard, G; Bévant, K; Boudjema, K; Coulouarn, C; Desoteux, M; Ferlier, T; Leroux, R; Louis, C; Maillot, B; Sulpice, L, 2023
)
0.91
"Doxorubicin (DOX) is an anti-neoplastic therapy, but its use is limited by its deleterious toxic effects including nephrotoxicity and cardiotoxicity."( Ceratonia siliqua pods (Carob) methanol extract alleviates doxorubicin-induced nephrotoxicity via antioxidant, anti-inflammatory and anti-apoptotic pathways in rats.
Atta, AH; Atta, SA; El-Aziz, THA; Emam, SR; Ibrahim, MA; Khattab, MS; Mouneir, SM; Nasr, SM, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Clearance studies in mice show that the half-life of 125I-TGF-beta 1 in the circulation (1."( Interaction of transforming growth factor-beta 1 with alpha 2-macroglobulin. Role in transforming growth factor-beta 1 clearance.
O'Connor-McCourt, MD; Philip, A, 1991
)
0.28
" A detailed pharmacokinetic and tissue distribution study was performed to support the clinical development of rhTGF-beta 1 for wound healing indications."( Pharmacokinetics and tissue distribution of recombinant human transforming growth factor beta 1 after topical and intravenous administration in male rats.
Chen, SA; Green, JD; Lewis, D; Lucas, C; Mora-Worms, M; Mordenti, J; Richardson, L; Zioncheck, TF, 1994
)
0.53
" Pharmacokinetic analysis demonstrated that hepatic uptake clearance was large and accounted almost completely for total body clearance; in addition the clearance values decreased as the dose increased, suggesting that the hepatic uptake of decorin is mediated by a specific mechanism which becomes saturated at higher doses."( Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice.
Hashida, M; Masuda, H; Takakura, Y, 1999
)
0.3
" The pharmacokinetic profiles of M and inactive morphine-3-glucuronide (M3G) in morphine-treated mice nearly overlapped those in heroin-treated mice, with the only difference being the presence of 6-monoacetylmorphine (AM) in profiles of the latter group."( Pharmacokinetics and cytokine production in heroin and morphine-treated mice.
Bacosi, A; di Carlo, S; Pacifici, R; Pichini, S; Zuccaro, P, 2000
)
0.31
" For pharmacokinetic analyses, concentrations of aptamers in plasma and aqueous humor were determined over time following bilateral subconjunctival administration to Dutch-belted rabbits using a hybridization-based pseudo-enzyme-linked immunosorbent assay (ELISA) assay."( Pharmacologic and pharmacokinetic assessment of anti-TGFbeta2 aptamers in rabbit plasma and aqueous humor.
Epstein, DM; Gilbert, M; Kurz, JC; Lewis, SD; Marsh, HN; McCauley, TG; Merlino, PG, 2006
)
0.33

Compound-Compound Interactions

ExcerptReferenceRelevance
" alpha-CD3 combined with IL-2 significantly reversed AF suppression at 100 units IL-2/ml and at 1000 units/ml completely reversed suppression by two of three highly suppressive samples of AF."( Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody.
Clark, DA; Hirte, HW; Mazurka, J; O'Connell, G; Rusthoven, J, 1992
)
0.28
"The modulation of cell growth by tumor necrosis factor-alpha (TNF-alpha), or TNF-alpha in combination with transforming growth factor-beta (TGF-beta) or interferon-gamma (IFN-gamma) was investigated."( Downregulation of c-myc expression by tumor necrosis factor-alpha in combination with transforming growth factor-beta or interferon-gamma with concomitant inhibition of proliferation in human cell lines.
Hori, M; Kamijo, R; Nagumo, M; Takeda, K, 1994
)
0.29
"This report shows for the first time that platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor-beta (TGF-beta) can interact in a synergistic manner with retinoic acid to stimulate the production of tissue inhibitor of metalloproteinases (TIMP) from human skin and synovial fibroblasts."( Effect of retinoic acid in combination with platelet-derived growth factor-BB or transforming growth factor-beta on tissue inhibitor of metalloproteinases and collagenase secretion from human skin and synovial fibroblasts.
Bigg, HF; Cawston, TE, 1996
)
0.29
"The purpose of this study was to investigate the efficacy of BCP granules combined with rhBMP-2 for ectopic bone formation in rats."( [Ectopic bone induction in recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with biphasic calcium phosphate (BCP)].
Higuchi, T; Ishikawa, I; Kinoshita, A; Oda, S; Shizuya, T, 1996
)
0.29
"Tricalcium phosphate (TCP) was combined with amylopectin to form a deliverable carrier paste for recombinant human transforming growth factor beta 1 (rhTGF-beta 1) intended for bone repair applications."( Development of tricalcium phosphate/amylopectin paste combined with recombinant human transforming growth factor beta 1 as a bone defect filler.
Beck, LS; DeGuzman, L; Lee, WP; Nguyen, T; Ongpipattanakul, B; Osaka, G; Wong, R; Zioncheck, TF, 1997
)
0.73
" Most importantly, we developed a procedure to specifically stain the mineralized matrix green in combination with a red staining of the NCPs."( Immunolocalization and quantification of noncollagenous bone matrix proteins in methylmethacrylate-embedded adult human bone in combination with histomorphometry.
Birkenhäger-Frenkel, DH; Bosman, FT; Derkx, P; Houtsmuller, AB; Nigg, AL; Pols, HA; van Leeuwen, JP, 1998
)
0.3
"We investigated ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) in the rat dorsum."( Ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2).
Higuchi, T; Ishikawa, I; Kinoshita, A; Oda, S; Shizuya, T, 1997
)
0.3
" Moreover, naive OVA323-339-specific Th cells that were stimulated by APCs and OVA323-339 peptide differentiated toward Th1 cells after priming in the presence of IL-4 in combination with TGF-beta."( IL-4 in combination with TGF-beta favors an alternative pathway of Th1 development independent of IL-12.
Hoehn, P; Kerdine, S; Koelsch, S; Lingnau, K; Neudoerfl, C; Palm, N; Ruede, E; Schmitt, E, 1998
)
0.3
" Here we show that in addition to the apoptosis-inhibitory effect, AIM induces strong, long-term inhibition of B lymphocyte proliferation in combination with transforming growth factor-beta1 (TGF-beta1 in vitro), resulting in almost complete block of proliferation and immunoglobulin secretion."( AIM, a murine apoptosis inhibitory factor, induces strong and sustained growth inhibition of B lymphocytes in combination with TGF-beta1.
Miyazaki, T; Ohnishi, S; Onodera, T; Yusa, S, 1999
)
0.3
" Combined with rhBMP-2, this cement was rapidly resorbed and completely healed the defects."( Healing of segmental bone defects in rats induced by a beta-TCP-MCPM cement combined with rhBMP-2.
Hamanishi, C; Matsuda, N; Ohura, K; Tanaka, S, 1999
)
0.3
"Oncostatin M in combination with interleukin-1 (IL-1) induced a rapid and reproducible release of collagen from bovine nasal cartilage in culture."( Transforming growth factor beta1 blocks the release of collagen fragments from boving nasal cartilage stimulated by oncostatin M in combination with IL-1alpha.
Cawston, T; Hui, W; Rowan, AD, 2000
)
1.75
" Administration of TGF-beta 1 alone or in combination with Ca(OH)2 increases the synthesis of TGF-beta 1 in osteoblast cultures."( TGF-beta 1 alone and in combination with calcium hydroxide is synergistic to TGF-beta 1 production by osteoblasts in vitro.
Gutmann, JL; Harper, RP; Jaunberzins, A; Witherspoon, DE, 2000
)
0.31
" The possible association of a C 509-->T polymorphism in the promoter region of the transforming growth factor-beta1 gene, alone or in combination with a T869-->C (Leu10-->Pro) polymorphism, with bone mineral density and genetic susceptibility to osteoporosis was investigated in 625 postmenopausal Japanese women."( Association of the C-509-->T polymorphism, alone of in combination with the T869-->C polymorphism, of the transforming growth factor-beta1 gene with bone mineral density and genetic susceptibility to osteoporosis in Japanese women.
Harada, A; Miyauchi, A; Mizuno, M; Takagi, Y; Tanaka, M; Yamada, Y, 2001
)
0.31
"This study was designed to examine the effect of aging on bone formation induced by recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with a fibrous collagen membrane (FCM)."( Effect of aging on bone formation induced by recombinant human bone morphogenetic protein-2 combined with fibrous collagen membranes at subperiosteal sites.
Kato, H; Kawanami, M; Matsumoto, A; Yamaji, K, 2001
)
0.31
" We designed the present study to investigate histomorphometrically whether combination with recombinant human TGF-beta1 could promote bone repair caused by OCP per se (Control/OCP)."( Implantation of octacalcium phosphate combined with transforming growth factor-beta1 enhances bone repair as well as resorption of the implant in rat skull defects.
Kagayama, M; Kamakura, S; Katou, F; Motegi, K; Nakajo, S; Sasano, Y; Shimizu, T; Suzuki, O, 2001
)
0.31
" This pilot study indicates that rhBMP-2 increases the rate and extent of bone formation in combination with dental implants."( Effect on bone healing of bone morphogenetic protein placed in combination with endosseous implants: a pilot study in beagle dogs.
Buser, D; Fiorellini, JP; Howell, TH; Riley, E, 2001
)
0.31
"The purpose of this study was to evaluate the availability of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with hydroxyapatite (HA) and autogenous bone."( Hydroxyapatite granule graft combined with recombinant human bone morphogenic protein-2 for solid lumbar fusion.
Konishi, S; Nagayama, R; Nakamura, H; Seki, M; Yamano, Y, 2002
)
0.31
"To investigate the effects of the mixed endothelin receptor antagonist, bosentan, combined with the long-acting calcium channel blocker, amlodipine, compared to the angiotensin-converting enzyme inhibitor, cilazapril, on the progressive renal injury in spontaneous hypertensive rats (SHR) with diabetes."( Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W, 2002
)
0.31
"Bosentan combined with amlodipine can offer similar renoprotective effects on that of cilazapril and may be a potent therapy to attenuate renal injury by reducing renal protein levels of TGF-beta1 in diabetes with a hypertensive state."( Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W, 2002
)
0.31
"Oncostatin M (OSM) in combination with tumour necrosis factor alpha (TNF alpha) promotes marked collagen breakdown from bovine cartilage in explant culture."( Transforming growth factor beta 1 and insulin-like growth factor 1 block collagen degradation induced by oncostatin M in combination with tumour necrosis factor alpha from bovine cartilage.
Cawston, T; Hui, W; Rowan, AD, 2003
)
1.76
"The expression of the TGF-beta 1 in conjunctival epithelium of 24 patients with dry eye were studied by impression cytology combined with immunohistochemical staining and observed by microscope."( [Application of cellulose acetate membrane with the technique of impression cytology combined with immunohistochemical staining for detection of dry eye].
Feng, G; Lin, J; Luo, L; Zhang, P; Zhen, H; Zhong, X, 2000
)
0.31
" Combined with immunohistochemistry staining, it is suitable to observe the conjunctival cells by this technique which has an important value for the examination of the ocular surface disease."( [Application of cellulose acetate membrane with the technique of impression cytology combined with immunohistochemical staining for detection of dry eye].
Feng, G; Lin, J; Luo, L; Zhang, P; Zhen, H; Zhong, X, 2000
)
0.31
" Alternative approaches aimed at overcoming this problem have included a special design of the revision prosthesis and allo- or autogeneic bone grafting in combination with or without biomaterials."( Repair of a proximal femoral bone defect in dogs using a porous surfaced prosthesis in combination with recombinant BMP-2 and a synthetic polymer carrier.
Horiuchi, H; Murakami, N; Nawata, M; Nozaki, K; Okada, T; Ota, H; Saito, N; Takahashi, J; Takaoka, K, 2003
)
0.32
"028) only when applied in combination with autogenous bone (62."( Effects of platelet-rich plasma on bone healing in combination with autogenous bone and bone substitutes in critical-size defects. An animal experiment.
Kessler, P; Kloss, FR; Nkenke, E; Schlegel, KA; Schultze-Mosgau, S; Wiltfang, J; Zimmermann, R, 2004
)
0.32
"Beta-tricalcium phosphate (beta-TCP) combined with recombinant human bone morphogenetic protein-2 (BMP-2) was examined as a substitute for autograft for packing into interbody fusion cages in the canine lumbar spine model."( Beta-tricalcium phosphate combined with recombinant human bone morphogenetic protein-2: a substitute for autograft, used for packing interbody fusion cages in the canine lumbar spine.
Iwata, H; Kubo, Y; Ohyama, T; Taki, W, 2004
)
0.32
"5 mg/mL) could be successful for achieving posterolateral spine fusion when combined with an osteoconductive bulking agent that can support the induced new bone formation."( Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates.
Barnes, B; Boden, SD; Louis-Ugbo, J; Minamide, A; Park, JS; Park, MS; Tomak, PR, 2005
)
0.33
" There were no signs of a stimulating effect of PC on bone formation in combination with autografts or bone substitutes at any time point (P = ."( Bone regeneration in standardized bone defects with autografts or bone substitutes in combination with platelet concentrate: a histologic and histomorphometric study in the mandibles of minipigs.
Broggini, N; Buser, D; Hjôrting-Hansen, E; Jensen, SS; Schenk, R; Weibrich, G,
)
0.13
"To study in vitro sustained release behaviour of the recombinant human bone morphogenetic protein 2 (rhBMP-2) from the sample which porous calcium phosphate cement (PCPC) was combined with rhBMP-2, and to evaluate the effect of PCPC/rhBMP-2 composite on repairing bone defect in the animal study."( [Experimental studies on the porous calcium phosphate cement combined with recombinant human bone morphogenetic protein 2 for bone defects repair].
Cao, X; Chen, J; Liu, C, 2006
)
0.33
"To experimentally evaluate the ectopic osteogenetic capacity of synthesized BMP2-derived peptide P24 combined with poly lactic-co-glycolic acid (PLGA), Wistar rats were divided into two groups: group A, in which BMP2-derived peptide P24/PLGA complex was implanted, and group B which received simple PLGA implant."( Experimental research on ectopic osteogenesis of BMP2-derived peptide P24 combined with PLGA copolymers.
Chen, S; Duan, Z; Guo, X; Yuan, Q; Zheng, Q, 2007
)
0.34
" The study objective was to determine and compare the ability of adenovirus BMP2 ex vivo gene therapy in combination with three types of collagen carriers to release BMP2 in vitro and to induce heterotopic bone formation in vivo."( Adenovirus BMP2-induced osteogenesis in combination with collagen carriers.
Davis, AR; Fouletier-Dilling, CM; Gannon, FH; Gugala, Z; Lindsey, RW; Olmsted-Davis, EA, 2007
)
0.34
"To investigate the effects of reconstruction of maxillary sinus lateral bone wall and mucosa defect with collagen sponge and acellular cancellous bone combined with bone morphogenetic protein (BMP)-2 in situ."( [Reconstruction of maxillary sinus lateral bone wall and mucosa defect of with collagen sponge and acellular cancellous bone combined with bone morphogenetic protein-2].
Li, XS; Sun, JJ, 2007
)
0.34
" Acellular porcine cancellous vertebral bone was obtained, combined with BMP-2, trimmed to suit the defect, and put into the defect of the experimental group with collagen sponge soaked in venous blood, fixed by protein glue."( [Reconstruction of maxillary sinus lateral bone wall and mucosa defect of with collagen sponge and acellular cancellous bone combined with bone morphogenetic protein-2].
Li, XS; Sun, JJ, 2007
)
0.34
" Collagen sponge and acellular cancellous bone combined with BMP-2 can be used to repair the defects of the maxillary sinus bone wall and mucosa."( [Reconstruction of maxillary sinus lateral bone wall and mucosa defect of with collagen sponge and acellular cancellous bone combined with bone morphogenetic protein-2].
Li, XS; Sun, JJ, 2007
)
0.34
"A chitosan-coated pressed calcium sulfate pellet combined with recombinant human bone morphogenetic protein 2 (rhBMP-2) has been developed with increased compressive strength and osteoinduction, but with a resorption profile only slightly slower than uncoated pellet."( Effects of chitosan-coated pressed calcium sulfate pellet combined with recombinant human bone morphogenetic protein 2 on restoration of segmental bone defect.
Cui, X; Gao, Y; Wang, Y; Zhang, B, 2008
)
0.35
"To compare the effect of PLGA and collagen sponge combined with rhBMP-2 on repairing of articular cartilage defect in rabbits respectively."( [The comparative study on the reparative effect of PLGA and collagen sponge combined with BMP on the articular cartilage defect of rabbits].
Cui, Y; Hu, Y; Wu, J, 2008
)
0.35
"To evaluate the effect of autologous bone marrow mesenchymal stem cells (BMSCs) seeded bio-derived bone materials (BBM) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) in repairing defect of osteonecrosis of femoral head (ONFH)."( Treatment of osteonecrosis of femoral head with BMSCs-seeded bio-derived bone materials combined with rhBMP-2 in rabbits.
Jiang, H; Wu, ZG; Xiao, ZM; Zhan, XL; Zhang, XL, 2008
)
0.35
" Then the animals were divided into three groups according to the type of implants for bone repair: 12 rabbits with nothing (Group I, the blank control group), 12 with BBM combined with rhBMP-2 (Group II), and 12 with BMSCs-seeded BBM combined with rhBMP-2 (Group III)."( Treatment of osteonecrosis of femoral head with BMSCs-seeded bio-derived bone materials combined with rhBMP-2 in rabbits.
Jiang, H; Wu, ZG; Xiao, ZM; Zhan, XL; Zhang, XL, 2008
)
0.35
"Our findings indicate a superior choice of repairing the experimental defect of ONFH with BMSCs- seeded BBM combined with rhBMP-2."( Treatment of osteonecrosis of femoral head with BMSCs-seeded bio-derived bone materials combined with rhBMP-2 in rabbits.
Jiang, H; Wu, ZG; Xiao, ZM; Zhan, XL; Zhang, XL, 2008
)
0.35
"The therapeutic effects of anluohuaxian tablet combined with gamma-IFN on schistosomal liver fibrosis and its mechanism were studied in a murine model and clinical cases of schistosomal liver fibrosis."( Effect of anluohuaxian tablet combined with gamma-IFN on schistosomal liver fibrosis.
Ai, G; Huang, H; Huang, J; Huang, T; Jiao, Y; Li, L; Ma, K; Xiao, F; Yu, H, 2009
)
0.35
" In this article, the allograft bone combined with growth factors transplantation for repairing bone defects were reviewed."( [Study progress of allograt bone combined with growth factors transplantation].
Fan, XL; Zhan, X; Zhou, H, 2009
)
0.35
" Chitosan-coated pressed calcium sulfate pellets combined with recombinant human bone morphogenetic protein 2 (rhBMP-2) have been developed that exhibit decreased resorption speed and increased compressive strength and osteoinduction."( Effects of chitosan-coated pressed calcium sulfate pellets combined with recombinant human bone morphogenetic protein 2 on bone formation in femoral condyle-contained bone defects.
Chen, H; Cui, X; Tang, P; Tian, X; Wang, Y; Yu, X; Zhang, B, 2010
)
0.36
" The effects of casein or soya protein combined with palm or safflower-seed oil on various serum parameters and renal histology were investigated on hyperuricaemic rats."( Relative efficacy of casein or soya protein combined with palm or safflower-seed oil on hyperuricaemia in rats.
Chiou, HY; Lai, SH; Lo, HC; Wang, YH; Yang, Y, 2010
)
0.36
" We investigated the potential synergistic anti-tumor activity of TbetaR1-KI in combination with doxorubicin in animal models of metastatic breast cancer."( Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.
Agyin, J; Bandyopadhyay, A; De, K; Lin, S; Sun, LZ; Tang, Y; Wang, L; Yeh, IT, 2010
)
0.36
" Simultaneous treatment with TNF-alpha and chemokine resulted in up to a fifteen-fold stimulation of MMP-9 secretion and treatment with TGF-beta and chemokine resulted in up to a fifteen-fold stimulation of MMP-2 secretion, while TNF-alpha in combination with CCL4 stimulated MMP-14 expression five-fold."( Divergent and synergistic regulation of matrix metalloprotease production by cytokines in combination with C-C chemokines.
Richardson, VJ,
)
0.13
" If PRP is combined with these scaffolds clinically, no exogenous activation with thrombin is required to achieve growth factor release, which may be of benefit for articular cartilage repair applications."( Platelet-rich plasma activation in combination with biphasic osteochondral scaffolds-conditions for maximal growth factor production.
Brooks, R; Fortier, LA; Getgood, A; Henson, F; Rushton, N, 2011
)
0.37
" TBT, when given alone and also in combination with forskolin, decreased IL-1β, TNFα, IFNγ, IFNα, Mx3, and IGF-1 gene expression."( Immune-regulatory transcriptional responses in multiple organs of Atlantic salmon after tributyltin exposure, alone or in combination with forskolin.
Arukwe, A; Pavlikova, N, 2011
)
0.37
" These data demonstrate that TNF-α in combination with TGF-β efficiently generates preosteoclasts in vitro."( Characterization and identification of subpopulations of mononuclear preosteoclasts induced by TNF-α in combination with TGF-β in rats.
Funakubo, N; Ichigi, Y; Kukita, A; Kukita, T; Matsubara, R; Miyamoto, H; Nonaka, K; Qu, PF; Takigawa, I, 2012
)
0.38
" CPT-11 treatment alone or combined with blocking monoclonal antibodies (mAb) against co-stimulatory molecules (LFA-1 and CD154) was evaluated in the prevention of heart transplant rejection in alloantigen-primed mice."( Irinotecan combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice.
Chen, J; Chen, Z; Cheng, P; He, Z; Liu, Z; Qi, Z; Yang, R; Zhang, S, 2013
)
0.39
"Steady-state tissue renewal in the native human colonic epithelium is dependent on canonical Wnt signals combined with suppressed TGFβ/BMP pathways."( Canonical Wnt signals combined with suppressed TGFβ/BMP pathways promote renewal of the native human colonic epithelium.
Bigwood, L; El Hadi, A; Hernon, J; Jamieson, C; Kam, C; Kapur, S; Lewis, M; Mitchell, E; Münsterberg, A; Oue, N; Parris, A; Reynolds, A; Sargen, K; Sobolewski, A; Speakman, C; Stebbings, W; Tighe, R; Wharton, N; Wharton, R; Williams, MR; Yasui, W, 2014
)
0.4
" However, it remains unclear whether expression of BAMBI alone or in combination with Smad7 is associated with the progression of gastric cancer."( Expression of BAMBI and its combination with Smad7 correlates with tumor invasion and poor prognosis in gastric cancer.
Sun, M; Sun, X; Wei, M; Xiao, Q; Xu, H; Yu, Z; Zhang, J; Zhang, Y; Zhu, Z, 2014
)
0.4
" Results showed that JAG1-DC treatment combined with anti-CD40L monoclonal antibody (mAb) administration significantly prolonged cardiac allograft survival in mice, with long-term survival (>110 days) of 50% of the allografts in the recipients."( Overexpression of Jagged-1 combined with blockade of CD40 pathway prolongs allograft survival.
Chen, J; Chen, W; Gao, C; Jin, N; Li, C; Li, J; Lin, Y; Ma, P; Qi, Z; Xu, S; Yan, G, 2015
)
0.42
" For that purpose, a primary stable silica-embedded nanohydroxyapatite (HA) bone substitute in combination with blood, bone marrow, expanded, or directly retransplanted mesenchymal stem cells, recombinant human bone morphogenetic protein 2 (rhBMP-2), and different carrier materials (fibrin, cell culture medium, autologous serum) was tested subcutaneously for 4 or 12 weeks in the sheep model."( Autologous serum improves bone formation in a primary stable silica-embedded nanohydroxyapatite bone substitute in combination with mesenchymal stem cells and rhBMP-2 in the sheep model.
Arkudas, A; Beier, JP; Boos, AM; Deschler, G; Gerber, T; Horch, RE; Kneser, U; Weigand, A, 2014
)
0.4
"This study was aimed to investigate the therapeutic potential of coenzyme Q10 and its combination with metformin on streptozotocin (STZ)-nicotinamide-induced diabetic nephropathy (DN)."( Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats.
Balaraman, R; Maheshwari, RA; Sen, AK; Seth, AK,
)
0.13
" Due to the lack of scientific grounds for a PRP -based muscle regeneration therapy, we have designed a study using human myogenic progenitors and evaluated the potential of PRP alone and in combination with decorin (a TGF-β inhibitor), to alter myoblast proliferation, metabolic activity, cytokine profile and expression of myogenic regulatory factors (MRFs)."( Platelet-rich plasma, especially when combined with a TGF-β inhibitor promotes proliferation, viability and myogenic differentiation of myoblasts in vitro.
Gradisnik, L; Kelc, R; Rupnik, MS; Trapecar, M; Vogrin, M, 2015
)
0.42
"To examine the effects and possible mechanism of the immunosuppressant agent cyclophosphamide (CP) combined with bone marrow mesenchymal stromal cells (BM-MSCs) on bleomycin induced lung fibrosis in mice."( Cyclophosphamide Combined with Bone Marrow Mesenchymal Stromal Cells Protects against Bleomycin-induced Lung Fibrosis in Mice.
Li, L; Li, Y; Xiong, J; Xu, J; Ye, Q; Zheng, Y, 2015
)
0.42
" Recombinant human bone morphogenetic protein-2 (rhBMP2), an osteoinductive growth factor capable of cell recruitment and differentiation towards the osteoblast lineage, has been utilized in combination with various biomaterials to further enhance new bone formation."( In vitro characterization of an osteoinductive biphasic calcium phosphate in combination with recombinant BMP2.
Fujioka-Kobayashi, M; Miron, RJ; Sculean, A; Shuang, Y; Yizhen, L; Zhang, Y, 2016
)
0.43
" Both BCP and rhBMP2 were able to significantly increase cell proliferation at 3 and 5 days post seeding and cell number was further enhanced when rhBMP2 was combined with BCP."( In vitro characterization of an osteoinductive biphasic calcium phosphate in combination with recombinant BMP2.
Fujioka-Kobayashi, M; Miron, RJ; Sculean, A; Shuang, Y; Yizhen, L; Zhang, Y, 2016
)
0.43
"The results from the present study demonstrate that 1) the osteoinductive potential of BCP bone particles is equally as osteopromotive as rhBMP2 on in vitro osteoblast differentiation and 2) BCP particles in combination with rhBMP2 is able to further increase the osteopromotive differentiation of osteoblasts in vitro when compared to either rhBMP2 alone or BCP alone."( In vitro characterization of an osteoinductive biphasic calcium phosphate in combination with recombinant BMP2.
Fujioka-Kobayashi, M; Miron, RJ; Sculean, A; Shuang, Y; Yizhen, L; Zhang, Y, 2016
)
0.43
" Here, we show that Activin A also has an ability to efficiently propagate ESCs without differentiation to EpiSCs when combined with a MEK inhibitor PD0325901."( Activin A in combination with ERK1/2 MAPK pathway inhibition sustains propagation of mouse embryonic stem cells.
Ashida, Y; Hirota, A; Nakajima-Koyama, M; Nishida, E; Yamamoto, T, 2017
)
0.46
" However, human bone formation effect of rhBMP-2 loaded calcium phosphate cememts (CPC) combined with allogenic BMSCs is still undefined."( rhBMP2-loaded calcium phosphate cements combined with allogenic bone marrow mesenchymal stem cells for bone formation.
Gu, F; Huang, Y; Luo, G, 2017
)
0.46
"It was showed that combined with CPC+BMSC or CPC/rhBMP-2+BMSC induced stronger ability of the proliferation of allogenic BMSCs observed by scanning electron microscopy (SEM)."( rhBMP2-loaded calcium phosphate cements combined with allogenic bone marrow mesenchymal stem cells for bone formation.
Gu, F; Huang, Y; Luo, G, 2017
)
0.46
"To investigate the bone-inducing properties of two types of collagen membranes in combination with recombinant human bone morphogenetic protein (rhBMP)-2 and rhBMP-9 on osteoblast behavior."( Comparison of Two Porcine Collagen Membranes Combined with rhBMP-2 and rhBMP-9 on Osteoblast Behavior In Vitro.
Fujioka-Kobayashi, M; Miron, RJ; Nakamura, T; Noguchi, K; Schaler, B; Shirakata, Y; Zhang, Y,
)
0.13
" While both rhBMPs were shown not to affect cell proliferation, collagen membranes combined with rhBMP-9 significantly increased ALP activity at 7 days and ALP mRNA levels at either 3 or 14 days compared with the control tissue culture plastic."( Comparison of Two Porcine Collagen Membranes Combined with rhBMP-2 and rhBMP-9 on Osteoblast Behavior In Vitro.
Fujioka-Kobayashi, M; Miron, RJ; Nakamura, T; Noguchi, K; Schaler, B; Shirakata, Y; Zhang, Y,
)
0.13
"The results from this study suggest that both porcine-derived collagen membranes combined with rhBMP-9 accelerated the osteopromotive potential of ST2 cells."( Comparison of Two Porcine Collagen Membranes Combined with rhBMP-2 and rhBMP-9 on Osteoblast Behavior In Vitro.
Fujioka-Kobayashi, M; Miron, RJ; Nakamura, T; Noguchi, K; Schaler, B; Shirakata, Y; Zhang, Y,
)
0.13
" Besides, we also evaluated the calvarial defect repair effect using MgHA combined with rhBMP-2 in goat model."( Repair of the calvarial defect in goat model using magnesium-doped porous hydroxyapatite combined with recombinant human bone morphogenetic protein-2.
Deng, L; Kang, P; Li, D; Xie, X; Yang, Z, 2017
)
0.46
" It was also demonstrated that LT mouse models treated with TIM‑4 blockade in combination with exogenous TGF‑β injections, increased the survival times of mice and enhanced the amelioration of AR in LT."( TIM‑4 blockade of KCs combined with exogenous TGF‑β injection helps to reverse acute rejection and prolong the survival rate of mice receiving liver allografts.
Gong, J; Li, J; Li, M; Wu, H; Xu, X, 2018
)
0.48
"To observe the effect of stromal vascular fraction cells (SVFs) from rat fat tissue combined with sustained release of recombinant human bone morphogenetic protein-2 (rhBMP-2) in promoting the lumbar fusion in rat model."( [Sustained release of recombinant human bone morphogenetic protein-2 combined with stromal vascular fraction cells in promoting posterolateral spinal fusion in rat model].
Qian, J; Wang, M; Wang, X; Yuan, W; Zheng, J; Zhou, X, 2017
)
0.46
"To evaluate the osteogenic effect of dextran sulfate/recombinant human bone morphogenetic protein 2/chitosan (DS/rhBMP-2/CS) combined with coralline hydroxyapatite (CHA) in repairing large segmental bone defects by radiographic feature."( [Radiological evaluation of dextran sulfate/recombinant human bone morphogenetic protein 2/chitosan composite microspheres combined with coral hydroxyapatite artificial bone in repairing large segmental bone defects].
Chen, Z; Lin, Z; Xia, H; Xia, Y; Ye, X; Yin, Q; Zhang, Y, 2017
)
0.46
" The major objective of the present study was to explore the effect of immunomodulator-levamisole in combination with Glucantime in end-stage unresponsive patients with anthroponotic CL (ACL)."( A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models.
Aflatoonian, MR; Bamorovat, M; Fekri, A; Heshmatkhah, A; Keyhani, A; Khosravi, A; Mostafavi, M; Naderi, A; Oliaee, RT; Parizi, MH; Sharifi, I; Varma, RS, 2019
)
0.51
"Radiotherapy can be synergistically combined with immunotherapy in mouse models, extending its efficacious effects outside of the irradiated field (abscopal effects)."( TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.
Azpilikueta, A; Barbes, B; Barcelos-Hoff, MH; Berraondo, P; Bolaños, E; Calvo, FA; Etxeberria, I; Labiano, T; Mayorga, L; Melero, I; Perez-Gracia, JL; Ponz-Sarvise, M; Rodríguez, I; Rodríguez-Ruiz, ME; Sanmamed, MF, 2019
)
0.51
" The aim of the present study was to assess the bone at the cleft area using low dose of rhBMP-2 combined with autogenous bone graft for reconstruction of the alveolar cleft."( Recombinant Human Bone Morphogenic Protein-2 Combined With Autogenous Bone Graft for Reconstruction of Alveolar Cleft.
Eslami, N; Irani, S; Jahanbin, A; Kermani, H; Zarch, HH,
)
0.13
" Particularly, the expression of tumour-suppressing gene Ccdc80 was induced by vactosertib and further induced by vactosertib in combination with nal-IRI/5-FU/LV."( Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
An, H; Heo, JS; Hong, CP; Hong, E; Kang, JM; Kim, SJ; Lee, S; Ooshima, A; Park, J; Park, JO; Park, S; Park, SH, 2020
)
0.56
" Can increase the effectiveness of PRP or EGF treatment in surgical treatment of large bone defects with Masquelet technique? Aim of this study examined potential therapeutic benefits of the Masquelet technique with induced membranes in combination with platelet-rich plasma (PRP) or epidermal growth factor (EGF) in a rat model of segmental femur defect."( Epidermal growth factor or platelet-rich plasma combined with induced membrane technique in the treatment of segmental femur defects: an experimental study.
Bahar, AY; Bilal, Ö; Kınaş, M; Kızıldağ, B; Kurutaş, EB; Topak, D, 2020
)
0.56
"A case-control study is performed in this paper to explore various possible effects and clinical value of the photodynamic therapy combined with thymosin for the treatment process of the condyloma acuminatum (CA) in the anal canal."( A Case-Control Study of Photodynamic Therapy Combined with Thymosin in the Treatment of Condyloma Acuminatum in Anal Canal.
Hong, K; Hu, Y; Wang, XQ, 2022
)
0.72
" This study aimed to compare the efficacy of rhBMP-2 in combination with different materials for bone regeneration in critical-sized rat calvarial defects."( Comparison of rhBMP-2 in Combination with Different Biomaterials for Regeneration in Rat Calvaria Critical-Size Defects.
Alister, JP; Olate, S; Uribe, F; Vásquez, B, 2022
)
0.72
" MCF-7 cells may acquire sensitivity against the doxorubicin combined with ozone treatment through activating tumor necrosis factor alpha, MMP-2, and MMP-9 expressions."( Ozone combined with doxorubicin exerts cytotoxic and anticancer effects on Luminal-A subtype human breast cancer cell line.
Karagulle, OO; Yurttas, AG, 2022
)
0.72
" The trial will explore different doses of AdAPT-001 both alone and in combination with an approved checkpoint inhibitor or another immunotherapy, which blocks the ‘off' signal on immune cells, to determine the safest and best dose."( BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Barve, MA; Bessudo, A; Caroen, S; Chacon, E; Conley, AP; Gastman, BR; Kesari, S; Larson, C; Li, L; Madere, D; Nabell, LM; Oronsky, B; Reid, T; Spencer, C; Stirn, M; Villaflor, VM; Williams, J, 2022
)
0.72
" It remains unclear whether cytokines in combination with CEA could be used as biomarkers for the diagnosis of CRC."( Diagnostic value of carcinoembryonic antigen combined with cytokines in serum of patients with colorectal cancer.
Bi, Y; He, L; Li, D; Ma, Y; Wang, D; Wang, M; Wang, X; Zhang, Y, 2022
)
0.72
"Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β "trap") fused to a human IgG1 mAb blocking PD-L1, is being evaluated for efficacy and safety in solid tumor indications as monotherapy and in combination with small-molecule drugs."( Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach.
Dong, JQ; Helwig, C; Locke, G; Rolfe, PA; Venkatakrishnan, K; Vugmeyster, Y, 2022
)
0.72
" Thus, in the present study we investigated the significance of TGF-β-specific T-cell immunity in patients with PC treated with ICI combined with radiotherapy in a randomized phase 2 study (CheckPAC)."( Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.
Andersen, MH; Chen, IM; Hasselby, JP; Holmström, MO; Johansen, J; Lisle, TL; Marie Svane, I; Met, Ö; Mortensen, REJ; Nielsen, DL; Willemoe, GL, 2023
)
0.91
"Vinpocetine treatment and its combination with enalapril decreased the glucose levels compared to diabetic rats."( Effect of vinpocetine alone and in combination with enalapril in experimental model of diabetic cardiomyopathy in rats: possible involvement of PDE-1/TGF-β/ Smad 2/3 signalling pathways.
Arava, SK; Arora, T; Kaur, T; Kumar, N; Shah, S; Singh, AP; Vishwakarma, VK; Yadav, HN; Yadav, RK; Yadav, S, 2023
)
0.91
"The aim of this study was to study the curative effect and the relative mechanism of modified photodynamic therapy combined with Taohong Siwu Decoction in the treatment of hyperplastic scar after severe burn, in order to provide a stable, safe and satisfactory scheme for scar repair."( Clinical study of modified photodynamic therapy combined with Taohong Siwu Decoction in treating hypertrophic scar after severe burn.
Ding, J; He, S; Yu, Q; Zhang, Z, 2023
)
0.91
" The control group was treated with ordinary laser therapy combined with Taohong Siwu Decoction, while the observation group was treated with modified photodynamic therapy combined with Taohong Siwu Decoction."( Clinical study of modified photodynamic therapy combined with Taohong Siwu Decoction in treating hypertrophic scar after severe burn.
Ding, J; He, S; Yu, Q; Zhang, Z, 2023
)
0.91
"Modified photodynamic therapy combined with Taohong Siwu Decoction shows remarkable efficacy in patients with hyperplastic scars after severe burns."( Clinical study of modified photodynamic therapy combined with Taohong Siwu Decoction in treating hypertrophic scar after severe burn.
Ding, J; He, S; Yu, Q; Zhang, Z, 2023
)
0.91

Bioavailability

Endoglin has the capacity to bind transforming growth factor beta (TGF-beta) and can reduce the bioavailability of TGF- beta. Results point to a potential mechanosensitive mechanism for fibrillin-1 in regulating TGFB bioavailability and microfibril integrity.

ExcerptReferenceRelevance
" Second, because many of the changes induced by TGF beta resembled changes reported to occur during the formation of various kinds of subcapsular cataracts, the results suggest that detailed studies of factors that influence the ability of lens cells to respond to TGF beta and the bioavailability of TGF beta in the ocular media may provide important insights into the etiology of some forms of cataract."( Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta.
Chamberlain, CG; Hales, AM; Liu, J; McAvoy, JW, 1994
)
0.52
" Expression of IGFBP-1 to -6 by MC suggests that these proteins may modulate IGF-I bioavailability in the glomerulus."( Characterization of insulin-like growth factor binding proteins and regulation of IGFBP3 in human mesangial cells.
Abboud, HE; Abboud, SL; Fouqueray, B; Grellier, P; Sabbah, M; Woodruff, K; Yee, D, 1996
)
0.29
" Therefore, IGF-II mediates autocrine proliferation in neuroblastoma cells under the control of IGFBPs secreted by the cells, its bioavailability being enhanced as a result of plasmin-induced IGFBP-2 proteolysis."( Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: modulation by transforming growth factor-beta and retinoic acid.
Babajko, S; Binoux, M; Menouny, M, 1997
)
0.3
" Endoglin has the capacity to bind transforming growth factor beta (TGF-beta) and can reduce the bioavailability of TGF-beta."( Expression of endoglin in the transition between psoriatic uninvolved and involved skin.
De Jong, EM; Rulo, HF; van de Kerkhof, PC; van Pelt, JP; van Vlijmen-Willems, IM, 1998
)
0.58
" Thus, the latency of TGF-beta is essential to the regulation of the bioavailability and activity of this cytokine."( [Activation of latent TGF-beta. A required mechanism for vascular integrity].
Gleizes, PE; Rifkin, DB, 1999
)
0.3
" The present study was performed to investigate whether modulation of suture fusion can be achieved by blocking the bioavailability of TGF-beta."( The role of transforming growth factor-beta in the modulation of mouse cranial suture fusion.
Gosain, AK; Khanna, A; Yu, P, 2001
)
0.31
" Insulin-like growth factor-binding protein-5 (IGFBP-5), by regulating the bioavailability of IGFs, is involved in controlling IGF-dependent differentiation."( Transforming growth factor-beta inhibition of insulin-like growth factor-binding protein-5 synthesis in skeletal muscle cells involves a c-Jun N-terminal kinase-dependent pathway.
Atfi, A; Dubois, C; Lallemand, F; Mazars, A; Montarras, D; Pinset, C; Prunier, C; Rousse, S, 2001
)
0.31
" High glucose inhibits nitric oxide (NO) bioavailability and decreased NO increases TGF-beta activity and extracellular matrix accumulation."( Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-beta activation in mesangial cells.
Darley-Usmar, V; Murphy-Ullrich, JE; Poczatek, MH; Shiva, S; Wang, S, 2002
)
0.31
" Because metzincins can modulate the bioavailability of these peptides, they may serve as unique target molecules to control cytokine and growth factor action in the extracellular environment."( Exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability.
Fowlkes, JL; Winkler, MK, 2002
)
0.31
" Limitations of BMP administration to periodontal lesions include need for high-dose bolus delivery, BMP transient biological activity, and low bioavailability of factors at the wound site."( Gene therapy of bone morphogenetic protein for periodontal tissue engineering.
Anusaksathien, O; Giannobile, WV; Jin, QM; Rutherford, RB; Webb, SA, 2003
)
0.32
" Bioavailability studies in healthy rats have revealed that significant portion (3."( Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats.
Bobinac, D; Bosukonda, D; Maric, I; Poljak, L; Sampath, KT; Vukicevic, S; Zoricic, S, 2003
)
0.32
" This effect of TGF-beta on IGF-I bioavailability may promote local bone formation."( Transforming growth factor-beta regulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts.
Bale, LK; Chen, BK; Conover, CA; Ortiz, CO; Overgaard, MT; Oxvig, C, 2003
)
0.32
" It also represents a prototype for binding proteins that control bioavailability of other TGFbeta-related growth factors such as the bone morphogenetic proteins."( The role of follistatin domains in follistatin biological action.
Keutmann, HT; Schneyer, AL; Sidis, Y, 2004
)
0.32
" Based on our observations, we propose that a mechanism exists that differentially regulates the bioavailability of endogenous and exogenous myostatin to muscle cells."( Differential response to exogenous and endogenous myostatin in myoblasts suggests that myostatin acts as an autocrine factor in vivo.
Arce, VM; Carneiro, I; Devesa, J; Fernández-Nocelos, S; Ríos, R, 2004
)
0.32
"These results indicate that tissue kallikrein protects against renal fibrosis in hypertensive DSS rats through increased nitric oxide bioavailability and suppression of oxidative stress and TGF-beta expression."( Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress.
Bledsoe, G; Chao, J; Chao, L; Kato, K; Zhang, JJ, 2004
)
0.32
" The oral bioavailability of SD-208 was verified by demonstrating the inhibition of TGF-beta-induced Smad phosphorylation in spleen and brain."( SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Almirez, R; Aulwurm, S; Herrlinger, U; Higgins, LS; Liu, YW; Ma, JY; Mangadu, R; Murphy, A; Platten, M; Uhl, M; Weiler, M; Weller, M; Wick, W; Wischhusen, J; Wong, DH, 2004
)
0.67
" A major obstacle for GDNF therapy is the protein delivery to the brain, as well as its sustained bioavailability over time."( Viral vector strategy for glial cell line-derived neurotrophic factor therapy for stroke.
Alexander, OB; Borlongan, CV; Stahl, CE; Wang, Y; Woodward-Pu, YM, 2006
)
0.33
" LTBPs-1, -3 and -4 associate with and regulate the bioavailability of TGF-betas."( Sequential deposition of latent TGF-beta binding proteins (LTBPs) during formation of the extracellular matrix in human lung fibroblasts.
Hyytiäinen, M; Keski-Oja, J; Koli, K; Ryynänen, MJ, 2005
)
0.33
" Replacement of the N-terminal amino acid sequence of GDF-5 by the corresponding sequence of BMP-2 did not result in an increased osteogenic activity as heparin binding capacity is not the main reason for the bioavailability of GDF-5."( [Comparison of the osteogenic activity of bone morphogenetic protein (BMP) mutants].
Depprich, R; Handschel, J; Kübler, NR; Sebald, W; Würzler, KK, 2005
)
0.33
" LTBP-3 regulates the bioavailability of TGF-beta especially in the bone."( Induction of human LTBP-3 promoter activity by TGF-beta1 is mediated by Smad3/4 and AP-1 binding elements.
Kantola, AK; Keski-Oja, J; Koli, K, 2005
)
0.33
" The complex regulation of TGF-beta bioavailability includes its synthesis as a proprotein, proteolytic processing by furin-like proteases, assembly in a latent complex, and finally liberation from latency by multiple effector mechanisms, a process collectively referred to as activation."( Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.
Naumann, U; Weller, M; Wick, W, 2006
)
0.33
" Taken together, these results suggest that the bioavailability of the TGFbeta-specific receptor rather than TGFbeta dictates pituitary gonadotrope selectivity to activin, which is necessary to maintain normal reproductive function."( Cell-specificity of transforming growth factor-beta response is dictated by receptor bioavailability.
Suszko, MI; Woodruff, TK, 2006
)
0.33
" This study demonstrated a possible functional role of LTBP-4 for TGF-beta bioavailability with respect to carcinogenesis of human mammary tumours in vivo and in vitro."( Latent transforming growth factor binding protein 4 (LTBP-4) is downregulated in human mammary adenocarcinomas in vitro and in vivo.
Etschmann, B; Kruse, B; Mauel, S; Schaerig, M; Sterner-Kock, A; Stövesand, K; von der Schulenburg, AG; Wilcken, B, 2007
)
0.34
" Together, these extracellular interactions determine the final bioavailability of TGFbeta to vascular cells, and dysregulation is associated with an increasing number of vascular pathologies."( Extracellular control of TGFbeta signalling in vascular development and disease.
Arthur, HM; ten Dijke, P, 2007
)
0.34
" In the present study, our data showed that isoflavones aglycones AglyMax, genistein, and equol, but not daidzein, within the range of plasma concentration, displayed bioavailability in regulating the secretion of leukemia inhibitory factor (LIF) and transforming growth factor beta (TGF-beta) in Ishikawa cells, which was blocked by an estrogen receptor antagonist ICI 182 780, mitogen-activated protein kinase kinase (MEK)1/2 inhibitor PD98059, and p38 mitogen-activated protein kinase inhibitor SB203580."( Isoflavones regulate secretion of leukemia inhibitory factor and transforming growth factor {beta} and expression of glycodelin in human endometrial epithelial cells.
Ikeda, K; Miki, T; Pan, WJ; Shiotani, M; Watanabe, J; Xu, JW; Yamori, Y; Yanaihara, A; Yasui, N, 2008
)
0.53
"These data suggest a novel function of ADAM-12m in chondrocyte proliferation and cloning in OA cartilage through enhanced bioavailability of IGF-1 from the IGF-1-IGFBP-5 complex by selective IGFBP-5 digestion."( ADAM-12 (meltrin alpha) is involved in chondrocyte proliferation via cleavage of insulin-like growth factor binding protein 5 in osteoarthritic cartilage.
Fujita, Y; Iwamoto, Y; Kimura, T; Matsumoto, H; Mochizuki, S; Okada, A; Okada, Y; Sehara-Fujisawa, A; Shiomi, T; Yatabe, T, 2008
)
0.35
" It is produced as a latent complex and the main limiting step in TGFbeta bioavailability is its activation."( Tryptase activates TGFbeta in human airway smooth muscle cells via direct proteolysis.
Jenkins, G; Knox, A; Pang, L; Porte, J; Tatler, AL, 2008
)
0.35
" They have also suggested that the relative composition of fibrillin-rich microfibrils imparts contextual specificity to TGFbeta and BMP signaling by concentrating the ligands locally so as to regulate cell differentiation within a spatial context during organ formation (positive regulation) and by restricting their bioavailability so as to modulate cell performance in a timely fashion during tissue remodeling/repair (negative regulation)."( Biogenesis and function of fibrillin assemblies.
Ramirez, F; Sakai, LY, 2010
)
0.36
" Ex vivo assays indicate that activation of the low affinity adenosine A2B receptor subtype (A2BAR) mediates TGF-beta1 release from glomeruli of diabetic rats, a pathogenic event that could support progression of glomerulopathy when the bioavailability of adenosine is increased."( Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats.
Escudero, C; Fuentealba, V; Gajardo, C; Pastor-Anglada, M; Quezada, C; Roa, H; San Martin, R; Sobrevia, L; Troncoso, E; Yáñez, A, 2009
)
0.35
" The post-transcriptional control of TGF-beta bioavailability points out the need to determine TGF-beta at the protein level."( Bioactive TGF-beta levels can be preserved in plasma samples collected into heparin but not EDTA.
Jallow, IK; Jeffries, D; Walther, B; Walther, M, 2009
)
0.35
"Loss-of-function mutations in genes coding for transforming growth factor-beta/bone morphogenetic protein receptors and changes in nitric oxide(*) (NO(*)) bioavailability are associated with hereditary hemorrhagic telangiectasia and some forms of pulmonary arterial hypertension."( Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia.
Belik, J; Davis, A; Henkelman, M; Husain, M; Jerkic, M; Kabir, MG; Letarte, M; McIntyre, BA; Stewart, DJ; Toporsian, M; Wang, YJ; Yu, LX; Zhou, YQ, 2010
)
0.36
" Heydemann and colleagues implicate dimorphic variation in latent TGF-beta-binding protein 4 (LTBP4), a regulator of TGF-beta bioavailability and activation, as a modifier of muscular dystrophy in gamma-sarcoglycan-deficient mice."( TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions.
Dietz, HC, 2010
)
0.36
" By contrast, in a mouse model of age-related dermal fibrosis, where MMP14 activity and TGFbeta bioavailability are chronically elevated, or in mice that ectopically express TGFbeta in the epidermis, cutaneous vessels are resistant to acute leakage."( Stromal regulation of vessel stability by MMP14 and TGFbeta.
Affara, NI; Boudreau, N; Coussens, LM; Cuevas, I; Dehne, K; Egeblad, M; Junankar, S; Korets, L; Krane, SM; Lee, J; Morrison, CJ; Overall, CM; Shen, J; Sounni, NE; van Kempen, L; Werb, Z; Wiesen, J,
)
0.13
" The resultant increase in bone matrix remodeling enhances cytokine/growth factor bioavailability thus creating a vicious cycle that stimulates tumor progression."( Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis.
Lynch, CC, 2011
)
0.37
" Some of the activity associated with bisphosphonates is observed in non-osteoclast cells; therefore, the bioavailability of bisphosphonates is briefly discussed."( The molecular basis of bisphosphonate activity: a preclinical perspective.
Clézardin, P; Green, J, 2010
)
0.36
"Control of the bioavailability of the growth factor TGFbeta is essential for tissue formation and homeostasis, yet precisely how latent TGFbeta is incorporated into the extracellular matrix is unknown."( Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta.
Baldock, C; Baldwin, AK; Chaudhry, SS; Chiu, M; Choudhury, R; Kielty, CM; Massam-Wu, T; McGovern, A; Shuttleworth, CA, 2010
)
0.36
" In this study, we demonstrate that fibrillin-1 and -2, the structural components of extracellular microfibrils, differentially regulate TGF-β and bone morphogenetic protein (BMP) bioavailability in bone."( Fibrillin-1 and -2 differentially modulate endogenous TGF-β and BMP bioavailability during bone formation.
Arteaga-Solis, E; Carta, L; Ducy, P; Karsenty, G; Lee-Arteaga, S; Levasseur, R; Nistala, H; Ono, RN; Ramirez, F; Sakai, LY; Sengle, G; Siciliano, G; Smaldone, S, 2010
)
0.36
" Moreover, fibrillin-1 has a major role in storing and regulating the bioavailability of TGF-ß and other cytokines, and fibrillin-1 mutations are implicated in a congenital form of scleroderma called stiff skin syndrome."( Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
Bhattacharyya, S; Tourtellotte, WG; Varga, J; Wei, J, 2011
)
0.37
" Because the pericellular fibrinolytic system activation is able to degrade adhesive proteins, activate matrix metalloproteinase (MMP), induce SMC disappearance and increase the bioavailability of TGF-β, the aim was to investigate the plasminergic system in TAA."( Fibrinolytic activity is associated with presence of cystic medial degeneration in aneurysms of the ascending aorta.
Borges, LF; Freymuller, E; Gomez, D; Gutierrez, PS; Jandrot-Perrus, M; Jondeau, G; Leclercq, A; Meilhac, O; Michel, JB; Quintana, M; Touat, Z; Vranckx, R, 2010
)
0.36
" Microfibrils regulate bioavailability of TGFβ superfamily growth factors and are structurally crucial in the ocular zonule."( Genetic and functional linkage between ADAMTS superfamily proteins and fibrillin-1: a novel mechanism influencing microfibril assembly and function.
Apte, SS; Hubmacher, D, 2011
)
0.37
" Further ex vivo/in vitro experiments with wild type and MMP-2 null osteoclast and osteoblast cultures identified that 1) the absence of MMP-2 did not have a deleterious effect on osteoclast function (cd11B isolation, osteoclast differentiation, transwell migration and dentin resorption assay); and 2) that osteoblast derived MMP-2 promoted tumor survival by regulating the bioavailability of TGFβ, a factor critical for cell-cell communication in the bone (ELISA, immunoblot assay, clonal and soft agar assays)."( An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.
Edwards, JR; Fingleton, B; Lynch, CC; Matrisian, LM; Rifkin, DB; Thiolloy, S, 2012
)
0.38
" The ECM serves to concentrate latent TGFβ at sites of intended function, to influence the bioavailability and/or function of TGFβ activators, and perhaps to regulate the intrinsic performance of cell surface effectors of TGFβ signal propagation."( Matrix-dependent perturbation of TGFβ signaling and disease.
Dietz, HC; Doyle, JJ; Gerber, EE, 2012
)
0.38
" Ferritin is a major regulator of the bioavailability of iron, and its functions are determined largely by the combination of H- and L-subunits present in its outer protein shell."( Expression of the H- and L-subunits of ferritin in bone marrow macrophages of patients with osteoarthritis.
Becker, PJ; Frantzen, DJ; Hall, AN; Koorts, AM; Levay, PF; van der Merwe, CF; Viljoen, M, 2012
)
0.38
" Mutations in FBN1 are therefore associated with increased activity and bioavailability of TGF-β1, which is suspected to be the basis for phenotypical similarities of FBN1 mutations in MFS and mutations in the receptors for TGFβ in Marfan syndrome-related diseases."( Exogenous activation of BMP-2 signaling overcomes TGFβ-mediated inhibition of osteogenesis in Marfan embryonic stem cells and Marfan patient-specific induced pluripotent stem cells.
Li, S; Longaker, MT; Quarto, N; Renda, A, 2012
)
0.38
" E-selectin ligand-1 (ESL-1), a Golgi apparatus-localized protein, acts as a negative regulator of TGF-β bioavailability by attenuating maturation of pro-TGF-β during cartilage homeostasis."( E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment.
Ambrose, CG; Bae, Y; Bertin, TK; Chen, S; Chen, Y; Grafe, I; Jiang, MM; Lee, B; Yang, T, 2013
)
0.39
" Results from gene signature analyses, quantification of STAT5 phosphorylation levels, cytokine neutralization experiments, cytokine supplementation studies, and evaluations of intracellular cytokine levels collectively argue for a scenario in which T reg cells regulate NK cell functions by controlling the bioavailability of limiting amounts of IL-2 in the islets, generated mainly by infiltrating CD4(+) T cells."( Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2.
Benoist, C; Garcia, KC; Mathis, D; Ring, A; Sitrin, J, 2013
)
0.39
" Thus, the development of scaffolds that provide temporal and/or spatial control of TGF-β bioavailability has appeal as a mechanism to induce the chondrogenesis of stem cells in vitro and in vivo for articular cartilage repair."( Transforming growth factor Beta-releasing scaffolds for cartilage tissue engineering.
Cucchiarini, M; Johnstone, B; Madry, H; Rey-Rico, A; Venkatesan, JK, 2014
)
1.85
"Glycoprotein A repetitions predominant (GARP) is expressed on the surface of activated human regulatory T cells (Treg) and regulates the bioavailability of transforming growth factor-β (TGF-β)."( Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4⁺ T cells.
Becker, C; Correll, A; Hahn, SA; Jonuleit, H; Schneider, FJ; Stahl, HF; Tuettenberg, A, 2013
)
0.39
" Heparanase (HPSE) is an endo-β-D-glucuronidase that cleaves heparan-sulfate thus regulating the bioavailability of growth factors (FGF-2, TGF-β)."( Heparanase is a key player in renal fibrosis by regulating TGF-β expression and activity.
Gambaro, G; Lupo, A; Masola, V; Onisto, M; Secchi, MF; Zaza, G, 2014
)
0.4
" The bioavailability of Adaprev saw a 40% reduction at the site of administration over 45 minutes and tendon fibroblasts tolerated up to 120 minutes of exposure without significant loss of cell viability or tensile strength."( Reduction of tendon adhesions following administration of Adaprev, a hypertonic solution of mannose-6-phosphate: mechanism of action studies.
Bush, J; Ferguson, MW; Garcon, A; Goldspink, N; McGrouther, DA; Metcalfe, AD; Platt, C; Wong, JK; Wong, R, 2014
)
0.4
" There was a marked decrease in nitric oxide (NO) bioavailability and antioxidant enzyme capacity."( Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A, 2014
)
0.4
" However, poor water solubility and low bioavailability of curcumin limit its clinical applications."( [Recent advances in curcumin and its derivatives for treatment of liver diseases].
Peng, ML; Sun, Y, 2014
)
0.4
" Indeed, TN-X has been shown to regulate the bioavailability of the Transforming Growth Factor (TGF)-β and to modulate epithelial cell plasticity."( Tenascin-X: beyond the architectural function.
Alcaraz, LB; Bartholin, L; Exposito, JY; Lethias, C; Valcourt, U, 2015
)
0.42
" Therapy using soluble TGF-β and IL-2 administration is hindered by the cytokines' toxic pleiotropic effects and hence bioavailability to CD4(+) T cell targets."( Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells.
Fahmy, TM; Gao, W; Horwitz, DA; McHugh, MD; Park, J; Uhrich, R, 2015
)
0.42
" Collectively, our findings show that fibrillin-1 regulates MSC activity by modulating TGFβ bioavailability within the microenvironment of marrow niches."( Fibrillin-1 Regulates Skeletal Stem Cell Differentiation by Modulating TGFβ Activity Within the Marrow Niche.
Cheng, SH; Clayton, NP; del Solar, M; Pascual, G; Ramirez, F; Schaffler, MB; Smaldone, S; Wentworth, BM, 2016
)
0.43
" In this study, we investigated the therapeutic potential of EW-7197, an orally bioavailable transforming growth factor-β signaling inhibitor which has recently been approved as an Investigational New Drug (NIH, USA), to suppress CML-LICs in vivo."( Novel oral transforming growth factor-β signaling inhibitor EW-7197 eradicates CML-initiating cells.
Bae, E; Gu, YK; Hirao, A; Ishihara, K; Jeong, ES; Jin, CH; Jomen, Y; Kim, DH; Kim, DK; Kim, DW; Kim, SJ; Krause, DS; Li, S; Naka, K; Ooshima, A; Oshima, H; Oshima, M; Sheen, YY; Takihara, Y, 2016
)
0.43
"Metalloproteases involved in extracellular matrix remodeling play a pivotal role in cell response by regulating the bioavailability of cytokines and growth factors."( In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1.
Bonnier, D; Laurent, MA; Moroy, G; Théret, N; Tufféry, P, 2016
)
0.43
"The bioavailability of members of the transforming growth factor β (TGF-β) family is controlled by a number of mechanisms."( Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins.
Rifkin, DB; Robertson, IB, 2016
)
0.43
" TGF-β superfamily members, such as TGF-β and bone morphogenetic proteins, are multifunctional proteins that regulate production of extracellular matrix proteins, which in turn control the bioavailability of TGF-β superfamily members and modulate their signaling activities."( Disruption of transforming growth factor-β superfamily signaling: A shared mechanism underlying hereditary cerebral small vessel disease.
Ihara, M; Yamamoto, Y, 2017
)
0.46
" Resveratrol is a promising anti-restenotic natural drug but subject to low bioavailability when systemically administered."( Restenosis Inhibition and Re-differentiation of TGFβ/Smad3-activated Smooth Muscle Cells by Resveratrol.
Binder, BY; DiRenzo, D; Goel, SA; Guo, LW; Ke, J; Kent, A; Kent, KC; Li, L; Little, C; Murphy, WL; Roenneburg, DA; Shi, XD; Shi, Y; Takayama, T; Urabe, G; Wang, B; Zhang, M; Zhou, Y; Zhu, Y, 2017
)
0.46
" A previous study indicated that bleomycin (BLM) treatment increased LTBP-4 expression in lung fibroblasts of Thy-1 knockout mice with lung fibrosis, and LTBP-4 further promoted TGF-β bioavailability as well as SMAD3 phosphorylation."( Increased expression of latent TGF-β-binding protein 4 affects the fibrotic process in scleroderma by TGF-β/SMAD signaling.
Chu, H; Ding, W; Jiang, S; Jin, L; Liu, Q; Lu, J; Ma, Y; Pu, W; Shi, X; Tu, W; Wang, J; Wang, L; Wu, W; Zhou, X, 2017
)
0.46
" The second role is instructive in that these macroaggregates modulate a large variety of sub-cellular processes by interacting with mechanosensors, and integrin and syndecan receptors, and by modulating the bioavailability of local TGFβ signals."( Marfan syndrome; A connective tissue disease at the crossroads of mechanotransduction, TGFβ signaling and cell stemness.
Caescu, C; Galatioto, J; Ramirez, F; Wondimu, E, 2018
)
0.48
" Additionally, using Axin-2 gain- and loss-of-function experiments, we demonstrated that the TGFβ-induced increased response to Wnt activation characteristic of SSc fibroblasts depended on reduced bioavailability of Axin-2."( Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2.
Corinaldesi, C; Del Galdo, F; Denton, CP; Derrett-Smith, E; Doody, GM; Emery, P; Esteves, F; Gillespie, J; McDermott, MF; Ross, RL, 2018
)
0.48
"This study highlights the importance of reduced bioavailability of Axin-2 in mediating the increased canonical Wnt response observed in SSc fibroblasts."( Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2.
Corinaldesi, C; Del Galdo, F; Denton, CP; Derrett-Smith, E; Doody, GM; Emery, P; Esteves, F; Gillespie, J; McDermott, MF; Ross, RL, 2018
)
0.48
" Our technology overcomes this by on-site chemokine production and reduced degradation, which together ensure prolonged chemokine bioavailability that instructed local immune cells and enhanced wound healing."( Accelerated wound healing in mice by on-site production and delivery of CXCL12 by transformed lactic acid bacteria.
Huss, F; Lofton, H; Mortier, A; Öhnstedt, E; Phillipson, M; Proost, P; Roos, S; Vågesjö, E, 2018
)
0.48
" These results suggested that the newly synthesized derivative of CD can be used as a complexing agent to enhance the bioavailability of flavonoids such as baicalein, especially in restoring collagen synthesis."( Inclusion complexes of cysteinyl β-cyclodextrin with baicalein restore collagen synthesis in fibroblast cells following ultraviolet exposure.
Ahn, E; Ahn, S; Cho, E; Jung, S; Kim, H; Kim, SY; Lee, J; Park, S; Shin, Y; Sung, J, 2019
)
0.51
" AICAR induced sinusoidal vasodilation by improving NO bioavailability and ameliorating endothelial dysfunction in vivo and in vitro."( AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Dong, Z; George, J; Hu, L; Lv, Y; Su, L; Wang, J; Wu, Y, 2019
)
0.51
" Dysfunctional fibrillin increases TGF-β bioavailability and concentration in the extracellular matrix, leading to activation of proinflammatory transcription factors."( Marfan syndrome: A therapeutic challenge for long-term care.
Arif, R; Kallenbach, K; Müller, OJ; Remes, A; Wagner, AH; Zaradzki, M, 2019
)
0.51
"These data suggest that VWR may protect against collagen accumulation through a TGF-β-mediated pathway by improving nitric oxide bioavailability and redox balance in rats."( Voluntary Wheel Running Attenuates Salt-Induced Vascular Stiffness Independent of Blood Pressure.
Edwards, DG; Farquhar, WB; Guers, JJ; Lennon, SL, 2019
)
0.51
" In addition, Oxy210 displays encouraging drug-like properties, including chemical scalability, metabolic stability and oral bioavailability in mice."( Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that Antagonizes TGFβ and Hedgehog Signaling.
Parhami, F; Stappenbeck, F; Tang, LY; Wang, F; Zhang, YE, 2019
)
0.51
" To improve bioavailability and biodegradation of the peptide, TAIP was conjugated to polyamidoamine (PAMAM) dendrimers."( Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor β-induced protein and improves survival in sepsis.
Bae, JS; Kim, H; Kim, IS; Kim, SW; Kwon, OK; Lee, W; Na, DH; Park, EJ; Seo, YK; Yoo, Y, 2020
)
0.56
" In addition, 20f demonstrated good bioavailability (F = 41."( Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
Chen, L; Chen, Y; Deng, D; Liu, K; Pei, H; Tang, M; Xue, L; Yang, T; Yang, Z; Ye, H; Zheng, S, 2020
)
0.56
" Fibrillins assemble into microfibrils which are not only indispensable for conferring elasticity to the skin, but also control the bioavailability of growth factors targeted to the extracellular matrix architecture."( The fibrillin microfibril/elastic fibre network: A critical extracellular supramolecular scaffold to balance skin homoeostasis.
Adamo, CS; Sengle, G; Zuk, AV, 2021
)
0.62
" The ECM orchestrates local cell behavior in part by regulating bioavailability of signaling molecules through sequestration, release and activation during the constant bone remodeling process."( Signaling pathways affected by mutations causing osteogenesis imperfecta.
Eckes, B; Etich, J; Rehberg, M; Semler, O; Sengle, G; Zaucke, F, 2020
)
0.56
" These results point to a potential mechanosensitive mechanism for fibrillin-1 in regulating extracellular transforming growth factor beta (TGFB) bioavailability and microfibril integrity."( Steered molecular dynamic simulations reveal Marfan syndrome mutations disrupt fibrillin-1 cbEGF domain mechanosensitive calcium binding.
Dudley, AT; Haller, SJ; Roitberg, AE, 2020
)
0.77
" IGFBP3 is known as to modulate the bioavailability of IGF1, which is abundant in the bone microenvironment and regulates osteoclast differentiation."( The downregulation of IGFBP3 by TGF-β signaling in oral cancer contributes to the osteoclast differentiation.
Chung, WY; Jung, MJ; Park, J, 2021
)
0.62
" Bay 58-2667 (cinaciguat) is able to re-activate defective sGC; however, the drug suffers from poor bioavailability and its systemic administration is linked to adverse events such as severe hypotension, which can hamper the therapeutic effect."( Targeted Delivery of Soluble Guanylate Cyclase (sGC) Activator Cinaciguat to Renal Mesangial Cells via Virus-Mimetic Nanoparticles Potentiates Anti-Fibrotic Effects by cGMP-Mediated Suppression of the TGF-β Pathway.
Fleischmann, D; Goepferich, A; Harloff, M; Maslanka Figueroa, S; Schlossmann, J, 2021
)
0.62
" As the FBG-like domain is highly conserved among the Tenascin family members, we hypothesized that Tenascin-C (TN-C), Tenascin-R (TN-R) and Tenascin-W (TN-W) might share with TN-X the ability to regulate TGF-β bioavailability through their C-terminal domain."( Latent TGF-β Activation Is a Hallmark of the Tenascin Family.
Aguero, S; Alcaraz, LB; Aubert, A; Berthier, L; Lambert, E; Liot, S; Mercier-Gouy, P; Moali, C; Prigent, L; Terreux, R; Valcourt, U; Verrier, B, 2021
)
0.62
" Here we focus on functional interactions and mechanisms that were described to control BMP bioavailability in a spatio-temporal manner within the respective tissue context."( Controlling BMP growth factor bioavailability: The extracellular matrix as multi skilled platform.
Correns, A; Furlan, AG; Sengle, G; Spanou, CES; Zimmermann, LA, 2021
)
0.62
" C7 is not simply a structural protein but also has multiple functions, including the regulation of TGFβ bioavailability and the inhibition of skin scarring."( Systemic Collagen VII Replacement Therapy for Advanced Recessive Dystrophic Epidermolysis Bullosa.
Bruckner-Tuderman, L; Chen, M; de Souza, MP; Gretzmeier, C; Kern, JS; Nyström, A; Pin, D; Woodley, DT, 2022
)
0.72
" Therefore, a drug discovery programme to identify an orally bioavailable small molecule αvβ6 arginyl-glycinyl-aspartic acid (RGD)-mimetic was initiated."( Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease.
Barksby, BS; Barnes, R; Barrett, JW; Barrett, TN; Borthwick, LA; Burgoyne, RA; Fisher, AJ; Gower, E; Hatley, RJD; Jenkins, RG; John, AE; Luckett, JC; Macdonald, SJF; Man, Y; Marshall, RP; Morrison, VS; Procopiou, PA; Pun, KT; Roper, JA; Slack, RJ; Wilkinson, AL, 2021
)
0.62
" We found that in Tgfbr2 knockout tumors, the tumor microenvironment (TME) was converted to a fibro-mucinous state, and T cells excluded, concomitant with upregulated TGFβ and TGFβ-mediated fibroblast activation, indicating that TGFβ-receptor loss on cancer cells increased TGFβ bioavailability and its immunosuppressive effects on the TME."( Spatial CRISPR genomics identifies regulators of the tumor microenvironment.
Akturk, G; Baccarini, A; Bektesevic, A; Bhardwaj, N; Brown, BD; Buckup, M; Dhainaut, M; Gnjatic, S; Le Berichel, J; Lee, BH; Merad, M; Nielsen, SR; Park, ES; Pe'er, D; Pia, L; Rahman, AH; Rose, SA; Roudko, V; Sweeney, R; Wilk, CM; Wroblewska, A, 2022
)
0.72
" Previously we developed a nano micellar CO donor SMA/CORM2 which shows superior bioavailability and therapeutic potential in many inflammatory disease models."( Nanoformulation of a carbon monoxide releasing molecule protects against cyclosporin A-induced nephrotoxicity and renal fibrosis via the suppression of the NLRP3 inflammasome mediated TGF-β/Smad pathway.
Cui, Y; Fang, J; Guo, C; Hu, W; Song, B; Xia, M; Xia, Z; Xu, D; Xue, Y; Zhang, C; Zhang, S, 2022
)
0.72
" Here we evaluated the anti-metastatic therapeutic potential of vactosertib, an orally bioavailable TGF-β type I receptor (activin receptor-like kinase 5, ALK5) inhibitor, via suppression of radiation-induced EMT and CSC properties, oxidative stress generation, and breast to lung metastasis in a breast cancer mouse model and breast cancer cell lines."( Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer.
Cho, I; Choi, J; Park, J; Sheen, Y, 2022
)
0.72
"Curcumin, belongs to the curcuminoid family, is a natural phenolic compound, presenting low bioavailability and pleiotropic activity."( Role of curcumin in ameliorating hypertension and associated conditions: a mechanistic insight.
Dwivedi, J; Joshi, P; Joshi, S; Semwal, DK; Sharma, S; Verma, K, 2022
)
0.72
" In the present study, specific inhibitor of Smad3 (SIS3) is developed into a self-carried nanodrug (SCND-SIS3) using the reprecipitation method, which largely improves its solubility and bioavailability while reduces its nephrotoxicity."( Self-carried nanodrug (SCND-SIS3): A targeted therapy for lung cancer with superior biocompatibility and immune boosting effects.
Chen, J; Huang, XR; Lan, HY; Lee, CS; Li, M; Lian, GY; Mak, TS; Tang, PM; Wan, Y; Wang, QM; Wang, ZY; Yu, XQ; Zhang, J, 2022
)
0.72
" In a mouse lung transplant model, we show that ECP blunts alloimmune responses and inhibits BOS through lowering airway TGF-β bioavailability without altering its expression."( Reprogramming alveolar macrophage responses to TGF-β reveals CCR2+ monocyte activity that promotes bronchiolitis obliterans syndrome.
Byers, DE; Cano, M; Gelman, AE; Hachem, R; Heo, GS; Huang, HJ; Kreisel, D; Krupnick, AS; Kulkarni, HS; Leuhmann, HP; Li, W; Liao, F; Liu, Y; Liu, Z; Parks, A; Scozzi, D; Tague, LK; Wong, BW; Zhou, D; Zhu, J, 2022
)
0.72
" A subset of this superfamily, including ADAMTS6, ADAMTS10 and ADAMTSL2, are involved in elastic fiber assembly and bind to fibrillin and other matrix molecules that regulate the extracellular bioavailability of the potent growth factor TGFβ."( ADAMTS6 cleaves the large latent TGFβ complex and increases the mechanotension of cells to activate TGFβ.
Baldock, C; Cain, SA; Kimber, SJ; Singh, M; Woods, S, 2022
)
0.72
" Embryo absorption rate was counted."( Effect of baotaiyin on IL-23 /Th17 immune inflammatory axis in mouse model of spontaneous abortion.
Jiang, L; Niu, H; Qian, Y; Wan, Q; Yang, L; Zhan, X, 2022
)
0.72
"Compared with the model group, the absorption rate of embryo and Th17/Treg cell ratio in baotaiyin medium- and high-dose groups were decreased significantly (all P<0."( Effect of baotaiyin on IL-23 /Th17 immune inflammatory axis in mouse model of spontaneous abortion.
Jiang, L; Niu, H; Qian, Y; Wan, Q; Yang, L; Zhan, X, 2022
)
0.72
" However, the reduced bioavailability and the absorption of flavonoids are the major limitations inhibiting their use against bone-related complications."( Bioactivity, Molecular Mechanism, and Targeted Delivery of Flavonoids for Bone Loss.
Bat-Ulzii, A; Bhattacharya, M; Chakraborty, C; Chatterjee, S; Lee, SS; Lee, YH; Sharma, AR, 2023
)
0.91
" The effect is mirrored in patients with extracapillary glomerulonephritis associated with thromboinflammation, TGF β -dependent glomerulosclerosis, and increased bioavailability of TPO."( Thrombopoietin-Dependent Myelo-Megakaryopoiesis Fuels Thromboinflammation and Worsens Antibody-Mediated Chronic Renal Microvascular Injury.
Bruneval, P; Caligiuri, G; Clement, M; Delbosc, S; Douté, M; Even, G; Gaston, AT; Loyau, S; Mouthon, L; Nicoletti, A; Sannier, A; Tran, TT; Witko-Sarsat, V, 2023
)
0.91
" In humans, extracapillary glomerulonephritis is associated with thromboinflammation, TGF β -dependent glomerulosclerosis, and increased bioavailability of TPO."( Thrombopoietin-Dependent Myelo-Megakaryopoiesis Fuels Thromboinflammation and Worsens Antibody-Mediated Chronic Renal Microvascular Injury.
Bruneval, P; Caligiuri, G; Clement, M; Delbosc, S; Douté, M; Even, G; Gaston, AT; Loyau, S; Mouthon, L; Nicoletti, A; Sannier, A; Tran, TT; Witko-Sarsat, V, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" A positive dose-response relationship was observed when colon cells were treated with bFGF concentrations from 1 pM to 1 nM."( Identification of basic fibroblast growth factor sensitivity and receptor and ligand expression in human colon tumor cell lines.
New, BA; Yeoman, LC, 1992
)
0.28
" The sCT dose-response curves showed a higher cAMP production from 10(-9) M to 10(-7) M of sCT in the presence of 500 pg/ml TGF-beta than in control cultures."( Transforming growth factor-beta enhances calcitonin-induced cyclic AMP production and the number of calcitonin receptors in long-term cultures of human umbilical cord blood monocytes in the presence of 1,25-dihydroxycholecalciferol.
Bouizar, Z; De Vernejoul, MC; Jullienne, A; Mbalaviele, G; Orcel, P, 1992
)
0.28
" In higher passages of WB cells the dose-response for inhibition of DNA synthesis by TGF-beta 1 was shifted to the right."( TGF-beta 1 inhibits DNA synthesis and phosphorylation of the retinoblastoma gene product in a rat liver epithelial cell line.
Itakura, K; Whitson, RH, 1992
)
0.28
" They were designated as YE-1, YE-2 and YE-3 according to the degree of malformation which was found to be related to the dosage of antibodies injected to the blastomere."( [The effect of microinjection of anti-TGF beta-1 antibodies on the early development of Xenopus laevis].
Shou, WN, 1992
)
0.28
" Each growth factor, however, induced a different dose-response pattern."( Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-beta on corneal cell chemotaxis.
Adams, JL; Grant, MB; Khaw, PT; Schultz, GS; Shimizu, RW, 1992
)
0.28
" Dose-response curves for analogous populations of normal and leukemic cells were indistinguishable."( Granulocyte-macrophage colony-stimulating factor modulation of the inhibitory effect of transforming growth factor-beta on normal and leukemic human hematopoietic progenitor cells.
Cashman, JD; Eaves, AC; Eaves, CJ, 1992
)
0.28
" We studied the relationship between tolloid and dpp by analyzing the phenotypes of tolloid embryos with elevated numbers of the dpp gene and found that doubling the dpp+ gene dosage completely suppressed weak tolloid mutants and partially suppressed the phenotypes of tolloid null mutants."( Localized enhancement and repression of the activity of the TGF-beta family member, decapentaplegic, is necessary for dorsal-ventral pattern formation in the Drosophila embryo.
Anderson, KV; Ferguson, EL, 1992
)
0.28
" Control animals subjected to the same TGF beta 1 dosing regimen displayed no discernable immunosuppressive or toxic effects even after 4 wk of treatment."( Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals.
Allen, JB; Brandes, ME; Ogawa, Y; Wahl, SM, 1991
)
1.72
" The availability of large quantities of recombinant TGF-beta will allow study of the pharmacokinetics with different routes of administration, dosage effects, and details of the pleiotropic effects on other cell systems."( Role of transforming growth factor-beta 1 in regulation of hematopoiesis.
Birchenall-Roberts, M; Broxmeyer, HE; Dubois, C; Engelmann, GL; Jacobsen, SE; Keller, JR; Ruscetti, FW, 1991
)
0.28
" Dose-response curves generated by using purified porcine TGF-beta showed that aqueous humor contained sufficient concentrations of TGF-beta to account for the observed inhibition in several assays for T cell activation and proliferation."( Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor.
Cousins, SW; Danielpour, D; McCabe, MM; Streilein, JW, 1991
)
0.28
" Lung colonies were measured 2 weeks after inoculation in syngeneic F344 rats, and a bell-shaped dose-response curve with 2- to 3-fold increase in number of surface lung metastases was seen."( Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential.
Fabra, A; Nakajima, M; Welch, DR, 1990
)
1.72
" Likewise, in androgen-maintained ventral prostate organ cultures in vitro, there was a dose-response relationship between glandular cell death and TGF beta 1 concentration in the medium."( Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells.
Isaacs, JT; Kyprianou, N; Martikainen, P, 1990
)
0.28
" The dose-response curves of induction of HGF secretion by cholera toxin and forskolin were nearly parallel with those of the intracellular cAMP levels."( Expression of hepatocyte growth factor is up-regulated through activation of a cAMP-mediated pathway.
Gohda, E; Iwao, M; Kataoka, H; Matsunaga, T; Takebe, T; Wu, YL; Yamamoto, I, 1994
)
0.29
" Although a short treatment with any of the molecules decreased the growth of colony-forming unit granulocyte/macrophage (CFU-GM) and burst-forming unit-erythroid (BFU-E) progenitors (except for TNF-alpha as it is a greater inhibitor for CFU-GM), further experiments using a 6-day liquid culture in the presence of a combination of growth factors (recombinant human interleukin-3 [rhIL-3], IL-6, IL-1 beta, GM colony-stimulating factor [GM-CSF], G-CSF, erythropoeitin [Epo], and stem cell factor [SCF]) allowed us to determine a number of differences between their effects: 1) TGF-beta and TNF-alpha induced a stronger decrease in the proliferation and clonogenicity of CD34+ subsets than MIP-1 alpha and AcSDKP, 2) the dose-response curves appeared different, and 3) contrary to TGF-beta and TNF-alpha, AcSDKP and MIP-1 alpha required repeated addition to induce inhibition."( Comparison of the inhibitory effect of AcSDKP, TNF-alpha, TGF-beta, and MIP-1 alpha on marrow-purified CD34+ progenitors.
Bonnet, D; Guigon, M; Lemoine, FM; Najman, A, 1995
)
0.29
" Various doses and dosing regimens were tested."( Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors.
Chadwick, CA; Hendry, H; Hewitt, D; Lord, BI; Owen, G; Potten, CS; Woolford, LB, 1995
)
0.29
" In contrast, the dose-response of interleukin-3 (IL-3) and granulocyte-macrophage-CSF (GM-CSF) in colony formation was normal."( Severe congenital neutropenia: abnormal growth and differentiation of myeloid progenitors to granulocyte colony-stimulating factor (G-CSF) but normal response to G-CSF plus stem cell factor.
Abrahamsen, TG; Hestdal, K; Keller, JR; Lie, SO; Ruscetti, FW; Welte, K, 1993
)
0.29
" The dose-response relationship for these responses to estradiol treatment was biphasic with maximal increases at 10(-10) M-10(-11) M of added estradiol."( Thrombospondin co-localises with TGF beta and IGF-I in the extracellular matrix of human osteoblast-like cells and is modulated by 17 beta estradiol.
Mason, RS; Patava, J; Slater, M, 1995
)
0.29
" In gerbils on the standard diet at 6 wk after dosing with iron, in situ hybridization analysis documented a dramatic increase of signal for collagen mRNA around iron foci onto liver fat storing cells (FSC), as identified by immunocytochemistry with desmin antibody."( Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents.
Casalgrandi, G; Gualdi, R; Montosi, G; Pietrangelo, A; Ventura, E, 1995
)
0.29
" In this study, the dose-response curve for such enhancement was measured."( Enhancement of periosteal chondrogenesis in vitro. Dose-response for transforming growth factor-beta 1 (TGF-beta 1).
Commisso, CN; Fitzsimmons, JS; Gallay, SH; Miura, Y; O'Driscoll, SW, 1994
)
0.29
" These two phenomena followed a similar time course and shared a parallel dose-response sensitivity to hrIL-1 beta."( Nitric oxide and energy production in articular chondrocytes.
Evans, CH; Georgescu, HI; Stadler, J; Stefanovic-Racic, M, 1994
)
0.29
" Asn-17 Ras inhibited both TGF beta-dependent and basal expression of inducible promoters (skeletal alpha-actin and plasminogen activator inhibitor-1), with equivalent dose-response relations."( p21 Ras as a governor of global gene expression.
Abdellatif, M; MacLellan, WR; Schneider, MD, 1994
)
0.29
" Moreover, the dose-response to TGF-beta 1 (0."( TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors.
Abrass, IB; Reed, MJ; Sage, EH; Vernon, RB, 1994
)
0.29
" The use of specifically designed and modified growth factors, growth-factor inhibitors, and sequential and combinatorial dosing regimes offer further possibilities for enhancing wound healing."( Growth factors: therapeutic advances in wound healing.
Robinson, CJ, 1993
)
0.29
" Insulin showed a two-phase dose-response curve, increasing [3H]thymidine uptake by 34 +/- 9% at 10 ng/ml and by 63 +/- 13% at 10 micrograms/ml."( Role of growth factors and estrogen as modulators of growth, differentiation, and expression of gonadotropin subunit genes in primary cultured sheep pituitary cells.
Barber, PC; Chaidarun, SS; Eggo, MC; Sheppard, MC; Stewart, PM, 1994
)
0.29
" Addition of vanadate per se induces proliferation of only a very limited amount of cells, but results in a shift of the dose-response curves for other growth factors to lower concentrations."( Orthovanadate both mimics and antagonizes the transforming growth factor beta action on normal rat kidney cells.
Rijksen, G; Van Zoelen, EJ; Völler, MC, 1993
)
0.54
" Antibody dose-response experiments revealed that TGF beta 2 was the predominant isoform inhibiting early RTE cell growth."( Growth regulation of primary rat tracheal epithelial cell cultures by endogenous transforming growth factor-beta s.
Nettesheim, P; Rundhaug, JE, 1993
)
0.29
" Finally, a dose-response study demonstrated that TGF-beta increased TAE nuclear binding proteins at lower doses with a different response curve than NF-1 nuclear binding proteins."( Regulation of the alpha 1(I) collagen promoter via a transforming growth factor-beta activation element.
Fine, A; Goldstein, RH; Ritzenthaler, JD; Smith, BD, 1993
)
0.29
"Treatment of Sprague-Dawley (SD) rats with a dosing regimen of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) maintaining a steady-state liver concentration of 150 ng/g results in enhanced hepatocyte proliferation in the periportal region, but reduced proliferation in the remainder of the hepatic lobule (Fox et al."( 2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibits DNA synthesis in rat primary hepatocytes.
Greenlee, WF; Hushka, DR, 1995
)
0.29
" Time course and dose-response experiments performed 48 hours after the last application of CPA showed that apoptotic nuclei with chromatin condensed at the nuclear periphery (AN) were already visible 2 hours after injection (0."( The antiandrogen cyproterone acetate induces synthesis of transforming growth factor beta 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation.
Bouzahzah, B; Carr, B; Fröschl, G; Nagy, P; Oberhammer, F; Thorgeirsson, SS; Tiefenbacher, R, 1996
)
0.54
" Results demonstrated that the characteristic bell- shaped growth response following treatment with increasing doses of DHT was converted to a linear dose-response curve as the growth of inhibition seen at the high dose by DHT was abolished."( Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP.
Ahn, HJ; Kim, IY; Kim, JH; Lee, C; Sensibar, JA; Zelner, DJ, 1996
)
0.29
" Nevertheless, if Dex and TGF-beta 1 were dosed together with one of these immunosuppressants, suppressions of histamine and ischemic edema were 53%, 45% (FK506), 45%, 49% (CsA), 44%, 48% (Rapa) and 39%, 51% (DSP), respectively."( Immunosuppressants and TGF-beta 1 accelerated and prolonged the nitric oxide/oxyradicals-dependent suppression by dexamethasone in paw edema of mice.
Oyanagui, Y, 1996
)
0.29
" Dose-response analysis showed that the TGF-beta concentration needed to induce hepatocyte death (2."( Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates.
Alvarez, AM; Benito, M; Fabregat, I; Sánchez, A, 1996
)
0.29
" Eleven of them, 4 to 8 months later, underwent ovulation induction with approximately the same dosage of gonadotropins plus a standard dosage of GH."( Intrafollicular insulin-like growth factor-II levels in normally ovulating women and in patients with polycystic ovary syndrome.
Artini, PG; Barreca, A; Del Monte, P; Genazzani, AR; Minuto, F; Ponzani, P, 1996
)
0.29
" Preoperative indexes of veno-occlusive function (flow to maintain, venous outflow resistance and pressure decay measurements using repeat dosing pharmacocavernosometry) were correlated with postoperative erectile tissue computer assisted color histomorphometry (percent trabecular smooth muscle to total erectile tissue area)."( Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure.
de las Morenas, A; Goldstein, I; Huang, YH; Krane, RJ; Moreland, RB; Nehra, A; Nugent, M; Pabby, A; Saenz de Tejada, I; Udelson, D, 1996
)
0.29
" In contrast, significant increases in mRNA for collagen 1 (6-fold), collagen IV (4-fold), fibronectin 1 (4-fold) and TGF-beta 1 (2-fold) were seen with insulin alone (10(-6)M) in rat mesangial cells, and a dose-response effect could be demonstrated for insulin (10(-9) to 10(-6)M)."( Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells.
Anderson, PW; Correale, JD; Graf, K; Hsueh, WA; Law, RE; Tian, J; Xi, XP; Yang, D; Zhang, XY, 1996
)
0.29
"To characterize the dose-response relationship of recombinant human bone morphogenetic protein-2 in a spinal fusion model."( Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion.
Dawson, EG; Delamarter, RB; Kabo, JM; Kanim, LE; Liu, D; Sandhu, HS; Toth, JM; Zeegen, EN, 1996
)
0.29
" This characteristic bell-shaped dose-response curve was maintained in the presence of TGF-beta (10 ng/ml) or a maximally-effective dose of forskolin (6."( Activin-A stimulates, while transforming growth factor beta 1 inhibits, chorionic gonadotrophin production and aromatase activity in cultured human placental trophoblasts.
France, JT; Keelan, J; Song, Y, 1996
)
0.59
" In addition, neuronal death induced by brief NMDA exposure in both mixed neuronal-glial and pure neuronal cultures was increased by TGFbeta2 (1-30 ng/ml) with a similar dose-response curve."( Transforming growth factor-beta2 increases NMDA receptor-mediated excitotoxicity in rat cerebral cortical neurons independently of glia.
Brown, GJ; Kane, CJ; Phelan, KD, 1996
)
0.29
" administration of 5 microg of IL-10 significantly attenuated the increase in regional cerebral blood flow, brain water content, intracranial pressure, and CSF white blood cell count, whereas a lower dosage of IL-10 (0."( Systemically (but not intrathecally) administered IL-10 attenuates pathophysiologic alterations in experimental pneumococcal meningitis.
Bernatowicz, A; Fontana, A; Frei, K; Koedel, U; Pfister, HW, 1996
)
0.29
" Oral dosing with immunostimulatory components of Escherichia coli also changed the quality of inflammation."( Cytokine gene expression in the BB rat pancreas: natural course and impact of bacterial vaccines.
Kleemann, R; Kolb, H; Rothe, H; Rowsell, P; Scott, FW; Wörz-Pagenstert, U, 1996
)
0.29
" Late function of Decapentaplegic locally determines two additional cell identities in a dosage dependent manner."( Specification of the embryonic limb primordium by graded activity of Decapentaplegic.
Goto, S; Hayashi, S, 1997
)
0.3
" The dose-response curves for both of these factors was bell-shaped with maximum activity in the 1-10 ng/ml range."( Chemotaxis of skeletal muscle satellite cells.
Bischoff, R, 1997
)
0.3
" Dose-response experiments suggested that steroid doses currently used in clinical medicine are suboptimal in repressing NFkappaB-mediated cytokine production in the inflammatory lesions."( Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras.
Brack, A; Goronzy, JJ; Kaltschmidt, C; Rittner, HL; Weyand, CM; Younge, BR, 1997
)
0.3
" These data imply that NCSCs exhibit cell-intrinsic biases in the timing and relative dosage sensitivity of their responses to instructive factors that influence the outcome of lineage decisions in the presence of multiple factors."( Integration of multiple instructive cues by neural crest stem cells reveals cell-intrinsic biases in relative growth factor responsiveness.
Anderson, DJ; Shah, NM, 1997
)
0.3
" The effect of rPEDF on microglial metabolic activity showed a dose-response relationship both in serum-containing medium and in chemically defined medium and was blocked with anti-PEDF antibody."( Pigment epithelium-derived factor (PEDF) has direct effects on the metabolism and proliferation of microglia and indirect effects on astrocytes.
Becerra, SP; Chader, GJ; Schwartz, JP; Sugita, Y, 1997
)
0.3
" Enzyme dosage ranged from 120 to 480 U/kg of body weight/month."( Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
Aerts, JM; Barton, NW; Brady, RO; Dambrosia, JM; DeGraba, T; Heyes, MP; Oliver, K; Parker, CC; Patterson, MC; Schiffmann, R; Tedeschi, G; Zirzow, GC, 1997
)
0.3
" DA rats received a total dosage of 0, 6, 60, 600 micrograms/rat of bovine MBP on ten consecutive days prior to immunization."( Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA.
Bai, XF; Li, HL; Link, H; Shi, FD; van der Meide, PH; Xiao, BG, 1997
)
0.3
" Cells were treated with IL-1 alpha, EGF, and TGF-beta for dose-response and time course experiments."( Interleukin-1 alpha, epidermal growth factor, and transforming growth factor-beta exhibit differential kinetics on endothelin-1 synthesis in amnion cells.
Kniss, DA; McKenna, DS; Samuels, P; Zimmerman, PD,
)
0.13
" The EMT-6/PRK5 beta 1E tumor was markedly resistant to a dosage range of cyclophosphamide, cisplatin, melphalan and thiotepa compared with the EMT-6/Parent tumor."( Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Ara, G; Herbst, RS; Ikebe, M; Keyes, SR; Teicher, BA,
)
0.13
" Dose-response curves for TGF-beta-mediated signaling in primary fibroblasts and thymocytes isolated from either wild-type or FKBP12-deficient mice were identical."( FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes.
Bassing, CH; Heitman, J; Matzuk, MM; Muir, S; Shou, W; Wang, XF, 1998
)
0.56
" Twenty Wistar rats were separated into 4 groups consisting of 5 animals each dosed with 2, 10, and 50 micrograms/700 microliters of rhBMP-2 and a control group (BCP only)."( Ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2).
Higuchi, T; Ishikawa, I; Kinoshita, A; Oda, S; Shizuya, T, 1997
)
0.3
" Our data suggested that conventional dosage of alpha-tocopherol at 100 IU/kg chow lowered kidney TGF beta 1 to control values and increasing the dose by 2 1/2-fold or even 5-fold resulted in no further reduction in TGF beta 1 mRNA."( alpha-Tocopherol reduces proteinuria, oxidative stress, and expression of transforming growth factor beta 1 in IgA nephropathy in the rat.
Chan, JC; Chan, W; Krieg, RJ; Norkus, EP, 1998
)
0.53
" About 20 per cent of Smad2 heterozygous embryos have severe gastrulation defects and lack mandibles or eyes, indicating that the gene dosage of Smad2 is critical for signalling."( Smad2 role in mesoderm formation, left-right patterning and craniofacial development.
Li, E; Nomura, M, 1998
)
0.3
" Acoustic velocity measurements showed significant differences between the groups of mice with an apparent dosage effect of TGF-beta1 expression on the anisotropic properties of the bone."( Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene.
Geiser, AG; Helvering, LM; Hirano, T; Sato, M; Turner, CH; Zeng, QQ, 1998
)
0.3
" In contrast, nasal administration of a mixture of MBP 68-86 and 87-99 completely blocked gp-MBP-induced EAE even at lower dosage compared to that being used for individual peptides."( Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.
Bai, XF; Levi, M; Li, HL; Link, H; Liu, JQ; Mustafa, M; Shi, FD; Wahren, B; Xiao, BG, 1998
)
0.3
" The volume of the oval shadow area in the muscle flap was dependent upon the dosage of rhBMP-2."( Prefabricated muscle flap including bone induced by recombinant human bone morphogenetic protein-2: an experimental study of ectopic osteoinduction in a rat latissimus dorsi muscle flap.
Akioka, J; Bessho, K; Fujimura, K; Iizuka, T; Kusumoto, K; Ogawa, Y, 1998
)
0.3
" A similar dose-response was also evident in cultures treated with transforming growth factor-beta (maximal 164% increase with 5 ng/ml), although the presence of serum in the culture medium altered the pattern of enhanced proteoglycan synthesis to favor the lower concentration of 1 ng/ml (191%)."( Differentiated cellular function in fetal chondrocytes cultured with insulin-like growth factor-I and transforming growth factor-beta.
Burton-Wurster, N; Lillich, JT; Lust, G; Mohammed, HO; Nixon, AJ, 1998
)
0.3
" The dose-response relationship required for the synergistic effect of GDNF and TGF-beta identifies 60 pg/ml of either factor combined with 2 ng/ml of the other factor as the EC50."( Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons.
Farkas, L; Galter, D; Henheik, P; Jaszai, J; Krieglstein, K; Krohn, K; Unsicker, K, 1998
)
0.3
" A dose-response experiment with TGF-beta (1, 10, 50 ng/ml) confirmed this differentiation-stage-independent effect of TGF-beta on proteoglycan synthesis."( Effect of transforming growth factor-beta on proteoglycan synthesis by chondrocytes in relation to differentiation stage and the presence of pericellular matrix.
Buma, P; van der Veen, SW; van Osch, GJ; Verwoerd-Verhoef, HL, 1998
)
0.3
" When CAM treatment at a dosage of 2 mg/kg of body weight orally for 21 days was commenced after inoculation of the tumor, no significant decrease in death rate was observed, although the loss in body weight was less than that in the untreated group."( Therapeutic effect of clarithromycin on a transplanted tumor in rats.
Fujishita, T; Kobayashi, M; Mizushima, Y; Oosaki, R; Sassa, K, 1999
)
0.3
" Numerous variables, including markedly different dose ranges and differing isoforms, dosing regimens, delivery methods, animal models, and various times and endpoint measures for analysis, make it difficult to comparatively assess the effects of transforming growth factor beta on bone healing."( The potential role of transforming growth factor beta in fracture healing.
Hicks, DG; O'Keefe, RJ; Rosier, RN, 1998
)
0.8
" The present study was designed to examine the dose-response effect of TSH-increasing (PB and PCN) and nonincreasing (3MC and PCB) UDP-GT inducers on apoptosis and TGF-beta1."( Dose-response examination of UDP-glucuronosyltransferase inducers and their ability to increase both TGF-beta expression and thyroid follicular cell apoptosis.
Klaassen, CD; Kolaja, KL, 1998
)
0.3
" One experimental group of 5 pigs was dosed orally for 26 weeks starting 26 weeks after irradiation with 1600 mg/120 kg body weight of pentoxifylline (PTX) included in the reconstituted food during its fabrication, and another group of 5 was dosed orally for the same period with a daily dose of 1600 mg/120 kg body weight of PTX combined with 2000 IU/120 kg body weight of alpha-tocopherol."( Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study.
Delanian, S; Lefaix, JL; Leplat, JJ; Martin, M; Tricaud, Y; Vozenin, MC, 1999
)
0.3
" No modifications were observed in the block of fibrotic scar tissue of pigs dosed with PTX alone."( Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study.
Delanian, S; Lefaix, JL; Leplat, JJ; Martin, M; Tricaud, Y; Vozenin, MC, 1999
)
0.3
" Although dosage studies using rhBMP-2 have been performed on species of lower phylogenetic level, they cannot be extrapolated to the primate."( The use of recombinant human bone morphogenetic protein 2 (rhBMP-2) to promote spinal fusion in a nonhuman primate anterior interbody fusion model.
Fischgrund, JS; Hecht, BP; Herkowitz, HN; Penman, L; Shirkhoda, A; Toth, JM, 1999
)
0.3
" An increased osteoblast-like cell activity on sintered HA surfaces in the presence of different TGF-beta dosage suggested that sintering of HA surfaces may play an important role in governing cellular response."( Effect of transforming growth factor-beta on osteoblast cells cultured on 3 different hydroxyapatite surfaces.
Carnes, DL; Ong, JL; Sogal, A,
)
0.13
" Expression of TGF-beta2 was examined immunohistochemically in forelimb buds of embryos 24 h after dosing to the mother on Day 12 of gestation in the rat."( Retinoid-induced limb defects 2: involvement of TGF-beta 2 in retinoid-induced inhibition of limb bud development.
Kishi, K; Tsuiki, H,
)
0.13
" We have previously shown that the dosage and timing of Ag administration are critical parameters in oral tolerance induction."( Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis.
Benson, JM; Cox, KL; Cross, AH; Gienapp, IE; Stuckman, SS; Trotter, JL; Wardrop, RM; Whitacre, CC, 1999
)
0.3
" Dosage was varied from 325 to 1500 ng."( Transforming growth factor-beta1 (TGF-beta1) is sufficient to induce fibrosis of rabbit corpus cavernosum in vivo.
Barrett, DM; Bostwick, DG; Gettman, MT; Goldstein, I; Krane, RJ; Moreland, RB; Nehra, A; Nugent, M, 1999
)
0.3
" dosage of 10,000 U/day every other day, and successfully treated EAE mice revealed reduced amounts of IFN gamma; no changes in the levels of IL4 were observed, although thera was a significant increase in IL10 and TGFbeta production."( Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion.
Al-Sabbagh, A; Diaz-Bardales, BM; Garcia, AA; Oliveira, EC; Santos, LM; Yasuda, CL,
)
0.13
" Because this study was designed to explore biological activity at environmental exposure levels, this exposure range does not necessarily define optimal dosing conditions from the therapeutic point of view."( Power frequency fields promote cell differentiation coincident with an increase in transforming growth factor-beta(1) expression.
Aaron, RK; Capuano, A; Ciombor, DM; Keeping, H; Polk, C; Wang, S, 1999
)
0.3
" Dose-response experiments using cer-S mRNA injections support the existence of an endogenous activity gradient of Xnrs."( Endodermal Nodal-related signals and mesoderm induction in Xenopus.
Agius, E; De Robertis, EM; Kemp, C; Oelgeschläger, M; Wessely, O, 2000
)
0.31
" In addition, these experiments have shown us the importance of gene dosage in this family, as several of its members yielded haploinsufficiency phenotypes."( Functions of mammalian Smad genes as revealed by targeted gene disruption in mice.
Deng, C; Weinstein, M; Yang, X,
)
0.13
" First, we observed that IL-11 by itself at any dosage had no stimulator activity on MK colony formation derived from CD34+ cells in CB, mPBL, and BM."( Suppressive effects of TNF-alpha, TGF-beta1, and chemokines on megakaryocytic colony formation in CD34+ cells derived from umbilical cord blood compared with mobilized peripheral blood and bone marrow.
Broxmeyer, HE; Cooper, RJ; Liu, HJ; Lu, L; Turner, K; Wang, LS; Weich, N, 2000
)
0.31
"A study was performed in dogs to evaluate the dose-response characteristics and effectiveness of recombinant human bone morphogenetic protein-2 with a collagen sponge carrier in a segmental defect model."( Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model.
Johnson, KD; Sciadini, MF, 2000
)
0.31
" In the recombinant human bone morphogenetic protein-2 implanted groups, osteogenesis increased with the dosage of recombinant human bone morphogenetic protein-2, as assessed by alkaline phosphatase activity and histologic findings."( Osteogenesis by recombinant human bone morphogenetic protein-2 at skeletal sites.
Bessho, K; Fujimura, K; Iizuka, T; Kusumoto, K; Ogawa, Y; Okubo, Y, 2000
)
0.31
" The lung tissue from three different mice per dosage and time point was analyzed by a combination of polymerase chain reaction (PCR), immunohistochemistry, and light microscopy."( Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation.
Richter, KD; Rube, C; Rube, CE; Schmid, KW; Schuck, A; Uthe, D; Wessel, J; Willich, N, 2000
)
0.6
" IL-10 concentrations in peritoneal fluids were increased after treatment with rIFN-gamma and the higher rIL-2 dosing (group A) but not in those treated with rIFN-gamma and the lower rIL-2 dosing (group B)."( Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Atkinson, EN; Edwards, CL; Freedman, RS; Kavanagh, JJ; Kudelka, AP; Levy, L; Melichar, B; Nash, M; Patenia, R; Platsoucas, CD; Scott, W; Templin, S; Verschraegen, C; Zhang, HZ, 2000
)
0.31
" Human RPE cells, choroidal endothelial cells (CECs), and scleral fibroblasts were isolated, and a dose-response for DT390-VEGF165 was determined by measurement of cell proliferation and cell number."( Selective killing of RPE with a vascular endothelial growth factor chimeric toxin.
Gill, P; He, S; Hinton, DR; Hoffmann, S; Masood, R; Ryan, SJ; Zhang, Y, 2000
)
0.31
" Here we analyze se(l);nodal compound mutants and find a dosage effect."( Nodal and bone morphogenetic protein 5 interact in murine mesoderm formation and implantation.
Iannaccone, PM; Kuehn, MR; Pfendler, KC; Taborn, GU; Yoon, J, 2000
)
0.31
" In freshly isolated human peripheral blood monocytes, fetuin stimulated proMMP-9 release with a dose-response curve similar to that observed in THP-1 cells."( Regulation of human monocyte proMMP-9 production by fetuin, an endogenous TGF-beta antagonist.
Dennis, JW; Swallow, CJ; Tajirian, T, 2000
)
0.31
" To better understand the mechanism of action of ethanol on bone metabolism, we have studied the dose-response effects of ethanol on conditionally immortalized human fetal osteoblasts (hFOB) in culture."( The dose-response effects of ethanol on the human fetal osteoblastic cell line.
Maran, A; Spelsberg, TC; Turner, RT; Zhang, M, 2001
)
0.31
" Dose-response studies showed that a majority of mice (68%) treated with rCT-B at a dose of 100 microg (times four daily doses) exhibited complete inhibition of the development of colitis, whereas a minority (30%) treated with rCT-B at a dose of 10 microg (times four daily doses) exhibited complete inhibition; in both cases, however, the remaining mice exhibited some reduction in the severity of inflammation."( Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis.
Boirivant, M; De Pascale, M; Ferroni, L; Fuss, IJ; Strober, W, 2001
)
0.31
" We have developed an animal model, based on the existing sex hormone-induced prostate carcinogenesis in the Noble rat, by substantially increasing the dosage of testosterone while keeping the level of estrogen unchanged."( The prostate gland and prostate carcinogenesis.
Tam, NN; Wang, YZ; Wong, YC, 1998
)
0.3
" The results of the dose-response study demonstrated that decorin suppresses formation of fibrous adhesion in a dose-dependent manner."( Suppression of fibrous adhesion by proteoglycan decorin.
Fukuda, A; Fukui, N; Kojima, K; Nakajima, K; Nakamura, K; Oda, H, 2001
)
0.31
" Nine patients were enrolled in this dose-escalation study, with secreted IL-12 doses ranging from 300 ng/24 hr for the first three patients to 1000, 3000, and 5000 ng/24 hr for two patients in each subsequent dosage level."( Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study.
Ahn, YC; Baek, CH; Bang, YJ; Choe, YH; Han, J; Huh, SJ; Jeong, HS; Kang, WK; Kang, YK; Kim, DW; Kim, JA; Kim, K; Kim, S; Kim, SH; Kim, WS; Kong, GS; Lee, ES; Lee, JH; Lee, MH; Lee, SN; Lotze, MT; Nam, SJ; Paik, NS; Park, C; Park, CH; Park, EY; Park, K; Park, MH; Ree, HJ; Robbins, PD; Son, YI; Tahara, H; Yang, JH; Yoon, HL; Yoon, SS, 2001
)
0.31
" Mice lacking one copy each of Smad2 and Smad3 suffered midgestation lethality due to liver hypoplasia and anemia, suggesting essential dosage requirements of TGF-beta signal components."( Smad proteins and hepatocyte growth factor control parallel regulatory pathways that converge on beta1-integrin to promote normal liver development.
Brodie, SG; Deng, CX; Li, C; Liu, Y; Mishra, L; Monga, SP; Tang, Y; Weinstein, M, 2001
)
0.31
" The active suppression mediated by these regulatory cells was seen only within a narrow range of antigen dosage (feeding), with the most prominent effect at 5 x 1 mg BLG."( Interleukin-10-secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance.
Kurisaki , J; Mizumachi, K; Tsuji, NM, 2001
)
0.31
"The proteoglycan synthesis was significantly reduced by irradiation 1 hour before or 1 day after BMP-2 incubation, if the dosage was at least 7 Gy."( Radiation-induced reduction of BMP-induced proteoglycan synthesis in an embryonal mesenchymal tissue equivalent using the chicken "limb bud" test.
Flentje, M; Knaus, P; Koelbl, O; Pohl, F; Sebald, W, 2001
)
0.31
" After the start of the trials, negative results from new preclinical studies suggesting suboptimal formulation and/or dosing led to an interim analysis of the ongoing clinical trials."( Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors.
Brandts, CH; Cagnoni, PJ; Derigs, HG; Emmons, R; Fay, J; Fields, K; Foncuberta, MC; LeVeque, F; Mandanas, R; Pouillart, P; Reed, E; Schrezenmeier, H; Sonis, ST; Thiel, E,
)
0.13
" SHRSP were exposed to high dietary salt intake (1% NaCl in drinking solution) from 8 to 14 weeks of age, with or without amlodipine or lacidipine at three dosage regimens producing similar effects on blood pressure."( Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats.
Godfraind, T; Krenek, P; Kyselovic, J; Wibo, M, 2001
)
0.31
" Dose-response and time-course were studied by MTT colorimetric method."( [Effects of various growth factors on human mandibular condylar cartilage cell proliferation].
Han, WL; Jiao, Y; Wang, D, 2000
)
0.31
" Based on these results, further studies regarding biodegradation, dosage of the protein and surgical technique are required."( Bone morphogenetic protein-2 and growth and differentiation factor-5 enhance the healing of necrotic bone in a sheep model.
Ewerbeck, V; Manggold, J; Richter, W; Ries, R; Sebald, W; Sergi, C; Simank, HG, 2001
)
0.31
" The participants emphasized the need for developing and choosing appropriate models, and for radiation dose-response studies to determine whether interventions remain effective at the radiation doses used clinically."( Modifying normal tissue damage postirradiation. Report of a workshop sponsored by the Radiation Research Program, National Cancer Institute, Bethesda, Maryland, September 6-8, 2000.
Coleman, CN; McBride, WH; Stone, HB, 2002
)
0.31
" Kinase assays demonstrated dose-response relationships between dietary salt intake and the activities of p38 MAP kinase and p42/44 MAP kinase."( Increased dietary salt activates rat aortic endothelium.
Sanders, PW; Ying, WZ, 2002
)
0.31
" In this study, we have investigated the dose-response effect of TGF-beta1 on progenitors ranging from primitive high proliferative potential (HPP)-Mix, -GM or -BFU-E to later BFU-E, CFU-G or CFU-M."( Specific dose-response effects of TGF-beta1 on developmentally distinct hematopoietic stem/progenitor cells from human umbilical cord blood.
Aoustin, L; Batard, P; Charpentier, A; Ducos, K; Fortunel, N; Hatzfeld, A; Hatzfeld, J; Monier, MN, 2000
)
0.31
" HGF actions were time- and dose-response dependent and required transcriptional activity."( Liver cell proliferation requires methionine adenosyltransferase 2A mRNA up-regulation.
Fabregat, I; Gorospe, I; Herrera, B; Nakamura, T; Pañeda, C; Varela-Nieto, I, 2002
)
0.31
" Accordingly, proper dosage of rhBMP-2 should be determined for successful clinical application."( Tooth eruption into the newly generated bone induced by recombinant human bone morphogenetic protein-2.
Baba, Y; Kawamoto, T; Kitamura, A; Kuroda, T; Motohashi, N; Suzuki, S, 2002
)
0.31
" In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy."( SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
Boulay, JL; Herrmann, R; Laffer, U; Lagrange, M; Lowy, A; Mild, G; Reuter, J; Rochlitz, C; Terracciano, L, 2002
)
0.31
"Developmental patterning relies on morphogen gradients, which generally involve feedback loops to buffer against perturbations caused by fluctuations in gene dosage and expression."( Robustness of the BMP morphogen gradient in Drosophila embryonic patterning.
Ashe, H; Barkai, N; Dorfman, R; Eldar, A; Shilo, BZ; Weiss, D, 2002
)
0.31
"The results indicate that the dosage and route of delivery of TGF-beta1 did not lead to overt improvement in the healing of the injured MCL."( Exogenous transforming growth factor beta 1 alone does not improve early healing of medial collateral ligament in rabbits.
Frank, CB; Hart, DA; Hildebrand, KA; Hiraoka, H; Shrive, NG, 2002
)
0.72
" TGF-beta2 heterozygous or wild-type mice were mated and the dams dosed with a teratogenic dose of RA, or with control vehicle."( Increased susceptibility to retinoid-induced teratogenesis in TGF-beta2 knockout mice.
Greene, RM; Nugent, P; Pisano, MM; Weinrich, MC,
)
0.13
" Adjustment of dosage should render TGF beta more potent at later time periods."( Osseointegration on metallic implant surfaces: effects of microgeometry and growth factor treatment.
Alexander, H; Dennis, M; Frenkel, SR; Ricci, JL; Simon, J, 2002
)
0.31
"Effects of PTX on the content change of hepatic TGF-beta1, type I and type III collagen in schistosomiasis japonica mice with liver fibrosis were related to the dosage of PTX, high dose PTX treated group could significantly reduce the content of TGF-beta1 (0."( Effects of pentoxifylline on the hepatic content of TGF-beta1 and collagen in Schistosomiasis japonica mice with liver fibrosis.
Cai, SQ; Luo, DD; Xiong, LJ; Zen, LL; Zhu, JF, 2003
)
0.32
"5 mg/kg, intraperitoneally, 3 times/wk) beginning immediately after the termination of CsA dosing and continued through 8 wk."( Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation.
Jha, S; Karetskaya, L; Ledbetter, S; Li, X; Ling, H; Pratt, B; Wang, W, 2003
)
0.32
" Further in vivo research is now required to optimize the dosing regimen of N-BPs to exploit fully their antitumor potential."( Antitumor effects of bisphosphonates.
Green, JR, 2003
)
0.32
"The effect of PTX on the content of hepatic TGF-beta 1, type I and type III collagen in mice was related to the dosage of PTX."( [Effect of pentoxifylline on the expression of hepatic TGF-beta 1, type I and type III collagen in mice with liver fibrosis due to Schistosoma japonicum infection].
Li, SL; Luo, DD; Xiong, LJ; Zeng, LL, 2002
)
0.31
" It also shows that BMP can augment fusion in a rat and that dosing plays a role in successful fusion."( The effects of BMP-7 in a rat posterolateral intertransverse process fusion model.
Althausen, PL; Gupta, MC; Laubach, J; Salamon, ML, 2003
)
0.32
"Rats were on low-salt diet and cyclosporin A (CsA) was administered once a day through gastrogavage at dosage of 30 mg/kg."( [Experimental study of compound salvia injection in preventing and treating chronic nephrotoxicity induced by cyclosporin A in rats].
Qiao, BP; Ruan, Q; Tang, XD, 2001
)
0.31
"We observed the effect of TGF-beta in varied time and dosage on the differentiation of hypertrophic chondrocytes in embryonic chick femora which were cultured in serum-free medium, using histochemical staining to detect the expression of alkaline phosphatase (ALP) and immunohistochemical staining to detect the expression of type I collagen and fibronectin."( [Transforming growth factor-beta can induce differentiation of hypertrophic chondrocytes into osteoblast-like cells in epiphyseal plate].
Li, A; Li, R; Wang, F; Yang, H; Zhang, B; Zhou, D, 2001
)
0.31
" The inducing effect might be closely related to time and dosage of TGF-beta."( [Transforming growth factor-beta can induce differentiation of hypertrophic chondrocytes into osteoblast-like cells in epiphyseal plate].
Li, A; Li, R; Wang, F; Yang, H; Zhang, B; Zhou, D, 2001
)
0.31
" However, this activity requires a higher Sox10 gene dosage than does the maintenance of neurogenic potential."( SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells.
Anderson, DJ; Dormand, E; Kim, J; Lo, L, 2003
)
0.32
"Mice with LPS-induced ALI that were treated with ambroxol at a dosage of 90 mg/kg per day significantly gained weight compared to the control and dexamethasone-treated groups."( Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide.
Bai, C; Song, Y; Su, X; Wang, L, 2004
)
0.32
"DHZCP of larger dosage could inhibit the hepatic stellate cells proliferation and secretion of TGF-beta 1, and reduce the genesis of collagen, so as to weaken the auto-secretion amplifying response of the cells, which might be one of the chief mechanisms of DHZCP in antagonizing liver fibrosis."( [Effect of dahuang zhechong pill on transforming growth factor-beta 1 in hepatic stellate cells in rats].
Li, L; Liu, ZL; Xu, M, 2003
)
0.32
" MC615 cells were dosed with BMP-2, CDMP-2, or both, cultured for 6 days, and then assayed as follows: (1)."( BMP-2 and CDMP-2: stimulation of chondrocyte production of proteoglycan.
Elmer, WA; Hutton, WC; Kim, KS; Li, J; Park, JS; Yoon, ST, 2003
)
0.32
"The effects of soluble mediators and medium supplements commonly used to induce chondrogenic differentiation in different cell culture systems were investigated to define their dose-response profiles and potentially synergistic effects on the chondrogenic differentiation of adipose-derived adult stromal (ADAS) cells."( Effects of transforming growth factor beta1 and dexamethasone on the growth and chondrogenic differentiation of adipose-derived stromal cells.
Awad, HA; Gimble, JM; Guilak, F; Halvorsen, YD, 2003
)
0.71
" A PAN untreated control group (N= 7) was dosed with an isotype specific, null antibody."( Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats.
Fogo, AB; Jha, S; Ledbetter, S; Ling, H; Ma, LJ; Pozzi, A, 2004
)
0.32
"These results show an in vivo dose-response with an agent that blocks the biologic activity of TGF-beta."( Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats.
Fogo, AB; Jha, S; Ledbetter, S; Ling, H; Ma, LJ; Pozzi, A, 2004
)
0.32
" The aim of this study was to find an optimal dosage of TGF-beta1 to accelerate the attachment process."( Transforming growth factor-beta1 accelerates bone bonding to a blended calcium phosphate ceramic coating: a dose-response study.
DeYoung, DW; Hajdu, SD; Nelson, ER; Szivek, JA; Yablonski, K, 2004
)
0.32
" This potential depends on the dosage and potentially on the application method and may limit the clinical use."( Local and controlled release of growth factors (combination of IGF-I and TGF-beta I, and BMP-2 alone) from a polylactide coating of titanium implants does not lead to ectopic bone formation in sheep muscle.
Haas, NP; Kandziora, F; Krummrey, G; Palasdies, N; Raschke, M; Schmidmaier, G; Wildemann, B, 2004
)
0.32
" Understanding physical interactions and transmembrane signaling will most likely be necessary to establish dosing paradigms and improve therapeutic efficacy."( Stimulation of growth factor synthesis by electric and electromagnetic fields.
Aaron, RK; Boyan, BD; Ciombor, DM; Schwartz, Z; Simon, BJ, 2004
)
0.32
" The present study addressed the dosage of rhOP-1 and the combination of an external (mould) and internal scaffold (granular BioOss)."( Prefabrication of vascularized bone grafts using recombinant human osteogenic protein-1--part 3: dosage of rhOP-1, the use of external and internal scaffolds.
Acil, Y; Menzel, C; Rueger, DR; Springer, IN; Terheyden, H; Wang, H, 2004
)
0.32
" Cultures of human corneal epithelial cells were incubated with the four blood products in dose-response experiments and the intracellular ATP quantified."( [Epitheliotrophic capacity of serum and plasma eyedrops. Influence of centrifugation].
Dibbelt, L; Geerling, G; Hartwig, D; Herminghaus, P; Wedel, T, 2004
)
0.32
" We also show that it is not necessary to administer Arz and 268 continuously during tumor progression to prevent cancer in the rat model because dosing of these drugs in combination for relatively short periods, each followed by drug-free rests, is highly effective."( The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
Berchuck, A; Heyman, RA; Krajewski, S; Lamph, WW; Liby, K; Reed, JC; Rendi, MH; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR, 2004
)
0.54
" Here we show that Smad2 and Smad3 are required at a full dosage for normal embryonic development."( Smad2 and Smad3 coordinately regulate craniofacial and endodermal development.
El-Hodiri, HM; Festing, M; Hester, M; Liu, Y; Rankin, S; Thompson, JC; Weinstein, M; Zorn, AM, 2004
)
0.32
" Addition of TGF-beta2 resulted in a steep, bell-shaped dose-response curve with a significant effect on TH+/dopamine cell survival."( The effects of transforming growth factor-beta2 on dopaminergic graft survival.
Horsch, AD; Macauley, SL; Oterdoom, M; Stewart, GR; Zheng, MH, 2004
)
0.32
" However, optimal dosing regimens for the use of osteogenic protein-1 and other bone morphogenetic proteins in large bone defects have not been determined conclusively."( The effect of osteogenic protein-1 dosing regimen on ectopic bone formation.
Lietman, SA; Love, DA, 2004
)
0.32
", MP is considered to be a suitable dosage form, which can be administered noninvasively."( Profile of rhBMP-2 release from collagen minipellet and induction of ectopic bone formation.
Fujioka, K; Maeda, H; Sano, A, 2004
)
0.32
" We refer to the capacity to buffer fluctuations in gene dosage or environmental conditions as 'robustness'."( Elucidating mechanisms underlying robustness of morphogen gradients.
Barkai, N; Eldar, A; Shilo, BZ, 2004
)
0.32
" Differential effectiveness between the isoforms was demonstrated in dose-response studies, as was differential binding to ILT2 and ILT4 in receptor-blocking studies."( Recombinant HLA-G5 and -G6 drive U937 myelomonocytic cell production of TGF-beta1.
Colonna, M; Hunt, JS; McIntire, RH; Morales, PJ; Petroff, MG, 2004
)
0.32
" We assessed a series of bone markers to determine a dosing regimen for TGF-beta1 that enhances collagenous matrix formation and preserves or increases osteoblastic differentiation."( Effects of transforming growth factor beta1 on bonelike tissue formation in three-dimensional cell culture. II: Osteoblastic differentiation.
Dauner, M; Lieb, E; Milz, S; Schulz, MB; Vogel, T,
)
0.52
" After a dosing study in rabbits, the engineered growth factor in fibrin was evaluated in a prospective clinical study for pancarpal fusion in dogs, where it induced statistically faster and more extensive bone bridging than equivalent treatment with cancellous bone autograft."( Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices.
Grätz, KW; Hubbell, JA; Schawalder, P; Schense, JC; Schmoekel, HG; Weber, FE, 2005
)
0.33
"Treatment was administered therapeutically, with dosing starting after the onset of established eosinophilic airway inflammation and hyper-reactivity."( Therapeutic administration of Budesonide ameliorates allergen-induced airway remodelling.
Lloyd, CM; McMillan, SJ; Xanthou, G, 2005
)
0.33
" Importantly anti-TGF-beta Ab was administered therapeutically, with dosing starting after the onset of established eosinophilic airway inflammation."( Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway.
Lloyd, CM; McMillan, SJ; Xanthou, G, 2005
)
0.33
" In a dose-response study, bone induction by AdBMP-2 in collagen (AdBMP-2/collagen) or by AdBMP-2 and FGF2 Fab' anti-adenovirus knob protein antibody in collagen (FGF2-AdBMP-2/collagen) was tested at fourteen days."( Bone induction by AdBMP-2/collagen implants.
Ambrosio, A; Amburn, E; Blease, K; Sampath, TK; Schreiber, RE; Sosnowski, B, 2005
)
0.33
" By combining the properties of the ACS with the CRM, the required dosage of rhBMP-2 was diminished by more than 3-fold in the non-human primate model."( Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates.
Barnes, B; Boden, SD; Louis-Ugbo, J; Minamide, A; Park, JS; Park, MS; Tomak, PR, 2005
)
0.33
" Forty New Zealand rabbits and 48 Sprague-Dawley (SD) rats were assigned randomly to one of the five groups: sham adhesion, adhesion with saline, adhesion with low dosage of the CT, adhesion with middle dosage of the CT and adhesion with high dosage of the CT."( Chinese medicine compound Changtong oral liquid on postoperative intestinal adhesions.
Hou, LB; Shi, HP; Yang, XX, 2005
)
0.33
" To minimize the immune response and improve the rebuilding of tissues there was developed a technology to treat tissues with a cells elimination and dosed out extraction of proteoglycanes (Alloplant."( The role of macrophages in the tissues regeneration stimulated by the biomaterials.
Khasanov, RA; Lebedeva, AI; Muldashev, ER; Musina, LA; Muslimov, SA; Nigmatullin, RT; Shangina, OR, 2005
)
0.33
" Bacillus clausii spores (Enterogermina: 2 billions spores/vial) were administered at the dosage schedule of 3 vials a day for 4 weeks."( Bacillus clausii exerts immuno-modulatory activity in allergic subjects: a pilot study.
Ciprandi, G; Cirillo, I; Tosca, MA; Vizzaccaro, A, 2005
)
0.33
" Reduction of Gpc3 gene dosage also increased UB cell proliferation, an effect that was enhanced in Gpc3+/-;Bmp2+/- mice to an extent greater than the sum of that observed in Gpc3+/- and Bmp2+/- mice."( Glypican-3 modulates inhibitory Bmp2-Smad signaling to control renal development in vivo.
Cella, C; Filmus, J; Hartwig, S; Hu, MC; Piscione, T; Rosenblum, ND, 2005
)
0.33
"The results suggest that sustained administration of TGF-beta1 may be more effective in suppressing terminal differentiation than intermittent dosing and thus effective for cartilage repair."( Adenoviral-mediated transfer of TGF-beta1 but not IGF-1 induces chondrogenic differentiation of human mesenchymal stem cells in pellet cultures.
Chu, CR; Fu, FH; Izzo, NJ; Kawamura, K; Niyibizi, C; Robbins, PD; Sobajima, S, 2005
)
0.33
" The level of MMP-13 mRNA expression had significant coherence with the dosage of TGF-beta."( [Regulating effects of transforming growth factor beta on gene expression of matrix metalloproteinase 13 mRNA in human hyaline chondrocytes].
Qi, J; Ye, W; Zhao, Q, 2005
)
0.64
" There was no significant difference between different dosage regimens."( Evaluation of recombinant human bone morphogenetic protein-2 in mandibular distraction osteogenesis in rabbits: Effect of dosage and number of doses on formation of bone.
Cheung, LK; Rabie, AB; Wong, MC; Zheng, LW, 2006
)
0.33
"Rats with a surgically induced 6-mm femoral critical size defect were separated into five dosing groups: Carrier, Carrier + ZA, OP-1, OP-1 + ZA, and OP-1 + ZA administered 2 weeks after surgery (2W)."( Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model.
Amanat, N; Bransford, R; Godfrey, CB; Little, DG; McDonald, M, 2005
)
0.33
"05) inhibited by a dose-response of DL compared with positive controls, in both NM (10(-5) m: 125+/-36 pg/mL, 10(-6) m: 95+/-22 pg/mL vs."( Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival.
Alobid, I; Bernal-Sprekelsen, M; Mullol, J; Picado, C; Pujols, L; Roca-Ferrer, J; Valero, A; Xaubet, A, 2006
)
0.33
" However, imatinib mesylate was effective independently of the dosing regime."( Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
Chaudhary, NI; Park, JE; Schnapp, A, 2006
)
0.33
" The evaluating score of neural symptoms, brain water ratio and cerebral infarction area improved obviously in every emodin group, especially in emodin low dosage group."( [Preventive effects of emodin on cerebral ischemia injury and expression of the inflammatory factors in rats with cerebral ischemia].
Fang, J; Liang, SW; Liu, JX; Lu, JS; Wang, D; Zhang, WY, 2005
)
0.33
"To assess the safety of inappropriately dosed or misdirected gene delivery to the spinal column in an in vivo model."( Safety assessment of intradiscal gene transfer: a pilot study.
Gilbertson, LG; Kang, JD; Kim, JS; Lattermann, C; McFadden, K; Oxner, WM; Robbins, PD; Sobajima, S; Wallach, CJ,
)
0.13
"Inappropriately dosed or directed gene delivery to the spinal column may result in significant complications."( Safety assessment of intradiscal gene transfer: a pilot study.
Gilbertson, LG; Kang, JD; Kim, JS; Lattermann, C; McFadden, K; Oxner, WM; Robbins, PD; Sobajima, S; Wallach, CJ,
)
0.13
"4 ng/mg creatinine at 1 month after discontinuation of CyA or reduction in CyA dosage (P<."( Urinary transforming growth factor-beta-induced gene-h3 (betaig-h3) as a sensitive predictor in chronic cyclosporine nephrotoxicity.
Cho, YJ; Ha, SW; Kim, CD; Kim, IS; Kim, YJ; Kim, YL; Kwon, TH; Lee, EG; Park, SH, 2006
)
0.33
" Using quantitative PCR (qPCR), the dose-response of 24 genes was determined after a single MEHP exposure of 10, 100, or 1000 mg/kg."( Testicular gene expression profiling following prepubertal rat mono-(2-ethylhexyl) phthalate exposure suggests a common initial genetic response at fetal and prepubertal ages.
Gaido, KW; Johnson, KJ; Lahousse, SA; Liu, D; Wallace, DG, 2006
)
0.33
" In addition, specific areas of the genome appear unstable in HCC, with the same regions undergoing either deletion or increased gene dosage in all HCC."( Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas.
Demetris, AJ; Keryanov, S; Luo, JH; Michalopoulos, GK; Monga, SP; Nalesnik, M; Ranganathan, S; Rao, UN; Ren, B; Strom, S; Tseng, GC; Yu, YP, 2006
)
0.33
"The dose-response in immunologic parameters after immunotherapy with dog extract is similar to that previously demonstrated with cat extract."( Immunologic response to administration of standardized dog allergen extract at differing doses.
Efaw, B; Harbeck, R; Lebo, T; Lent, AM; Nelson, HS; Schmidt, K; Sills, M; Strand, M, 2006
)
0.33
" Interestingly, although 1,25(OH)(2)D(3) alone did not increase expression of the 1,25D(3)-MARRS promoter-reporter, co-treatment of transfected IEC-6 cells with 1,25(OH)(2)D(3) and TGFbeta shifted the dose-response curve to a lower effective concentration (100 pM peptide)."( Regulation of expression of 1,25D3-MARRS/ERp57/PDIA3 in rat IEC-6 cells by TGF beta and 1,25(OH)2D3.
Farach-Carson, MC; Nemere, I; Rohe, B; Safford, SE, 2007
)
0.34
"The study was designed in 2 phases: Phase I consisted of a dose-response study where 21 New Zealand White rabbits underwent bilateral anterior cruciate ligament reconstructions."( Bone morphogenetic proteins-signaling plays a role in tendon-to-bone healing: a study of rhBMP-2 and noggin.
Deng, XH; Hays, P; Kawamura, S; Ma, CB; Rodeo, SA; Schneidkraut, J; Ying, L, 2007
)
0.34
" Our results show that the dosage of a single gene can determine the severity of aneurysm formation and imply that disturbed TGF-beta signaling underlies multiple aneurysm phenotypes."( Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice.
de Waard, MC; Dietz, HC; Duncker, DJ; Essers, J; Garinis, GA; Hanada, K; Kanaar, R; Kunen, MG; Maas, A; Meijers, C; Myers, L; Vermeij, M, 2007
)
0.34
" A safe, effective dosage of rh-BMP-2 in the cervical spine has yet to be determined."( Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study.
Anand, N; Cooper, M; Lauryssen, C; Perri, B,
)
0.13
"Cultured rat HSCs were divided into a no-treatment control group, a TGF b-treated group, and a TGFb plus different dosage pioglitazone-treated group."( [Effects of pioglitazone on the morphology and the expression of connective tissue growth factor of transforming growth factor beta-induced rat hepatic stellate cells in vitro].
Chen, WH; Jia, JB; Liu, M; Liu, Y; Lu, LG, 2007
)
0.56
" Dosing began three days after implantation and continued until the end of the study."( Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Aulwurm, S; Axon, J; Chakravarty, S; Dugar, S; Hart, B; Higgins, LS; Janssen, L; Kapoun, AM; Kerr, I; Kizer, DE; Lam, A; Ma, JY; McEnroe, G; Murphy, A; Protter, AA; Sriram, V; Tran, TT; Uhl, M; Webb, HK; Weller, M; Wick, W; Wong, DH, 2007
)
0.34
" In vitro addition of TGF-beta (in the presence of IL-2) induces Foxp3 expression in a dose-response manner."( CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression.
Ebling, F; Hahn, BH; La Cava, A; Singh, RP; Wong, M, 2007
)
0.34
" However, treatment with a high dosage of rhBMP-2 caused adverse side effects in some animals."( The short-term therapeutic effect of recombinant human bone morphogenetic protein-2 on collagenase-induced lumbar facet joint osteoarthritis in rats.
Han, B; Lee, CH; Lee, HS; Nimni, ME; Wen, ZH; Wu, SS; Yang, Z; Yeh, TT, 2007
)
0.34
" In the 10w rats, thickness of new bone (TNB) increased as the dosage increased from 0 microg to 4 microg, and decreased significantly as the dosage increased from 8 microg to 24 microg."( Effects of dose of recombinant human BMP-2 on bone formation at palatal sites in young and old rats.
Iwasaka, K; Kawanami, M; Matsumoto, A; Nishitani, Y; Odajima, T; Yamaji, K; Yoshimitsu, K; Yoshiyama, M, 2007
)
0.34
" In 2 atorvastatin-treated groups, mice were fed the same diets (chow or atherogenic) as described above except atorvastatin was added at the dosage of 10 mg x kg(-1) x day(-1) for the last 8 weeks before euthanasia."( Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment.
Andrys, C; Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P, 2007
)
0.34
" Dosing with the TNF-alpha neutralizing antibody infliximab did not reduce obesity, hypercholesterolemia, or hyperglycemia; however, haptoglobin, aortic BMP2, Msx2, Wnt3a, and Wnt7a and aortic calcium accumulation were downregulated by infliximab."( Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice.
Al-Aly, Z; Behrmann, A; Cai, J; Cheng, SL; Huang, E; Lai, CF; Shao, JS; Towler, DA, 2007
)
0.34
" The dose-response relationship was studied at 48 h and 72 h by the MTT colorimetric method."( [Effect of three growth factors on proliferation and cell phenotype of human fetal meniscal cells].
Deng, Z; Li, B; Ye, C, 2007
)
0.34
" To our knowledge, this is the first demonstration of a dose-response to a toxic particle in situ, and this response appears to be dependent on the number of fibres that deposits at the individual anatomic site."( Laser capture microdissection reveals dose-response of gene expression in situ consequent to asbestos exposure.
Brody, AR; Sullivan, DE; Yin, Q, 2007
)
0.34
" The stimulation of COL1A2 and fibronectin mRNA expression and promoter activity, and of corresponding protein levels, showed comparable time and dose-response in wild type and CCN2(-/-) MEFs, whereas stimulation of alpha smooth muscle actin and myofibroblast transdifferentiation showed subtle impairment in MEFs lacking CCN2."( Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness.
Hinchcliff, M; M Lyons, K; Mori, Y; Varga, J; Warner-Blankenship, M; Wu, M, 2008
)
0.35
" In the rat carotid injury model, SM16 dosed once daily orally at 15 or 30 mg/kg SM16 for 14 days caused significant inhibition of neointimal thickening and lumenal narrowing."( SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Arduini, RM; Boriack-Sjodin, PA; Bowes, S; Carter, MB; Cheung, HK; Choi, M; Chuaqui, CE; Corbley, MJ; Cornebise, M; Costa, D; Friedman, JE; Fu, K; Gill, A; Josiah, S; Lee, WC; Ling, LE; Lutterodt, F; Mead, JN; Newman, MN; Papadatos, JL; Shan, F; Singh, J; Sun, D; Sun, L; Sweigard, H; Zhang, X, 2008
)
0.35
" When dosed in the manner reported, very high rates of fusion are achievable as is eradication of infection."( Surgical treatment of vertebral osteomyelitis with recombinant human bone morphogenetic protein-2.
Kuklo, TR; O'Shaughnessy, BA; Ondra, SL, 2008
)
0.35
" Experimental hepatic fibrosis was induced by subcutaneous injection of carbon tetrachloride (CCl4 soluted in liquid paraffin with the concentration of 300 g/L, the dosage of injection was 3 mL/kg, twice per week for 8 wk)."( Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis.
Jiang, MD; Qin, JP; Wu, XL; Xu, H; Zeng, WZ, 2008
)
0.35
" Recently, data has been published demonstrating that improperly dosed or delivered adenoviral-mediated gene therapy within the subarachnoid space can result in significant morbidity in rabbits."( Safety assessment of intradiscal gene therapy II: effect of dosing and vector choice.
Gilbertson, LG; Juan, L; Kang, JD; Kim, JS; Larson, JW; Levicoff, EA; Robbins, PD; Sobajima, S; Vadala, G; Wallach, CJ; Xiao, X, 2008
)
0.35
"Properly dosed and directed gene therapy seems to be both safe and potentially efficacious."( Safety assessment of intradiscal gene therapy II: effect of dosing and vector choice.
Gilbertson, LG; Juan, L; Kang, JD; Kim, JS; Larson, JW; Levicoff, EA; Robbins, PD; Sobajima, S; Vadala, G; Wallach, CJ; Xiao, X, 2008
)
0.35
" We show that apparent gene dosage discrepancies between humans and model organisms can be reconciled by considering a broader combination of sequence variants."( Reduced NODAL signaling strength via mutation of several pathway members including FOXH1 is linked to human heart defects and holoprosencephaly.
Belmont, JW; Bowers, P; Feldman, B; Goldmuntz, E; Kantipong, A; Karkera, JD; Lacbawan, F; Muenke, M; Ouspenskaia, MV; Roessler, E; Towbin, JA; Vélez, JI, 2008
)
0.35
" The LCSA provides dose-response information, thereby allowing prediction of the relative ability of a substance to induce sensitization."( A new dendritic cell type suitable as sentinel of contact allergens.
Briechle, D; Peiser, M; Schreiner, M; Stahlmann, R; Wanner, R; Zuberbier, T, 2008
)
0.35
" A dose-response relationship was confirmed for the effects of GDF-5 in penile tissue."( Intracavernous growth differentiation factor-5 therapy enhances the recovery of erectile function in a rat model of cavernous nerve injury.
Bella, AJ; Fandel, TM; Lin, CS; Lin, G; Lue, TF; Pohl, J; Tantiwongse, K, 2008
)
0.35
"Specific growth factor binding agents, such as BBP, can be compounded into carriers used in fusion procedures to decrease the dosage of BMP and possibly decrease the side effects which are most likely dose-related."( The adjunctive effect of a binding peptide on bone morphogenetic protein enhanced bone healing in a rodent model of spinal fusion.
Alanay, A; Brochmann, EJ; Chen, C; Lee, S; Miyazaki, M; Murray, SS; Napoli, A; Wang, JC, 2008
)
0.35
" Exactly by which mechanism(s) one acquired somatic mutation, JAK2 V617F, can promote three different diseases remains a mystery, although gene dosage and host genetic variation might have important functions."( Aberrant signal transduction pathways in myeloproliferative neoplasms.
Caceres, N; Constantinescu, SN; Kota, J, 2008
)
0.35
"Proper dosing and delivery of INFUSE for posterior cervical/OC fixation is not currently known."( Occipitocervical fusion using recombinant human bone morphogenetic protein-2: adverse effects due to tissue swelling and seroma.
Kim, KD; Shahlaie, K, 2008
)
0.35
" When dosed back onto cells exogenously in soluble form, GAGs regulated MG-63 survival and growth in a dose-dependent manner, but not differentiation in either cell type."( Glycosaminoglycan composition changes with MG-63 osteosarcoma osteogenesis in vitro and induces human mesenchymal stem cell aggregation.
Cool, SM; Kumarasuriyar, A; Murali, S; Nurcombe, V, 2009
)
0.35
" The c-fos gene expression levels of the HSC increased as the dosage of PDGF increased and there were significant differences of c-fos gene expression among the three PDGF groups."( [Growth factors may enhance c-fos and c-jun gene expressions of hepatic stellate cells].
Ren, CH; Wang, AM; Xiang, Y, 2008
)
0.35
" Concerns regarding efficacy and safety and whether biomarkers can indicate these features, questions regarding appropriate dosing and timing of therapy, and identification of potential responders are critical challenges ahead."( Transforming growth factor beta as a therapeutic target in systemic sclerosis.
Pasche, B; Varga, J, 2009
)
1.8
" Biomarkers found to be significant were further analyzed for dose-response correlation with preterm birth by logistic regression, adjusted for pertinent demographic and clinical factors."( Differential patterns of 27 cord blood immune biomarkers across gestational age.
Hougaard, DM; Matoba, N; Mestan, K; Ortiz, K; Pearson, C; Porta, N; Skogstrand, K; Thorsen, P; Wang, X; Yu, Y; Zuckerman, B, 2009
)
0.35
" Additional studies are needed to clarify this issue, as well as to determine optimal dosing and carrier for usage in the posterior cervical spine."( Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.
Campbell, MJ; Carreon, LY; Crawford, CH; Glassman, SD; McGinnis, MD, 2009
)
0.35
" The development of such a model provides a rational basis for developing more biologically extensive models that may support the design of optimal dosing strategies for different therapies such as PTH-based anti-osteoporosis treatments."( A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level.
Kalyanasundaram, S; Qin, QH; Wang, Y, 2009
)
0.35
" Despite one fourth dosage of MSCs, significantly more PKH26-labeled donor cells were recovered with intratracheal administration than with intraperitoneal administration both during normoxia and hyperoxia."( Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats.
Chang, YS; Choi, EY; Choi, SJ; Jin, HJ; Kang, S; Kim, SY; Oh, W; Park, WS; Sung, DK; Yang, YS, 2009
)
0.35
" Here we investigated whether AIMP2 would give gene dosage effect on its pro-apoptotic and anti-proliferative activities using the wild-type, hetero- and homozygous AIMP2 cells and whether AIMP2 would be critical in preventing tumorigenesis using different in vivo tumor models."( Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis.
Choi, JW; Kim, S; Kundu, JK; Surh, YJ; Um, JY, 2009
)
0.35
" Six groups of 5 male Sprague-Dawley albino rats each were dosed once daily for 21 days, as follows: (1) negative control--oral corn oil, (2) positive control--Cyclosporine A (25 mg/kg), (3) Group 3--Apigenin (20 mg/kg), (4) Group 4--Cyclosporine A (25 mg/kg) +Apigenin (10 mg/kg), (5) Group 5--Cyclosporine A (25 mg/kg) +Apigenin (15 mg/kg) and (6) Group 6--Cyclosporine A (25 mg/kg) +Apigenin (20 mg/kg)."( Expression of transforming growth factor-beta and determination of apoptotic index in histopathological sections for assessment of the effects of Apigenin (4', 5', 7'- Trihydroxyflavone) on Cyclosporine A induced renal damage.
Chakravarthi, S; Chong, FW; Lee, N; Nagaraja, HS; Thanikachalam, PM, 2009
)
0.35
" This study aims to delineate the biofunctional characteristics of recombinant human BMP2/7 (rhBMP2/7) heterodimer in inducing osteoblastogenesis of MC3T3-E1 through in vitro time-course and dose-response studies."( rhBMP2/7 heterodimer: an osteoblastogenesis inducer of not higher potency but lower effective concentration compared with rhBMP2 and rhBMP7 homodimers.
Gu, Z; Sun, P; Wang, L; Wu, G; Zhao, J; Zheng, Y, 2010
)
0.36
" Implants in the optimally dosed groups had increased radiodensity, which was consistent with a significant increase in bone mineral content of the ossicles."( Antitumor necrotic factor agent promotes BMP-2-induced ectopic bone formation.
Eguchi, Y; Hashimoto, Y; Imai, Y; Naka, Y; Nakamura, H; Takaoka, K; Wakitani, S, 2010
)
0.36
"Ligands of the Transforming Growth Factor type beta (TGFbeta) family exert multiple and sometimes opposite effects on most cell types in vivo depending on cellular context, which mainly includes the stage of the target cell, the local environment of this cell or niche, and the identity and the dosage of the ligand."( Transforming Growth Factor type beta and Smad family signaling in stem cell function.
Huylebroeck, D; Sampaolesi, M; Seuntjens, E; Umans, L; Verfaillie, CM; Zwijsen, A,
)
0.13
" Small molecules inhibitors of TGF-betaR1 that are now in Phase I clinical trials and in preclinical stage are, therefore, of high interest and could provide a more versatile route to TGF-beta modulation through oral dosing while maintaining the same therapeutic benefits."( Strategies for TGF-beta modulation: a review of recent patents.
Bonafoux, D; Lee, WC, 2009
)
0.35
" IFN-alpha suppressed the production of IL-17 of immobilized anti-CD3-stimulated CD4+ T cells in a dose-response manner."( Suppressive influences of IFN-alpha on IL-17 expression in human CD4+ T cells.
Hirohata, S; Shibuya, H; Tejima, S, 2010
)
0.36
" Diminution of ALK1 gene dosage or systemic treatment with the ALK1-Fc fusion protein RAP-041 retarded tumor growth and progression by inhibition of angiogenesis in a transgenic mouse model of multistep tumorigenesis."( Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
Anderberg, C; Cunha, SI; Goumans, MJ; Hawinkels, L; Heldin, CH; Pardali, E; Pietras, K; Seehra, J; ten Dijke, P; Thorikay, M, 2010
)
0.36
" Ongoing clinical and basic-science research is focused on clearly defining guidelines for BMP use in spine surgery and on developing more affordable BMP formulations with dosing that predictably results in spine fusion yet minimizes the possible side effect profile."( Spinal reconstruction and bone morphogenetic proteins: open questions.
Oner, FC; Shimer, AL; Vaccaro, AR, 2009
)
0.35
" Sprague-Dawley rats underwent left anterior descending coronary artery ligation to induce experimental MI and then were randomized to receive GW788388 at a dosage of 50 mg."( Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction.
Connelly, KA; Gilbert, RE; Kelly, DJ; Tan, SM; Zhang, Y, 2010
)
0.36
"This prospective, randomized study was designed to objectively demonstrate that minimally invasive video-assisted thyroidectomy (MIVAT) improves postoperative pain compared with standard thyroidectomy, via the dosage of biochemical mediators measured before and after surgery."( Standard versus video-assisted thyroidectomy: objective postoperative pain evaluation.
Berti, P; Massi, M; Metelli, MR; Miccoli, P; Minuto, MN; Panicucci, E; Rago, R, 2010
)
0.36
"100 healthy adult male SD rats, with a mean weight of 200 g, were randomly divided into five groups in average: control group, reserpine treated group, atropine treated group, treatment groups with Lizhong Pill at high dose and low dose (equal to the dosage of crude drugs for 4 g/kg/d and 8 g/kg/d)."( Effects on neuroendocrinoimmune network of Lizhong Pill in the reserpine induced rats with spleen deficiency in traditional Chinese medicine.
Guo, Y; Jia, H; Liu, Z; Lu, A; Xu, S; Zha, Q; Zhang, W; Zhao, N, 2011
)
0.37
"To assess the safety, efficacy, and dosing of rhBMP-2 as an adjunct for instrumented posterior cervical arthrodesis."( Safety, efficacy, and dosing of recombinant human bone morphogenetic protein-2 for posterior cervical and cervicothoracic instrumented fusion with a minimum 2-year follow-up.
Chernavvsky, DR; Hamilton, DK; Reames, DL; Shaffrey, CI; Smith, JS; Williams, BJ, 2011
)
0.37
" For all volumes, in-field and out-of-field dose-response curves were obtained 8 weeks after irradiation."( Volume-dependent expression of in-field and out-of-field effects in the proton-irradiated rat lung.
Brandenburg, S; Coppes, RP; Faber, H; Gross, S; Langendijk, JA; Muijs, CT; Schippers, JM; van Luijk, P, 2011
)
0.37
" Depending on dosage and time of vitrectomy, PVR could be completely avoided (PVR score = 0) in 16 rabbits out of 30."( The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR).
Abd El-Nabi, E; Grisanti, S; Kamal, M; Lüke, J; Lüke, M; Nassar, K; Rohrbach, M; Soliman, M, 2011
)
0.37
"The lack of embryo-fetal effects may be due to dosage effects of neutralizing anti-BMP-2 antibodies, timing of exposure (stage and duration) to neutralizing anti-BMP-2 antibodies, and/or redundancy of effects of the various BMPs."( Assessment of immunization against recombinant human bone morphogenetic protein-2 (dibotermin alpha) on reproduction and development in rabbits.
Cukierski, M; Minck, DR; Nowak, J; Warner, G; Wright, DJ, 2011
)
0.37
" Cumulative genotype analysis of 13 SNPs with significant main effects exhibited a clear dose-response trend of escalating risk with increasing number of unfavorable genotypes."( Genetic variants in TGF-β pathway are associated with ovarian cancer risk.
Chang, DW; Hildebrandt, MA; Liang, D; Lin, J; Lu, K; Meyer, L; Wu, L; Wu, X; Yin, J, 2011
)
0.37
" Patients were treated for 3 months with zinc gluconate at a dosage of 90 mg/d."( Hidradenitis suppurativa: the role of deficient cutaneous innate immunity.
Blouin, E; Brocard, A; Dréno, B; Guillet, G; Khammari, A; Knol, AC; Léonard, F; Moyse, D, 2012
)
0.38
" Probiotics can be ineffective or even detrimental if not used at the optimal dosage for the appropriate purposes."( High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs.
Bui, T; Kocher, J; Li, G; Li, Y; Lin, L; Liu, F; Wen, K; Yang, X; Yuan, L, 2012
)
0.38
" Nonetheless, the choice of drug design and dosing strategy can affect the efficacy of TGF-β therapeutics."( Complexities of TGF-β targeted cancer therapy.
Akhurst, RJ; Connolly, EC; Freimuth, J, 2012
)
0.38
"01) at the dosage of2 g x kg(-1) and 34."( [Study on impact of vinegar processing on toxic effect of Stellera chamaejasme].
Li, Y; Liu, A; Liu, X; Pan, G; Weng, X; Yang, Q; Zhu, X, 2012
)
0.38
" We found that a two-fold reduction in Smad3 gene dosage led to complex effects on TGF-β responses; the growth-inhibitory response was retained, the pro-apoptotic response was lost, the migratory response was reduced, and the invasion response was enhanced."( Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression.
Chen, JQ; Du, Z; Flanders, KC; Heldman, M; Herrmann, MA; Kohn, EA; Nagano, Y; Stuelten, CH; Van Schyndle, CM; Wakefield, LM; Yang, YA, 2012
)
0.38
" In vivo 264RAD showed dose-dependent inhibition of Detroit 562 tumour growth, regressing established tumours when dosed at 20 mg/kg once weekly."( A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.
Alfred, A; Barry, ST; Bedian, V; Blakey, DC; Cao, A; Churchman, A; Eberlein, C; Foltz, IN; Jacobs, VN; Kang, JS; Kendrew, J; Marshall, JF; McDaid, K; Rinkenberger, J; Rooney, C; Ross, SJ; Smith, NR; Weir, HM, 2013
)
0.39
" TAA administration for 8 weeks induced extensive hepatic fibrosis, whereupon 1D11 dosing was initiated and maintained for 8 additional weeks."( Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats.
Arbeeny, C; Hempel, D; Ledbetter, S; Ling, H; Lonning, S; Roux, E; Smith, M; Tao, J; Zuk, A, 2013
)
0.39
" Optimal peptide dosage (1."( In vitro and in vivo enhancement of osteogenic capacity in a synthetic BMP-2 derived peptide-coated mineralized collagen composite.
Cui, FZ; Cui, H; Guo, WG; Liu, HY; Müller, WE; Zhang, X; Zhang, Y, 2016
)
0.43
" The findings suggest that early exposure to a low dosage of glyLDL transiently increases the proliferation of MEF through the upregulation of FGF, VEGF, and (or) PDGF, and prolonged exposure to high concentrations of glyLDL reduced cell viability, which possibly accelerates atherogenesis under diabetic condition."( Effects of glycated low-density lipoprotein on cell viability, proliferation, and growth factors of mouse embryo fibroblasts.
Shen, GX; Xie, X; Zhao, R, 2013
)
0.39
" The concentration and dosage of recombinant human bone morphogenetic protein 2 (rhBMP-2) used seems to have an effect on the rate of fusion and pseudarthrosis rate because no patient receiving more than 5 mg per level had apparent or detected pseudarthroses (n = 20/20)."( RhBMP-2 is superior to iliac crest bone graft for long fusions to the sacrum in adult spinal deformity: 4- to 14-year follow-up.
Bridwell, KH; Buchowski, JM; Dickson, DD; Kim, HJ; Koester, L; Zebala, LP, 2013
)
0.39
" MK2i or PBS was dosed daily for 14 days subsequent to bleomycin injury, beginning on either Day 7 or Day 14."( Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis.
Cummings, OW; Fisher, A; Gu, H; Lander, C; Mickler, EA; Panitch, A; Sandusky, GE; Vittal, R; Wilkes, DS, 2013
)
0.39
" Furthermore, the short half-life necessitates repeated dosage with large amounts of the growth factor, which may have dangerous side effects, hence the importance of temporal and spatial control of growth factor delivery."( Novel xylan-controlled delivery of therapeutic proteins to inflamed colon by the human anaerobic commensal bacterium.
Hamady, ZZ, 2013
)
0.39
" After 4 weeks of subpressor dosage of AngII infusion (0."( Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-β signalling.
Chu, ML; Dong, H; Khan, SA; Tsuda, T; Wu, J; Zhang, H, 2014
)
0.4
" High BMP-2 dosing can introduce serious side effects that include edema, bone overgrowth, cyst-like bone formation and significant inflammation."( The influence of collagen and hyaluronan matrices on the delivery and bioactivity of bone morphogenetic protein-2 and ectopic bone formation.
Bhakta, G; Cool, SM; Hui, JH; Lim, ZX; Lin, T; Nurcombe, V; Prestwich, GD; Rai, B; van Wijnen, AJ, 2013
)
0.39
" Potential causes include improper dosage and a closed space that prevents the egress of the postoperative BMP-2 fluid collection."( Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
Cha, TD; Fineberg, SJ; Khan, SN; Marquez-Lara, A; Nandyala, SV; Pelton, MA; Singh, K, 2013
)
0.39
" Confocal fluorescence microscopy showed locally dosed bisphosphonate entered and was retained in the femoral head."( Local delivery of recombinant human bone morphogenetic proteins and bisphosphonate via sucrose acetate isobutyrate can prevent femoral head collapse in Legg-Calve-Perthes disease: a pilot study in pigs.
Cantrill, LC; Carpenter, C; Cheng, TL; Little, DG; Mikulec, K; Murphy, CM; Schindeler, A, 2014
)
0.4
" Cost-related concerns, dosage considerations, carrier types, and theoretical carcinogenesis concerns were also presented."( Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery.
An, HS; Tannoury, CA, 2014
)
0.4
" Initially dose-response experiments (n = 4) were performed to determine the optimal concentrations of FSH (0."( The global effect of follicle-stimulating hormone and tumour necrosis factor α on gene expression in cultured bovine ovarian granulosa cells.
Glister, C; Hatzirodos, N; Hummitzsch, K; Knight, PG; Rodgers, RJ, 2014
)
0.4
" Research is needed for higher rhBMP-2 dosing and long-term follow-up."( Does recombinant human bone morphogenetic protein-2 use in adult spinal deformity increase complications and are complications associated with location of rhBMP-2 use? A prospective, multicenter study of 279 consecutive patients.
Akbarnia, BA; Ames, CP; Bess, S; Boachie-Adjei, O; Burton, DC; Deverin, V; Fu, KM; Gupta, M; Hart, RA; Hostin, R; Kebaish, K; Klineberg, E; Lafage, V; Line, BG; Mundis, G; O'Brien, M; Schwab, F; Shaffrey, CI; Shelokov, A; Smith, JS, 2014
)
0.4
"CoQ10 supplementation at a dosage of 500 mg appears to decrease the inflammatory markers (TNF-α, IL-6, and MMP-9) in patients with MS."( Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial.
Aryaeian, N; Azimi, A; Eghtesadi, S; Gohari, MR; Jazayeri, S; Khalili, M; Khodadadi, B; Sanoobar, M, 2015
)
0.42
" Reducing anti-RANKL yielded clinically similar results, suggesting that better targeting or dosing could improve patient survival."( An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.
Araujo, A; Basanta, D; Cook, LM; Lynch, CC, 2014
)
0.4
" Albumin induces DNA synthesis in a dose-response manner."( Plasma albumin induces cytosolic calcium oscilations and DNA synthesis in human cultured astrocytes.
Ortega, GJ; Pastor, J; Sola, RG; Vega-Zelaya, L, 2014
)
0.4
"Rabbits were divided into the control, model and three dosage groups of CASE (0."( Compound Astragalus and Salvia miltiorrhiza extract suppresses rabbits' hypertrophic scar by modulating the TGF-β/Smad signal.
Boye, A; Jiang, J; Jiang, Y; Wu, C; Yang, Y, 2014
)
0.4
"The aim of this study was to investigate the effect that dosage has on the efficiency of low-level laser therapy (LLLT) in bone formation in a rat study model."( The effect of dosage on the efficiency of LLLT in new bone formation at the expanded suture in rats.
Altan, AB; Avunduk, MC; Bicakci, AA; Esen, H, 2015
)
0.42
" However, further investigation of the effectiveness and determination of the optimal dosage of E-BMP-2 in large animals are still necessary before its full application in humans."( Efficient bone formation in a swine socket lift model using Escherichia coli-derived recombinant human bone morphogenetic protein-2 adsorbed in β-tricalcium phosphate.
Akiyama, K; Hara, ES; Kuboki, T; Nakajima, R; Oida, Y; Ono, M; Pham, HT; Shinkawa, S; Sonoyama, W; Yamamoto, K, 2014
)
0.4
" Similar to our observations at maximum dosage of 3 mg/kg, vaccination of normal rats with 300 μg/kg pcDNA-CCOL2A1 vaccine did not induce the production of anti-CII IgG."( Evaluation of humoral and cellular immune responses to a DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats.
Dongfa, D; Fang, Y; Fei, L; Jing, J; Juan, L; Kun, Y; Lili, D; Liuxin, T; Nan, L; Song, Y; Xiao, Z; Yongzhi, X; Yuna, H; Yuying, S; Zhijian, Z, 2015
)
0.42
" They are characterized by large interindividual variability in their pharmacokinetics; therefore, monitoring their blood concentrations is important to predict their optimal dosage following transplantation."( Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-β, tumour necrosis factor-α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients.
Aydin, F; Ciftci, HS; Karadeniz, MS; Kekik, C; Nane, I; Oguz, FS; Seyhun, Y; Tefik, T; Turkmen, A, 2015
)
0.42
" Other factors, such as patient age, diagnosis, number of vertebral levels fused, use of allograft or autograft, dosage of bone morphogenetic protein (BMP), and use of postoperative orthosis, were recorded."( The efficacy of routine use of recombinant human bone morphogenetic protein-2 in occipitocervical and atlantoaxial fusions of the pediatric spine: a minimum of 12 months' follow-up with computed tomography.
Brayton, A; Briceño, V; Fulkerson, D; Hadley, C; Jea, A; Luerssen, TG; Monaco, GN; Ryan, SL; Sayama, C; Sen, A; Tran, BH, 2015
)
0.42
" Microarrays suggest RANKL and MMP 10 followed IR energy density dose-response curves."( Visible red and infrared light alters gene expression in human marrow stromal fibroblast cells.
Guo, J; Le, AD; Shi, SH; Shi, ST; Wai, D; Wang, Q; Yen, SL; Zhang, QZ, 2015
)
0.42
" The high rhBMP-2 dosage may be required, in part, to overcome the presence of antagonists such as noggin."( Surface-mediated delivery of siRNA from fibrin hydrogels for knockdown of the BMP-2 binding antagonist noggin.
Kowalczewski, CJ; Saul, JM, 2015
)
0.42
" Results in the BET group suggest that investigation into types, dose, and dosage schedule of glucocorticoids may facilitate placental maturation."( Localization of TGF-β and TGF-β receptor in bovine term placentome and expression differences between spontaneous and induced parturition.
Fujii, T; Fukuda, S; Hirayama, H; Kageyama, S; Koyama, K; Naito, A; Sawai, K, 2015
)
0.42
"Our results show significant evidence, for instance, for inhibitory mechanisms between the transcription factors and reveal a previously unknown dependency between the dosage of the inducing cytokine TGF β and the expression of the master regulator of competing (induced) regulatory T cell lineage."( Analyzing Th17 cell differentiation dynamics using a novel integrative modeling framework for time-course RNA sequencing data.
Ahlfors, H; Chen, ZJ; Intosalmi, J; Lähdesmäki, H; Lahesmaa, R; Mannerstöm, H; Rautio, S; Stockinger, B, 2015
)
0.42
"Retinal axon specification and growth are critically sensitive to the dosage of numerous signaling molecules and transcription factors."( TGF-β Controls miR-181/ERK Regulatory Network during Retinal Axon Specification and Growth.
Banfi, S; Barbato, S; Carrella, S; Conte, I; D'Agostino, Y; Manfredi, A; Salierno, FG, 2015
)
0.42
" Prospective evaluation of rhBMP-2 dosing for ASD surgery is warranted to define the most appropriate dose that balances benefits, risks, and costs."( Long-Segment Fusion for Adult Spinal Deformity Correction Using Low-Dose Recombinant Human Bone Morphogenetic Protein-2: A Retrospective Review of Fusion Rates.
Ailon, T; Heller, JE; Kasliwal, MK; Kelleher, JP; Schmitt, PJ; Shaffrey, CI; Smith, JS, 2016
)
0.43
"Septation of the gas-exchange saccules of the morphologically immature mouse lung requires regulated timing, spatial direction, and dosage of transforming growth factor (TGF)-β signaling."( Initial Suppression of Transforming Growth Factor-β Signaling and Loss of TGFBI Causes Early Alveolar Structural Defects Resulting in Bronchopulmonary Dysplasia.
Ahlfeld, SK; Conway, SJ; Gao, Y; Snider, P; Wang, J, 2016
)
0.43
" To this aim, the present paper assesses in detail the extracellular vesicles phenomenon in the human glioblastoma cell line U251 and evaluates extracellular vesicles ability to promote the processes required to achieve the formation of new blood vessels in human brain microvascular endothelial cells, highlighting that they stimulate proliferation, motility, and tube formation in a dose-response manner."( From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis.
D'Ascenzo, S; Delle Monache, S; Di Francesco, M; Dolo, V; Festuccia, C; Giusti, I; Gravina, GL; Sanità, P, 2016
)
0.43
" Lack of clear dose-response relationships for BMP-2 vis-à-vis bone regeneration has contributed to the use of higher doses clinically."( Delivery vehicle effects on bone regeneration and heterotopic ossification induced by high dose BMP-2.
Esancy, C; Guldberg, RE; Klosterhoff, BS; Krishnan, L; Priddy, LB; Stevens, HY; Tran, L, 2017
)
0.46
"We developed a spinal nerve root wrapping rodent model to evaluate the relationship between recombinant human bone morphogenetic protein 2 (rhBMP-2) dosage and the degree of inflammation."( Dose-dependent Nerve Inflammatory Response to rhBMP-2 in a Rodent Spinal Nerve Model.
Hu, T; Lam, RWM; Liau, ZQG; Wong, HK, 2017
)
0.46
"To investigate the direct effects of recombinant human bone morphogenetic protein 2 (rhBMP-2) dosage and the degree of inflammation in rodent spinal nerve roots."( Dose-dependent Nerve Inflammatory Response to rhBMP-2 in a Rodent Spinal Nerve Model.
Hu, T; Lam, RWM; Liau, ZQG; Wong, HK, 2017
)
0.46
"To test the hypothesis that the addition of small amounts of rhVEGF to rhBMP2 in a polymer carrier can accomplish equivalent repair effect as a reduced dosage of rhBMP2 compared to rhBMP2 alone."( Repair of large saddle defects of the mandibular ridge using dual growth factor release-An experimental pilot study in minipigs.
Brockmeyer, P; Kauffmann, P; Klenke, A; Rau, A; Santander, P; Schliephake, H; Tröltzsch, M, 2017
)
0.46
" Addition of small amounts of rhVEGF can increase bone formation and at the same time reduce the dosage of rhBMP2."( Repair of large saddle defects of the mandibular ridge using dual growth factor release-An experimental pilot study in minipigs.
Brockmeyer, P; Kauffmann, P; Klenke, A; Rau, A; Santander, P; Schliephake, H; Tröltzsch, M, 2017
)
0.46
" Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients."( Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017
)
0.46
" The dual function and pleiotropic nature of TGF-β signaling make it a challenging target and imply the need for careful therapeutic dosing of TGF-β drugs and patient selection."( Targeting TGF-β Signaling in Cancer.
Colak, S; Ten Dijke, P, 2017
)
0.46
" Low dosage bFGF promotes cell proliferation while high dosage induces differentiation."( Roles of TGFβ and FGF signals during growth and differentiation of mouse lens epithelial cell in vitro.
Gong, X; Li, S; Liu, K; Wang, D; Wang, E; Xia, CH, 2017
)
0.46
"The evaluation showed that the combined delivery of bone morphogenetic protein BMP2 and VEGF in different dosage combinations did not enhance the overall quantity of ectopic bone formation compared to the delivery of BMP2 alone."( Experimental variation of the level and the ratio of angiogenic and osteogenic signaling affects the spatiotemporal expression of bone-specific markers and organization of bone formation in ectopic sites.
Epple, M; Goldstein, J; Kauffmann, P; Moser, N; Schliephake, H, 2018
)
0.48
"The findings suggest that structural organization rather than the quantity of ectopic bone formation is affected by the dosage and the ratio of BMP2 and VEGF levels at the observed intervals."( Experimental variation of the level and the ratio of angiogenic and osteogenic signaling affects the spatiotemporal expression of bone-specific markers and organization of bone formation in ectopic sites.
Epple, M; Goldstein, J; Kauffmann, P; Moser, N; Schliephake, H, 2018
)
0.48
" Expression of AP and Runx2 showed significant differences among the three dosage groups."( Do we need retarded delivery of bone growth factors in facial bone repair? An experimental study in rats.
Epple, M; Golstein, J; Kauffmann, P; Lohse, N; Moser, N; Schliephake, H; Sven, B, 2017
)
0.46
" The optimal dosing regimen of NPs for expansion of CD4+ and CD8+ Treg cells was determined in in vivo studies in mice without lupus and then tested in BDF1 mice with lupus."( Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor β.
Bickerton, S; Fahmy, TM; Horwitz, DA; Koss, M; La Cava, A, 2019
)
0.51
" The dose-response relationship showed that low dose (≤5 μmol/L) arsenic exposure up-regulated the expression of TGF-β1, whereas high doses had a tendency to down-regulate that of TGF-β1."( Bi-directional regulation of TGF-β/Smad pathway by arsenic: A systemic review and meta-analysis of in vivo and in vitro studies.
Dai, J; Hu, Y; Li, S; Li, Y; Niu, Q; Xu, M; Zhang, X, 2019
)
0.51
" Furthermore, we also used tandem mass spectrometry to analyze change of BMP-2 and BMP-7 expression after high dosage of irradiation (30,000 rad) and long-time of freezing (15 min)."( Bone morphogenetic protein activity preservation with extracorporeal irradiation- and liquid nitrogen freezing-treated recycled autografts for biological reconstruction in malignant bone tumor.
Chen, CF; Chen, CM; Chen, WM; Madda, R; Tsai, SW; Wang, JY; Wu, PK, 2019
)
0.51
" This vehicle system acted as a multicore structure for sustained release of BMP-2, which enabled pulsed dosing induction of osteogenic differentiation of the co-embedded BM-MSCs."( Dual delivery of encapsulated BM-MSCs and BMP-2 improves osteogenic differentiation and new bone formation.
Kong, Y; Li, D; Shen, H; Yan, M; Zhao, Y, 2019
)
0.51
" Moreover, this study provided a proof of concept regarding the use of exosomes in bone regeneration therapy, which might be used as a booster dose that will eventually reduce the dosage of BMP and hence circumvent the limitations associated with the use of BMP."( Nanohydroxyapatite Based Ceramic Carrier Promotes Bone Formation in a Femoral Neck Canal Defect in Osteoporotic Rats.
Kumar, A; Qayoom, I; Teotia, AK, 2020
)
0.56
" The dosage of opioids during and 24 h after operation, the pain score at 2, 8, 24, 48, and 72 h after operation, and the concentrations of serum VEGF and TGF-β before and 24 h after operation were observed in the two groups."( Effect of thoracic paraspinal block-propofol intravenous general anesthesia on VEGF and TGF-β in patients receiving radical resection of lung cancer.
Sen, Y; Xiyang, H; Yu, H, 2019
)
0.51
" In vitro and in vivo experiments have shown that the minimum effective dosage of rhBMP-2 is 10 μg/ml."( [Biocompatibility and osteoinductive properties of collagen and fibronectin hydrogel impregnated with rhBMP-2].
Babichenko, II; Bukharova, TB; Domogatsky, SP; Fatkhudinova, NL; Galitsyna, EV; Goldstein, DV; Kulakov, AA; Kuznetsova, VS; Leonov, GE; Osidak, EO; Vasilyev, AV, 2019
)
0.51
" Daily oral dosing for 10 days resulted in valvulopathy and/or aortic pathology at systemic exposures that would have been targeted clinically, preventing further development with this dosing schedule."( Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS-986260, mitigates class-based cardiovascular toxicity in dogs but not rats.
Augustine-Rauch, K; Graziano, MJ; Newsome, C; Rak, GD; Schulze, GE; White, MR, 2020
)
0.86
" Patients were randomized at a one-to-one ratio to receive either bintrafusp alfa 500 mg or the recommended phase 2 dosage of 1200 mg every 2 weeks."( Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
Alvarez, RM; Cho, BC; Di Nicola, M; Dussault, I; Felip, E; Flor, MJ; Gulley, JL; Helwig, C; Kim, TM; Lee, DH; Lee, KH; Lin, CC; Ojalvo, LS; Paz-Ares, L; Vicente, D, 2020
)
0.56
" Probiotics of a special type and a certain dosage could also reduce the inflammatory process in patients with active ulcerative colitis."( Enteral Nutrition Supplemented with Transforming Growth Factor-β, Colostrum, Probiotics, and Other Nutritional Compounds in the Treatment of Patients with Inflammatory Bowel Disease.
Triantafillidis, JK; Triantafyllidi, E; Tzouvala, M, 2020
)
0.56
" We found significantly negative dose-response relationships of all urinary acrylamide metabolites and TGF-β1 with all six HRV indices after adjusting for potential confounders (all P < 0."( Exposure to acrylamide and reduced heart rate variability: The mediating role of transforming growth factor-β.
Cen, X; Chen, A; Chen, W; Cheng, M; Guo, Y; He, H; Li, W; Ma, J; Mu, G; Qiu, W; Wang, B; Wang, D; Wang, X; Xiao, L; Yang, M; Yang, S; Zhang, X; Zhou, M; Zhou, Y; Zhu, C, 2020
)
0.56
" In this work, we studied the effects of these compounds used in non-toxic dosage on the processes associated with metastatic potential of tumor cells."( Cyano Enone-Bearing Triterpenoid Soloxolone Methyl Inhibits Epithelial-Mesenchymal Transition of Human Lung Adenocarcinoma Cells In Vitro and Metastasis of Murine Melanoma In Vivo.
Markov, AV; Odarenko, KV; Salakhutdinov, NF; Salomatina, OV; Sen'kova, AV; Zenkova, MA, 2020
)
0.56
"The results indicated that mifepristone promoted the expressions of CD80, CD86, and ICAM-1 in a dosage dependent manner."( Mifepristone regulates Tregs function mediated by dendritic cells through suppressing the expression of TGF-β.
Cao, L; Guo, Q; Huang, L; Li, Y; Niu, X; Qian, Z, 2021
)
0.62
" This work illustrates the importance of allele dosage and expression when artificial systems are used to model human genetic disease caused by activating PIK3CA mutations."( NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CAH1047R homozygosity in pluripotent stem cells.
Carragher, NO; Knox, RG; Linding, R; Longden, J; Macleod, KG; Madsen, RR; Moniz, LS; Robin, X; Semple, RK; Vanhaesebroeck, B; Völlmy, F, 2021
)
0.62
"The TGF-β dosage was elevated in the CRSsNP group and reduced in the CSwNP group."( BMP-7, MMP-9, and TGF-β tissue remodeling proteins and their correlations with interleukins 6 and 10 in chronic rhinosinusitis.
Bachi, ALL; do Amaral, JB; Lucas, BR; Pezato, R; Voegels, RL, 2021
)
0.62
" The primary objective of this study was to determine whether intraoperative dosing and corresponding costs changed with surgeon cost awareness."( Impact of surgeon rhBMP-2 cost awareness on complication rates and health system costs for spinal arthrodesis.
Feroze, AH; McGrath, M; Nistal, D; Robinson, E; Saigal, R, 2021
)
0.62
" Prior to cost awareness, the most frequent rhBMP-2 dosage level was x-small (38."( Impact of surgeon rhBMP-2 cost awareness on complication rates and health system costs for spinal arthrodesis.
Feroze, AH; McGrath, M; Nistal, D; Robinson, E; Saigal, R, 2021
)
0.62
" However, the dosage of rhBMP-9 is quintessential for the facilitation of adequate bone defect healing."( Evaluation of the optimal dosage of BMP-9 through the comparison of bone regeneration induced by BMP-9 versus BMP-2 using an injectable microparticle embedded thermosensitive polymeric carrier in a rat cranial defect model.
Bharadwaz, A; Gaihre, B; Jayasuriya, AC; Unagolla, JM, 2021
)
0.62
" NOD mice orally dosed with LL-CFA/I showed an increase in regulatory plasmacytoid DCs (pDCs) expressing IDO and TGF-β in pancreatic lymph nodes (PaLNs) and spleen three days post-treatment."( Oral probiotic promotes indoleamine 2,3-dioxygenase- and TGF-β-Producing plasmacytoid dendritic cells to initiate protection against type 1 diabetes.
Akgul, A; Bhagyaraj, E; Hoffman, C; Maddaloni, M; Nelson, AS; Pascual, DW, 2021
)
0.62
" Oral formulations (Vesanoid) treat acute promyelocytic leukemia, but oral dosing can induce severe side effects."( Oral Delivery of Encapsulated All-Trans Retinoic Acid Ameliorates Disease in Rodent Models of Colitis.
Auci, DL; Furtado, S; Green, B; Hammer, L; Mangano, K; Mathiowitz, E; Nicoletti, F, 2022
)
0.72
" Furthermore, while a single MSC injection was sufficient to improve locomotor recovery, fractionated dosing of MSC-sEVs over 3 days (F-sEVs) was required to achieve similar therapeutic effects."( Small extracellular vesicles released by infused mesenchymal stromal cells target M2 macrophages and promote TGF-β upregulation, microvascular stabilization and functional recovery in a rodent model of severe spinal cord injury.
Askenase, PW; Kocsis, JD; Lankford, KL; Morita, T; Nakazaki, M, 2021
)
0.62
" We optimized the formula ratio and dosage of AANG that effectively inhibit the proliferation of our unique human multidrug resistant subclone R-HepG2."( AANG: A natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-β/Smad signalling in hepatocellular carcinoma.
Chan, AS; Chan, MK; Chung, JS; Chung, JY; Lan, HY; Leung, KT; Meng, XM; Tang, PC; Tang, PM; To, KF, 2021
)
0.62
" There is a lack of literature regarding recombinant human BMP-2 (rhBMP-2) dosage in different spine surgeries."( Dose Adjustment Associated Complications of Bone Morphogenetic Protein: A Longitudinal Assessment.
Burks, JD; Burks, SS; De Stefano, FA; Elarjani, T; Levi, AD, 2021
)
0.62
" Subjects with persistent high levels of ΣHWM OH-PAH had a significant reduction in HRV over 6 years, and the incensement of TGF-β1 could aggravate above adverse effects in a dose-response manner."( Longitudinal relationships between polycyclic aromatic hydrocarbons exposure and heart rate variability: Exploring the role of transforming growth factor-β in a general Chinese population.
Chen, W; Cheng, M; Ma, J; Nie, X; Tan, Q; Wang, B; Wang, D; Wang, X; Xie, Y; Ye, Z; Zhou, M, 2022
)
0.72
" The randomly allocated experimental groups were divided by carrier and rhBMP-2 dosage as no rhBMP-2 (control), 5 μg rhBMP-2 loaded to PCL composite (Scaffold/rhBMP-2[5 μg]), 5 μg rhBMP-2 loaded to implant (Implant/rhBMP-2[5 μg]), 30 μg rhBMP-2 loaded to PCL composite (Scaffold/rhBMP-2[30 μg]), and 30 μg rhBMP-2 loaded to implant (Implant/rhBMP-2[30 μg])."( In vivo evaluation of 3D printed polycaprolactone composite scaffold and recombinant human bone morphogenetic protein-2 for vertical bone augmentation with simultaneous implant placement on rabbit calvaria.
Chang, YY; Cho, YS; Jeong, HJ; Lee, S; Lee, SJ; Yun, JH, 2022
)
0.72
" Therefore, strategies to reduce rhBMP-2 dosage are desirable."( Enhanced BMP-2-Mediated Bone Repair Using an Anisotropic Silk Fibroin Scaffold Coated with Bone-like Apatite.
Deininger, C; Freude, T; Grillari, J; Heimel, P; Redl, H; Salzer, E; Tempfer, H; Teuschl-Woller, AH; Traweger, A; Vila, XM; Wagner, A; Weißenbacher, N; Wichlas, F, 2021
)
0.62
" Further studies are required to establish whether the dosage and timing optimization of P144 administration, in different RIF phases, might entirely avoid fibrosis associated with STS brachytherapy."( P144 a Transforming Growth Factor Beta Inhibitor Peptide, Generates Antifibrogenic Effects in a Radiotherapy Induced Fibrosis Model.
Cruz-Morande, S; Dotor, J; San-Julian, M, 2022
)
1.18
" Moreover, these pharmaceutical dosage forms significantly increased skin collagen content compared to UV-injured group."( Coriander (Coriandrum sativum L.) essential oil and oil-loaded nano-formulations as an anti-aging potentiality via TGFβ/SMAD pathway.
Aborehab, NM; Haggag, YA; Hamdan, DI; Ibrahim, MT; Manaa, EG; Osama, N; Ragab, MF; Salem, MA, 2022
)
0.72
" By employing a conditioned medium method, we found that the nanoparticulate PDT at a sub-lethal dosage down-regulated TGFβ signaling pathways, leading to the decrease in drug resistance, proliferation, and migration of the cancer cells."( Modulating cancer-stroma crosstalk by a nanoparticle-based photodynamic method to pave the way for subsequent therapies.
Chen, F; Li, H; Liu, N; Liu, Y; Sun, K; Tao, K; Wang, T; Wu, X; Zhou, G, 2022
)
0.72
" Cette étude a également mesuré la production de DRO à l’aide du dosage DCFH-DA."( Oleracone C from Portulaca oleracea attenuates UVB-induced changes in matrix metalloproteinase and type I procollagen production via MAPK and TGF-β/Smad pathways in human keratinocytes.
Karadeniz, F; Kong, CS; Lee, JI; Oh, JH; Seo, Y, 2023
)
0.91
" Les concentrations sériques d'IL-10 et de TGF-β1 ont été mesurées par dosage immuno-enzymatique."( Long-term effects of ciclosporin and oclacitinib on mediators of tolerance, regulatory T-cells, IL-10 and TGF-β, in dogs with atopic dermatitis.
Bizikova, P; Herrmann, I; Holmes, J; Mamo, LB; Mohammed, JP; Murphy, KM, 2023
)
0.91
" Interleukin-33 (IL-33) is proposed to play a role in the development of IPF however the exclusive use of prophylactic dosing regimens means that the therapeutic benefit of targeting this cytokine in IPF is unclear."( The IL-33:ST2 axis is unlikely to play a central fibrogenic role in idiopathic pulmonary fibrosis.
Cohen, ES; Huntington, CE; Jenkins, RG; John, AE; Kelly, A; Overed-Sayer, CL; Porte, J; Stephenson, KE; Wallace, WA, 2023
)
0.91
" In vivo, the fibrotic potential of IL-33:ST2 signalling was assessed using a murine model of bleomycin (BLM)-induced pulmonary fibrosis and therapeutic dosing with an ST2-Fc fusion protein."( The IL-33:ST2 axis is unlikely to play a central fibrogenic role in idiopathic pulmonary fibrosis.
Cohen, ES; Huntington, CE; Jenkins, RG; John, AE; Kelly, A; Overed-Sayer, CL; Porte, J; Stephenson, KE; Wallace, WA, 2023
)
0.91
" Despite having effects on inflammation suggestive of target engagement, therapeutic dosing with the ST2-Fc fusion protein failed to reduce BLM-induced fibrosis measured by hydroxyproline content or Ashcroft score."( The IL-33:ST2 axis is unlikely to play a central fibrogenic role in idiopathic pulmonary fibrosis.
Cohen, ES; Huntington, CE; Jenkins, RG; John, AE; Kelly, A; Overed-Sayer, CL; Porte, J; Stephenson, KE; Wallace, WA, 2023
)
0.91
"" TGFβ in tumors was neutralized by approximately 90% in animals dosed with 10 mg/kg of BCA101 compared with 54% in animals dosed with equimolar TGFβRII-Fc."( BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth.
Alke, B; Ar, M; Banerjee, A; Bhatnagar, J; Boreddy, SR; Bughani, U; Dey, C; Dhamne, C; Govindappa, N; Krishn, SR; Kulkarni, H; Kuriakose, A; Kuriakose, MA; Marigowda, SB; Moole, PR; Mv, PK; Nair, P; Nair, R; Pandey, PK; Patel, S; Periyasamy, S; Rao, S; Reddy, RB; Sagar, M; Sharma, P; Shri, M; Sreenivas, S; Suresh, A; Tan, SL; Tiwari, V, 2023
)
0.91
" A particular emphasis is given to the relationship between sotatercept dosage and its efficacy or associated adverse reactions."( From bench to bedside: The promise of sotatercept in hematologic disorders.
Lan, Z; Lv, Z; Xiao, Y; Zuo, W, 2023
)
0.91
" However, serious clinical side effects related to supraphysiological dosing highlight the need for advances in novel biomaterials that can significantly reduce the amount of this biologic."( A supramolecular polymer-collagen microparticle slurry for bone regeneration with minimal growth factor.
Chang, K; Chen, CH; Chen, F; Chun, D; Cook, R; Driscoll, A; Greene, AC; Haleem, M; Hsu, EL; Hsu, WK; Jeong, SS; Ji, W; Kannan, A; Katchko, K; Lee, SS; Lubbe, R; McClendon, MT; Qiu, R; Sai, H; Sangji, MH; Sather, NA; Stock, SR; Stupp, SI; Weiner, J, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (47,661)

TimeframeStudies, This Drug (%)All Drugs %
pre-199032 (0.07)18.7374
1990's10452 (21.93)18.2507
2000's18303 (38.40)29.6817
2010's14053 (29.49)24.3611
2020's4821 (10.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.30 (24.57)
Research Supply Index10.81 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index157.13 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials560 (1.14%)5.53%
Reviews5,409 (11.01%)6.00%
Case Studies402 (0.82%)4.05%
Observational31 (0.06%)0.25%
Other42,717 (86.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]